

**NTP Technical Report
on Toxicity Studies of**

2-Hydroxy-4-methoxybenzophenone

(CAS Number: 131-57-7)

**Administered Topically and in Dosed Feed
to F344/N Rats and B6C3F₁ Mice**

**John Edgar French, PhD, Study Scientist
National Toxicology Program
P.O. Box 12233
Research Triangle Park, North Carolina 27709**

**NIH Publication No. 92-3344
October 1992**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
National Institutes of Health**

CONTRIBUTORS

The NTP Report on the Toxicity Studies of 2-Hydroxy-4-methoxybenzophenone is based primarily on 2- and 13-week studies that began in June, 1985, and concluded in July, 1988, at EG&G Mason Research Institute, Worcester, MA.

National Toxicology Program

Evaluated experiment, interpreted results, and reported findings

John Edgar French, PhD
Study Scientist
John R. Bucher, PhD
Leo T. Burka, PhD
Rajendra S. Chhabra, PhD
Michael P. Dieter, PhD
Michael R. Elwell, DVM, PhD
Joel F. Mahler, DVM
Robert R. Maronpot, DVM, PhD
H.B. Matthews, PhD
Morrow B. Thompson, DVM, PhD
Errol Zeiger, PhD

Coordinated report preparation

Jane M. Lambert, BS
Edison McIntyre, BA, BS
Diane Overstreet, BS
Kristine Witt, MS
Oak Ridge Associated Universities

NTP Pathology Working Group

Evaluated slides and prepared pathology report

Dawn Goodman, VMD
Chairperson
PATHCO
Michael R. Elwell, DVM, PhD
National Toxicology Program
Jerry Hardisty, DVM, EPL
Experimental Pathology Laboratories
William MacKenzie, DVM, MS
Experimental Pathology Laboratories
Margarita McDonald, DVM, PhD
National Toxicology Program
A.W. Macklin, DVM, PhD
Burroughs Wellcome Research Laboratories

EG&G Mason Research Institute, Worcester, MA

Principal contributors

A.G. Braun, ScD
Principal Investigator
M.E.P. Goad, DVM, PhD
H.S. Lilja, PhD
S. Niemi, DVM
L.E. Sendelbach, PhD
F.A. Voelker, DVM, ACVP

Experimental Pathology Laboratories, Inc.

Provided pathology quality assurance

Jerry Hardisty, DVM
William F. MacKenzie, DVM, MS

Environmental Health Research and Testing Inc.

Provided sperm morphology and vagina cytology evaluation

Teresa Cocanougher, BA
Dushant K. Gulati, PhD
Susan Russell, BA

Analytical Sciences, Inc.

Provided statistical analysis

Steven Seilkop, MS
Janet Teague, MS

TABLE OF CONTENTS

CONTRIBUTORS	2
TABLE OF CONTENTS	3
ABSTRACT	7
PEER REVIEW PANEL	9
SUMMARY OF COMMENTS	10
INTRODUCTION	13
Physical Properties, Production, Uses, and Exposure.....	13
Human Toxicity	14
Animal Toxicity.....	14
Absorption, Metabolism, and Distribution	14
Mutagenicity and Structural Activity Relationships.....	15
Study Rationale and Design.....	15
MATERIALS AND METHODS	16
Procurement and Characterization of 2-Hydroxy-4-methoxybenzophenone.....	16
Study Design.....	16
Genetic Toxicity.....	18
Statistical Methods	19
Quality Assurance	20
RESULTS	23
2-Week Dosed Feed Studies in Rats.....	23
13-Week Dosed Feed Studies in Rats.....	24
2-Week Dermal Studies in Rats, with Acetone and Lotion Vehicles.....	28
13-Week Dermal Studies in Rats, with Acetone Vehicle.....	30
2-Week Dosed Feed Studies in Mice.....	32
13-Week Dosed Feed Studies in Mice.....	37
2-Week Dermal Studies in Mice, with Acetone and Lotion Vehicles.....	40
13-Week Dermal Studies in Mice, with Acetone Vehicle.....	41
Genetic Toxicology.....	43
DISCUSSION	44
REFERENCES	49
TABLES	
Table 1 Materials and Methods and Experimental Design in the 2-Week and 13-Week Dosed Feed and Dermal Studies of 2-Hydroxy-4-methoxybenzophenone	21
Table 2 Survival, Weight Gain, and Feed Consumption of F344/N Rats in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone	23
Table 3 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for F344/N Rats in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone	24
Table 4 Survival, Weight Gain, and Feed Consumption of F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone.....	25

Table 5	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone.....	25
Table 6	Histopathologic Lesions in F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone	26
Table 7	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Acetone	29
Table 8	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Lotion	29
Table 9	Kidney Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in lotion	30
Table 10	Survival, Weight Gain, and Feed Consumption of B6C3F ₁ Mice in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone	32
Table 11	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for B6C3F ₁ Mice in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone.....	37
Table 12	Survival, Weight Gain, and Feed Consumption of B6C3F ₁ Mice in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone.....	38
Table 13	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for B6C3F ₁ Mice in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone.....	38
Table 14	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for B6C3F ₁ Mice in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Acetone.....	40
Table 15	Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios for B6C3F ₁ Mice in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Lotion	41

FIGURES

Figure 1	Body Weights of F344/N Rats Exposed to 2-Hydroxy-4-methoxybenzophenone by Dosed Feed for 13 Weeks.....	27
Figure 2	Body Weights of Rats Exposed Dermally to 2-Hydroxy-4-methoxybenzophenone for 13 Weeks	31
Figure 3	Body Weights of Mice Exposed to 2-Hydroxy-4-methoxybenzophenone by Dosed Feed for 13 Weeks.....	39
Figure 4	Body Weights of Mice Exposed Dermally to 2-Hydroxy-4-methoxybenzophenone for 13 Weeks	42

PLATES	34
---------------	-------	----

APPENDICES

Appendix A Organ Weights and Organ-Weight-to-Body-Weight Ratios.....A-1


Appendix B Hematology, Clinical Chemistry, and UrinalysisB-1

Appendix C Reproductive Tissue Evaluations and Estrous Cycle Characterization..... C-1

Appendix D Genetic Toxicology D-1

Appendix E Disposition of 2-Hydroxy-4-methoxybenzophenone in Rats Dosed Orally,
Intravenously, or Topically.....E-1

2-Hydroxy-4-methoxybenzophenone



CAS Number: 131-57-7

Molecular Weight: 228.26

Synonyms: Oxybenzone; 4-Methoxy-2-hydroxy-benzophenone; Cyasorb UV; Uvinul M 40; (2-hydroxy-4-methoxyphenyl)phenylmethanone; NSC-7778; Spectra-sorb UV; Syntase 62; UF 3; USAF CY-9; NCI-C60957

ABSTRACT

2-Hydroxy-4-methoxybenzophenone (HMB) occurs naturally in flower pigments and is synthesized for use in sunscreens, as a UV stabilizer in various cosmetic products, and in plastic surface coatings and polymers. Toxicity studies of HMB were performed in F344/N rats and B6C3F₁ mice, by administering HMB in feed and by topical application, in studies of 2 weeks' (5 animals/sex, dose and species) and 13 weeks' (10 animals/sex, dose and species) duration. Assessments included hematology, clinical chemistry, urinalysis, reproductive toxicity, and histopathologic evaluations.

In both 2- and 13-week dosed feed studies, rats received diets containing 0, 3125, 6250, 12500, 25000, or 50000 ppm HMB. One high-dose female rat died during the 2-week study. Body weight gains of high-dose male and female rats were reduced in the 13-week study. Liver and kidney weights were increased in dosed rats in both studies. In the 2-week studies, enlarged livers were associated with a marked hepatocyte cytoplasmic vacuolization in rats receiving diets containing concentrations of 6250 ppm HMB or higher; renal lesions, consisting of dilated tubules and regeneration of tubular epithelial cells, were found primarily in high-dose rats. In the 13-week studies, kidney lesions progressed to include papillary degeneration, or necrosis, and inflammation, while the liver lesion appeared to regress; liver enzymes in serum remained elevated. Rats receiving a diet with 50000 ppm HMB showed markedly lower epididymal sperm density and an increase in the length of the estrous cycle at the end of the 13-week studies.

In 2-week dermal studies, rats received topical applications of 1.25 to 20 mg of HMB in an acetone or lotion vehicle. The only effects noted were small and variable increases in liver and kidney weights, reaching statistical significance primarily in the higher dose groups. In 13-

week studies, rats received topical doses from 12.5 to 200 mg/kg HMB in acetone. Kidney weights were elevated in dosed groups of female rats. No other findings were attributed to HMB treatment.

In 2- and 13-week dosed feed studies, mice received feed containing 0, 3125, 6250, 12500, 25000, or 50000 ppm HMB. A dose-related increase in liver weight associated with hepatocyte cytoplasmic vacuolization was the only finding in mice in the 2-week studies. Decreased body weight gains were dose-related in mice in the 13-week studies; mild increases in liver weights were seen in dosed mice of both sexes. Kidney weights were increased variably in dosed females. Microscopic lesions were noted only in the kidneys of males receiving 50000 ppm HMB; these included eosinophilic protein casts in dilated renal tubules and a mild inflammation associated with the dilated tubules. Mice in the highest dose group exhibited a decrease in epididymal sperm density and an increase in length of the estrous cycle.

In 2-week dermal studies, mice received topical applications from 0.5 to 8 mg HMB in an acetone or lotion vehicle. The only effects noted were minimal, variable increases in liver and kidney weights, primarily in the higher dose groups. In 13-week studies, mice received topical doses of 22.75 to 364 mg/kg in acetone. Kidney weights were increased variably in dosed male mice. Epididymal sperm density was decreased at all 3 dose levels evaluated (22.75, 91, and 200 mg/kg).

The genetic toxicity of HMB also was evaluated in mutagenicity studies with *Salmonella typhimurium*, in cytogenetic studies with Chinese hamster ovary (CHO) cells, and by evaluation of micronucleated erythrocytes in peripheral blood smears from mice in the 13-week studies. HMB was weakly mutagenic in *Salmonella* with metabolic activation, and induced sister-chromatid exchanges and chromosomal aberrations in CHO cells in the presence of a metabolic activation system. There was no increase in the frequency of micronucleated erythrocytes in the blood of mice receiving HMB.

In summary, HMB produced generally similar effects following topical and oral administration to rats and mice. Consistent findings included decreases in epididymal sperm density, lengthened estrous cycle, and increased liver and kidney weights. Mice in the dosed feed studies exhibited microscopic changes in the kidneys, comprising tubular dilatation with eosinophilic protein casts. Dilatation, tubular regeneration, papillary degeneration, and inflammation were noted in the kidneys of rats; and liver lesions consisting of an apparently reversible hepatocyte cytoplasmic vacuolization occurred in both rats and mice. A no-observed-adverse-effect level (NOAEL) for microscopic lesions was 6250 ppm HMB in the diet for rats and mice. A NOAEL was not reached for decreased epididymal sperm density in the 13-week dermal study in mice (<23 mg/kg/day).

PEER REVIEW

Peer Review Panel

The members of the Peer Review Panel who evaluated the draft report on the toxicity studies on 2-hydroxy-4-methoxybenzophenone on November 21, 1991, are listed below. Panel members serve as independent scientists, not as representatives of any institution, company, or governmental agency. In this capacity, panel members act to determine if the design and conditions of the NTP studies were appropriate and to ensure that the toxicity study report fully and clearly presents the experimental results and conclusions.

National Toxicology Program's Board of Scientific Counselors Technical Reports Review Subcommittee

Paul T. Bailey, PhD
Mobil Oil Corporation
Toxicology Division
Princeton, NJ

David W. Hayden, DVM, PhD
Department of Veterinary Pathobiology
College of Veterinary Medicine
University of Minnesota
St. Paul, MN

Louis S. Beliczky, MS, MPH
Department of Industrial Hygiene
United Rubber Workers Intl. Union
87 South High Street
Akron, OH

Curtis D. Klaassen, PhD (Chair)
Department of Pharmacology and Toxicology
University of Kansas Medical Center
Kansas City, KS

Gary P. Carlson, PhD
Department of Pharmacology and Toxicology
Purdue University
West Lafayette, IN

* Daniel S. Longnecker, MD
Department of Pathology
Dartmouth Medical School
Hanover, NH

Kowetha A. Davidson, PhD
Health and Safety Research Division
Oak Ridge National Laboratory
Oak Ridge, TN

Barbara McKnight, PhD
Department of Biostatistics
University of Washington
Seattle, WA

Harold Davis, DVM, PhD
School of Aerospace Medicine
Brooks Air Force Base, TX

* Ellen K. Silbergeld, PhD
University of Maryland Medical School
Baltimore, MD

Robert H. Garman, DVM
Consultants in Veterinary Pathology
Murrysville, PA

Matthew J. van Zwieten, DVM, PhD
Department of Safety Assessment
Merck, Sharpe & Dohme Research Laboratories
West Point, PA

Jay I. Goodman, PhD
Department of Pharmacology and Toxicology
Michigan State University
East Lansing, MI

Lauren Zeise, PhD
California Department of Health Services
Berkeley, CA

*Could not attend meeting.

Summary of Peer Review Comments

Dr. J.E. French, NIEHS, introduced the short-term toxicity studies of 2-hydroxy-4-methoxybenzophenone (HMB) by reviewing the natural occurrences and uses of HMB, experimental design, and results. Review of unpublished proprietary information as well as FDA files led to the decision to use a sunscreen lotion base as a dose vehicle and to use both oral and dermal routes of exposure. Additionally, liver, kidney, and male and female reproductive organs were identified as target organs; only the kidney had been indicated in published literature.

Dr. Carlson, a principal reviewer, remarked that this report dealt with 8 studies and that a good job was done of handling a lot of data. He suggested that use of the term, "topical application," was more common and would be more correct than "dermal application." Dr. French commented that the NTP historically has used "dermal" as specific to skin, while "topical" could apply to other sites, e.g., the eye. Dr. Carlson noted that liver function was not determined as stated in the abstract, and that the enzyme changes were measures of damage.

Dr. Goodman, a second principal reviewer, commented that the report was well-written and the results clearly presented. He asked that a clearer rationale be given as to why the study was performed in view of the mention in the report that both an FDA panel and the Cosmetic Ingredient Panel concluded that HMB was safe with regard to its current uses. Dr. French responded that HMB was selected from a review of the ether chemical class study and was nominated primarily on the basis of human exposure and as a representative benzophenone derivative used as a UV screen and UV stabilizer. Dr. Goodman said it would be useful to indicate how the doses that produced toxicity compared with the dose one might anticipate from the "safe" human use of HMB. Dr. French remarked that this would be difficult to do; however, at least in the 2-week dermal studies, a lotion vehicle was used with HMB concentrations which represented the maximum amount to be applied in a sunscreen lotion to human skin.

Dr. Carlson commented that there appeared to be too much emphasis placed on the lack of a NOAEL for decreased epididymal sperm density in the 13-week dermal study in mice. Dr. Richard Davis, American Cyanamid, suggested adding other measures of male reproductive function, such as spermatid counts, in addition to sperm density counts. He said that this would improve the consistency in reporting, noting that for the 4 studies being reviewed there was a three-fold range for control groups alone in sperm density. Dr. B. Schwetz, NIEHS, reported that, since the time the HMB studies were conducted, spermatid head counts were being collected as a reflection of the activity of the spermatogenesis process. Dr. French responded that comparisons between reproductive endpoints collected in different laboratories are made, but that primary emphasis is placed on the concurrent control for interpretation and conclusion. [Subsequent studies of the effect of topically applied HMB on sperm production and characteristics in B6C3F₁ mice, sponsored by the Cosmetic Toiletry and Fragrance Association, failed to show statistically significant decreases in epididymal sperm density or other effects on the reproductive system (Daston, G.P. Gettings, S.D., Carlton, B.D. *et al.*,

(1992) Assessment of the reproductive toxic potential of dermally applied 2-hydroxy-4-methoxybenzophenone to male B6C3F₁ mice, Fundam. Appl. Toxicol., in press].

Seeing no objections, Dr. Klaassen accepted the report with the suggested editorial and other changes on behalf of the panel.

INTRODUCTION

Physical Properties, Production, Uses, and Exposure

2-Hydroxy-4-methoxybenzophenone (HMB), an extended phenyl ring ether, is a pale cream-colored powder (technical grade) with a melting point of 66°C and low volatility.

HMB occurs naturally and has been extracted from flower pigments (Stecher, 1958). Commercial use HMB is prepared by the Friedel-Crafts reaction of benzoyl chloride with 3-hydroxyanisole. The product is isolated by organic extraction and re-crystallized from water/methanol and dried (Cosmetic Ingredient Review, 1983a). The 1979 EPA-TSCA inventory of commercial chemicals listed 6 U.S. companies as manufacturers/importers of HMB., with production ranges varying from 0 - 1000 to 100,000 - 1,000,000 pounds per year. The U.S. International Trade Commission (1979) reported 1976 and 1977 production values at 2.4×10^5 kg and 3.6×10^5 kg, respectively.

HMB is used as a UV stabilizer in cosmetic, pharmaceutical, and plastic products. In 1979, the Cosmetic, Toiletry, and Fragrance Association (CTFA) identified 62 different cosmetic products containing HMB; the largest product lines identified were nail polish and enamel (Cosmetic Ingredient Review, 1983a). HMB is used in skin moisturizing products and sunscreen lotions, usually in conjunction with 2, 2'-dihydroxy-4-methoxy-benzophenone (Reynolds, 1982). In plastics manufacturing, HMB is used in surface coatings, and in the following polymers: ABS resins, cellulosic esters, polyesters, polystyrenes, rubber, flexible (plasticized and semi-rigid) and rigid vinyl, and vinylidene chloride (Abramoff, 1978-79).

Exposure to HMB occurs through both occupational and consumer routes. The National Occupational Health Survey conducted by NIOSH in 1972-1974 estimated 549 workers were exposed to the subject chemical during that period. Annual dermal exposure through cosmetic and sunscreen products was estimated in the NCI/SRI data base to be between 1.06×10^3 and 3.6×10^3 kg (NCI/SRI, 1977). HMB is an approved FDA OTC (over-the-counter) category I product. These products are considered to be a deterrent to ultraviolet radiation-induced skin cancer (U.S. FDA, 1978; Klingman *et al.*, 1980; Sayre, 1981; Cripps and de Dennis, 1981; Girard *et al.*, 1982; Folsom *et al.*, 1983).

HMB has been approved for over-the-counter use in sunscreen and other cosmetic preparations (U.S. FDA, 1978). The FDA Panel on Review of Topical Analgesics has proposed that HMB is safe and effective (Category I) at concentrations of 2-6% in over-the-counter use. The FDA has approved HMB for use as an indirect food additive; i.e., it is permitted in the formulation of rigid acrylic and modified acrylic plastics which are components of single- and repeated-use food contact surfaces (Code of Federal Regulations 21 CFR 177.1010, 1978). HMB may be present in concentrations between 0.01% and 0.05% in olefinic polymers as a UV stabilizer or as an antioxidant. The Cosmetic Ingredient Review Expert Panel, established by the Cosmetic, Toiletries, and Fragrance Association, concluded that HMB is safe for topical application to humans in the present practices of use and concentration in cosmetics (Cosmetic Ingredient Review, 1983a).

Human Toxicity

The Cosmetic Ingredient Review (1983a) cites several unpublished studies relevant to HMB under the heading of clinical assessment of safety. These clinical tests were designed to determine skin irritation and sensitivity under conditions of human use and were not in-depth toxicity studies. It was the opinion of the Review's expert panel that the subject chemical and other benzophenones were safe and effective under the conditions of current cosmetic use. Contact dermatitis, with topical photosensitivity reactions and eczematous eruptions, has been reported in one clinical case (Hölzel and Plewig, 1982).

Animal Toxicity

The acute toxicity of HMB is low. For rats, the oral LD₅₀ is greater than 12.8 g/kg (Lewerenz *et al.*, 1972a); the LD₅₀ in rabbits (dermal) is greater than 16.0 g/kg (Cosmetic Ingredient Review, 1983a).

In 13-week toxicity studies (Lewerenz *et al.* 1972b), Wistar rats were fed HMB in the diet at concentrations of 0, 0.02, 0.1, 0.5, and 1.0%. Rats fed the chemical at 0.5 and 1.0% of the diet exhibited depressed growth, leukocytosis, anemia, reduced organ weights, and renal toxicity characterized by tubule dilatation.

The potential of HMB to cause acute irritation was tested on intact and abraded skin of albino rabbits. HMB was reported to be nonirritating to skin at concentrations from 4% to 100% (Hölzle and Plewig, 1982). Phototoxicity and photosensitization of HMB also were studied in albino rabbits. Approximately 24 mg of HMB was applied to the shaved skin. The application site was irradiated with UV light, 5 times per week for 2 weeks (10 applications total). Mild erythema, mild edema, and desquamation were noted, but no phototoxicity was reported. The sensitization potential of HMB was tested in guinea pigs by intradermal application of 2.5 mg HMB with Freund's adjuvant, followed 2 weeks later by a topical application of 2.5 mg in petrolatum at a previously untreated site. No indication of HMB-induced skin sensitization was observed in this limited test.

Absorption, Metabolism, and Distribution

An NTP-sponsored study of ¹⁴C HMB absorption, distribution, and clearance following oral, intravenous, or topical administration demonstrated that this compound is readily absorbed from the gastrointestinal tract and excreted primarily in urine (El Dareer *et al.*, 1986; Appendix E). Absorption from the gastrointestinal tract was nearly complete at all doses administered across a range of approximately 3 mg/kg to 2.5 g/kg. Similarly, metabolism and clearance were unaffected by dose. Only a trace of the parent compound was excreted unmetabolized; HMB was converted to at least five metabolites and excreted in bile and urine. The major metabolites were identified as glucuronide conjugates of the parent compound and 2,4-dihydroxybenzophenone, and a sulfate ester of a hydroxylated derivative of the parent compound. Excretion was rapid following oral or i.v. administration and was nearly complete within 48 hours after administration. Approximately two-thirds of the dose, whether given intravenously or by oral gavage, was excreted in urine. An examination of residues in all major

tissues indicated some retention of HMB-derived material in liver and kidney, but the levels were relatively low, even in these tissues, accounting for less than 0.1% of the dose within 72 hours after exposure (El Dareer *et al.*, 1986).

Dermal absorption was studied by applying HMB, in either ethanol or a lotion formula, to an area of 1 cm². All dermal doses were shielded to prevent removal by grooming. Dermal absorption of low doses applied in ethanol or lotion was appreciable and accounted for approximately 58% of a dose of 0.2 mg/cm², but decreased significantly as the dose increased, accounting for only 20% (approximately) of a dose of 0.8 mg/cm².

Mutagenicity and Structural Activity Relationships

HMB was negative according to an unpublished *Salmonella* mutagenesis assay reviewed by the Cosmetic Ingredient Review Expert Panel (Cosmetic Ingredient Review, 1983b), in tests screening for mutagenic agents in dental materials (Jonsen *et al.*, 1980), and in tests screening for mutagenic agents in sunscreens (Morita *et al.*, 1981; Bonin *et al.*, 1982). The parent compound, benzophenone, also was negative in an NTP *Salmonella* mutagenesis assay (Mortelmans *et al.*, 1986), but both 2,2'-dihydroxy-4-methoxybenzophenone and 4,4'-bis(dimethylamino) benzophenone (Michler's Ketone) were mutagenic. Michler's ketone also was positive in the mouse lymphoma (L5178Y) mutation assay, in *in vitro* cell transformation, in a Rauscher leukemia virus/rat embryo assay, and in an assay for unscheduled DNA synthesis. Michler's ketone caused hepatocellular carcinomas in male and female rats and female mice, and hemangiosarcomas in male mice in 2-year studies (National Cancer Institute, 1979).

Study Rationale and Design

HMB was selected from a review of the ether chemical class study and was nominated, primarily, on the basis of human exposure and as a representative benzophenone derivative used as a UV screen (suntan lotions) and UV stabilizer in cosmetics and plastics. Because the toxicity and potential carcinogenicity of this chemical class is incompletely documented in the literature, or is unknown, the NTP conducted disposition studies of HMB by the dermal, oral, and i.v. routes (El Dareer *et al.*, 1986; Appendix E), and performed 2- and 13-week toxicity studies in F344 rats and B6C3F₁ mice by the dermal and oral routes, including assessments of hematology, clinical chemistry, urinalysis, and the reproductive system. The genetic toxicity of HMB was evaluated in *Salmonella* mutagenicity assays, in Chinese hamster ovary cell cytogenetics assays, and by examination of peripheral blood smears from mice in the 13-week studies for the presence of micronucleated erythrocytes.

MATERIALS AND METHODS

Procurement and Characterization of 2-Hydroxy-4-methoxybenzophenone

The HMB used in these studies was obtained from American Cyanamid Co. (Bridgewater, NJ), and samples were analyzed at Midwest Research Institute (Kansas City, MO). The infrared, ultraviolet/visible, and nuclear magnetic resonance spectra were consistent with the structure of HMB and with available literature references. Elemental analysis results for carbon were slightly high but agreed with theoretical values for hydrogen. Karl Fischer analysis for water indicated less than 0.04%. Analysis by two thin-layer chromatography systems indicated a single spot; no impurities with relative peak areas of greater than 0.1% of the major peak were detected by gas chromatography.

Dose formulation stability studies indicated that acetone solutions of HMB were stable for at least 3 weeks in the dark in sealed vials at room temperature, as were solutions stored for 3 hours open to light and air. HMB also was stable under similar conditions when formulated as part of a lotion comprised of lanolin oil (5.4%), white petrolatum (2.6%), stearic acid (4.3%), propyl paraben (0.05%), propylene glycol (5.4%), methyl paraben triethanolamine (0.1%), disodium EDTA (0.05%), and deionized water (80%). Stability studies conducted on a feed blend indicated a small but significant loss (~2%) after 3 weeks' storage in the dark in sealed containers at room temperature. No significant losses were observed with similar blends kept at 5°C or -20°C. Feed blends stored open to air and light for 3 days in a rat cage exhibited losses (~2%).

Study Design

Male and female F344/N rats and B6C3F₁ mice used in the 2-week studies were obtained from the Frederick Cancer Research Facility (Frederick, MD). Rats and mice used in the 13-week studies were obtained from Taconic Farms (Germantown, NY). Rats were housed 5/cage for the feed study and were housed individually for the dermal studies; mice were housed individually during all studies. Animals received NIH-07 diet (Zeigler Bros., Gardners, PA) and water *ad libitum* throughout the studies. Blood samples were collected, and the sera analyzed for viral titers from 5 animals per sex and species at study start and at termination in the 13-week studies. No positive antibody titers were detected in 5 viral screens performed in rats and 12 viral screens performed in mice (Boorman *et al.*, 1986; Rao *et al.*, 1989a, 1989b). Viral serology procedures for the male mice in the 13-week dermal studies were inadequately documented, and no results were available for males in those studies.

In 2-week dosed feed studies, groups of 5 rats and 5 mice of each sex received diets containing 0, 3125, 6250, 12500, 25000, and 50000 ppm HMB. In dermal studies, the same numbers of rats and mice of each sex received applications of HMB 5 days per week in acetone, while similar groups received applications of the chemical in the lotion. The dermal vehicles were formulated to concentrations of 0, 5, 10, 20, 40, or 80 mg/ml. A constant volume of 0.25 ml for rats and 0.1 ml for mice was applied over a fixed standard area (10%) of the interscapular

region. The area was clipped 24 hours prior to the initial application, and weekly thereafter, with an electric clipper. Complete necropsies were performed on all animals at termination; organ weights were recorded for the brain, liver, right kidney, thymus, heart, lung, and right testicle. Tissues examined microscopically are listed in Tables 1 and 2.

In 13-week studies, groups of 10 rats and 10 mice of each sex received diets containing 0, 3125, 6250, 12500, 25000, and 50000 ppm HMB, or received topical applications of HMB, 5 days per week in acetone, at doses of 0, 12.5, 25.0, 50.0, 100.0, and 200.0 mg/kg body weight for rats, and 0, 22.8, 45.5, 91.0, 182.0, and 364.0 mg/kg body weight for mice. Topical doses were given in a volume equal to 300 μ l/120 g body weight for rats and 100 μ l/120 g body weight for mice. Dosing volume was adjusted weekly based on changes in group mean body weight. When the dosing volume exceeded 300 μ l for rats or 100 μ l for mice, the volume was applied in two equal doses.

Male and female rats were anesthetized with CO₂ and bled from the retroorbital sinus at day 3, day 15, and after week 12 of treatment. Blood samples were collected with EDTA (~0.50 ml) and without EDTA (~0.75 ml) for the analysis of hematologic and biochemical variables, respectively. Prior to blood collection, rats were housed individually overnight (16 hours) in metabolism cages for the collection of urine; animals were provided water, but not food, and collection tubes were immersed in ice/water baths. Urine samples were measured or evaluated for volume, pH, specific gravity, appearance, and microscopic features.

Samples for hematologic determinations were analyzed using a Baker 7000 analyzer (Baker Instruments Corp., Allentown, PA). Platelet counts were measured using a Baker 810 platelet analyzer. Automated measurements and calculations were red blood cell count (RBC), hematocrit (HCT), hemoglobin concentration (HGB), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular hemoglobin (MCH), white blood cell count (WBC), and platelet count. WBC differential counts (absolute) were calculated from relative values determined from microscopic evaluation of Wright's stained blood smears. Reticulocyte counts (absolute) were calculated from relative values determined from the microscopic evaluation of blood smears prepared from samples incubated with equal volumes of blood and new methylene blue.

Biochemical analyses were performed on serum using a Gemini chemistry analyzer (Electro-Nucleonics, Inc., Fairfield, NJ). Except for sorbitol dehydrogenase (SDH), reagents and applications for all assays were obtained from the manufacturer. Reagents for SDH were obtained from Sigma Chemical Co. (St. Louis, MO), and the assay was adapted for the automated analyzer. The remaining analyses were alanine aminotransferase (ALT), alkaline phosphatase (AP), gamma-glutamyl transpeptidase (GGT), urea nitrogen (UN), and creatinine.

Sperm Morphology and Vaginal Cytology evaluations (SMVCE) were performed for rats and mice given diets containing 0, 3125, 12500, and 50000 ppm in the 13-week dosed feed studies. For the dermal studies, evaluations were performed for rats administered 0, 12.5, 50.0, and 200.0 mg/kg and mice administered 0, 22.8, 91.0, and 364.0 mg/kg HMB. Procedures described by Morrissey *et al.* (1988) were used. For the 12 days prior to sacrifice, females were subject to vaginal lavage with saline. The aspirated cells were air-dried onto slides, stained with

Toluidine Blue O, and cover slipped. The relative preponderance of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were used to identify the stages of the estrous cycle.

Sperm motility was evaluated at necropsy as follows: the cauda epididymis was removed at the junction of the vas deferens and the corpus epididymis, and a small cut was made in the distal cauda epididymis. The sperm that extruded from the epididymis were dispersed throughout the solution, cover slipped, and the number of moving and non-moving sperm in 5 fields of 30 sperm or less per field were counted. After sperm sampling for motility evaluation, the cauda was placed in phosphate buffered saline (PBS) and minced; the solution was mixed gently, and heat-fixed at 65°C. Sperm density was subsequently determined using a hemocytometer.

To quantify spermatogenesis, testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in PBS containing 10% DMSO. Homogenization-resistant spermatid nuclei were enumerated using a hemocytometer; the data were expressed as spermatid heads per total testis, and per gram of testis.

Complete necropsies were performed on all animals at termination; organ weights were recorded for the brain, liver, right kidney, thymus, heart, lung, and right testicle. In the dosed feed studies, all tissues from the control and 50000 ppm animals were evaluated microscopically; in the dermal studies, all tissues from the control and high-dose animals were evaluated microscopically. Gross lesions from all dose levels received microscopic evaluation in both studies. Tissues were preserved in 10% neutral buffered formalin and were routinely processed for preparation of histologic sections for microscopic examination. Tissues and groups examined for rats and mice are listed in Tables 1 and 2.

Upon completion of the histologic evaluation by the laboratory pathologist, the slides, paraffin blocks, and residual wet tissues were sent to the NTP Archives for inventory, slide/block match, and wet tissue audit. The slides, individual animal data records, and pathology tables were sent to an independent pathology laboratory where quality assessment was performed; the results were reviewed and evaluated by the NTP Pathology Working Group (PWG). The final diagnoses represent a consensus of contractor pathologists and the PWG. Details of these review procedures have been described by Maronpot and Boorman (1982) and Boorman *et al.* (1985).

Genetic Toxicity

Mutagenicity Studies

Mutagenicity studies of HMB in *Salmonella typhimurium* were conducted as described in Zeiger *et al.* (1988). Briefly, HMB was tested for mutagenicity in *S. typhimurium* strains TA97, TA98, TA100, TA1535, and TA1537, using a preincubation assay in both the absence or presence of Aroclor 1254-induced S9 from male Syrian hamster liver or male Sprague-Dawley rat liver. HMB was tested at doses up to 1000 µg/plate. Higher concentrations were toxic to the cells. A positive response was defined as a reproducible, dose-related increase in histidine-independent (revertant) colonies in any one strain/activation combination. An equivocal

response was defined as an increase in revertants which was not dose-related, not reproducible, or was of insufficient magnitude to support a determination of mutagenicity. A negative response was obtained when no increase in revertant colonies has observed following chemical treatment.

Chinese Hamster Ovary Cytogenetics Assays

Testing was performed as reported by Galloway *et al.* (1985, 1987). Briefly, Chinese hamster ovary cells (CHO) were incubated with HMB or solvent (dimethylsulfoxide) for induction of sister-chromatid exchanges (SCE) and chromosomal aberrations (ABS) both in the presence and absence of Aroclor 1254-induced male Sprague-Dawley rat liver S9 and cofactor mix. Additional details are provided in Appendix D.

Mouse Peripheral Blood Micronucleus Assays

At the termination of the 13-week study, blood smears were prepared from peripheral blood samples obtained from the retroorbital sinus of all dosed and control mice. The slides were stained with Hoechst 33258/pyronin Y (MacGregor *et al.*, 1983). Ten thousand normochromatic erythrocytes from each animal were scored for micronuclei.

Statistical Methods

Analysis of Continuous Variables

Two approaches were employed to assess the significance of pairwise comparisons between dosed and control groups in the analysis of continuous variables. Organ and body weight data, which are approximately normally distributed, were analyzed using the parametric multiple comparisons procedures of Williams (1971, 1972) and Dunnett (1955). Clinical chemistry and hematology data, which typically have skewed distributions, were analyzed using the nonparametric multiple comparisons methods of Shirley (1977) and Dunn (1964). Jonckheere's test (Jonckheere, 1954) was used to assess the significance of dose-response trends and to determine whether a trend-sensitive test (Williams, Shirley) was more appropriate for pairwise comparisons than a test capable of detecting departures from monotonic dose-response (Dunnett, Dunn). If the P-value from Jonckheere's test was greater than or equal to 0.10, Dunn's or Dunnett's test was used rather than Shirley's or Williams' test.

The outlier test of Dixon and Massey (1951) was employed to detect extreme values. No value selected by the outlier test was eliminated unless it was at least twice the next largest value or at most half of the next smallest value.

Analysis of Vaginal Cytology Data

Since these data are proportions (the proportion of the observation period that an animal was in a given estrous state), an arcsine transformation was used to bring the data into closer conformance with normality assumptions. Treatment effects were investigated by applying a

Multivariate analysis of variance (Morrison, 1976) to the transformed data to test for the simultaneous equality of measurements across dose levels.

Analysis of CHO Cytogenetics Assays

Statistical analyses were conducted on both the slopes of the dose-response curves and the individual dose points. An SCE frequency 20% above the concurrent solvent control value was chosen as a statistically conservative positive response (Margolin *et al.*, 1986). The probability of this level of difference occurring by chance at one dose point is less than 0.01; the probability for such a chance occurrence at two dose points is less than 0.001. A single increased dose was considered weak evidence of a positive response (+W); two increased doses were sufficient to evaluate the trial as positive (+). Chromosomal aberration data are presented as percentage of cells with aberrations. Both the dose-response and individual dose points were statistically analyzed. For a single trial, a statistically significant ($P < 0.05$) increase for one dose point and a significant trend ($P < 0.015$) was considered weak evidence for a positive response (W+); significant increases for two or more doses indicated the trial was positive (+) (Galloway *et al.*, 1987).

Analysis of Micronucleus Data

Statistical analyses for micronuclei were performed using linear trend tests on log-transformed data for normochromatic erythrocytes. The frequency of micronuclei in the dosed groups was compared with the frequency determined for the concurrent untreated control animals using Student's t-test.

Quality Assurance

The studies of HMB were performed in compliance with FDA Good Laboratory Practices regulations (Code of Federal Regulations 21 CFR 58). The Quality Assurance Unit of EG&G Mason performed audits and inspections of protocols, procedures, data, and reports throughout the course of the studies. The operations of the Quality Assurance Unit were monitored by the NTP.

TABLE 1 Materials and Methods and Experimental Design in the 2-Week and 13-Week Dosed Feed and Dermal Studies of 2-Hydroxy-4-methoxybenzophenone

ANIMALS AND ANIMAL MAINTENANCE	
Strain and Species	F344/N rats B6C3F ₁ mice
Animal Source	2-Week Studies: Frederick Cancer Research Facilities, Frederick, MD 13-Week Studies: Taconic Farms, Germantown, NY
Study Laboratory	EG&G Mason Research Institute, Worcester, MA
Time Held Before Study	2-Week Studies, Dosed Feed: 10-12 days 13-Week Studies, Dosed Feed: Male rats – 11-12 days; Female rats--18-19 days; Mice--13-14 days 2-Week Studies, Dermal: Male rats--12-14 days; Female Rats--13 -15 days; Male mice--11-12 days; Female mice--13 days 13-Week Studies, Dermal: Male rats--11-12 days; Female Rats--18-19 days; \ Mice--13-14 days
Age When Placed on Study	2-Week Studies: 6 wks 13-Week Studies: Male rats--6 wks; Female rats--7 wks; Mice--44-45 days
Age When Killed	2-Week Studies: 8 wks 13-Week Studies: Male rats -- 19 wks; Female rats -- 20 wks; Mice--19 wks
Method of Animal Distribution	Animals assigned to groups using a stratified weight method and then assigned to study groups in random order
Diet	NIH-07 Open Formula, <i>ad libitum</i> Zeigler Bros., Gardners, PA
Animal Room Environment	Temp--72 ± 3°F; relative humidity--50 ± 15%; fluorescent light 12 h/d; 10 air changes/h.
EXPERIMENTAL DESIGN	
Size of Study Groups	2-Week Studies, Dosed Feed: 5/sex/group of each species. Rats were housed 5 per cage, and mice were individually housed. 13-Week Studies, Dosed Feed: 10/sex/group of each species. Rats were housed 5 per cage, and mice were individually housed. 2-Week Studies, Dermal: 5/sex/group of each species. Rats and mice were individually housed. 13-Week Studies, Dermal: 10/sex/group of each species. Rats and mice were individually housed.
Doses/Duration of Dosing	2-Week Studies, Dosed Feed: 0, 3125, 6250, 12500, 25000, and 50000 ppm in the feed 13-Week Studies, Dosed Feed: 0, 3125, 6250, 12500, 25000, and 50000 ppm in the feed 2-Week Studies, Dermal: Doses administered dermally in an acetone or lotion vehicle in a constant volume of 0.25 ml for rats and 0.1 ml for mice: Rats--0, 1.25, 2.5, 5, 10, or 20 mg, Mice--0, 0.5, 1.0, 2, 4, or 8 mg 13-Week Studies, Dermal: Doses administered dermally in an acetone vehicle in a constant volume of 0.25 ml for rats and 0.1 ml for mice: Rats--0, 12.5, 25.0, 50.0, 100.0, and 200.0 mg/kg body weight; Mice--0, 22.8, 45.5, 191.0, 182, and 364 mg/kg body weight.

TABLE 1 Materials and Methods and Experimental Design in the 2-Week and 13-Week Dosed Feed and Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)

Type and Frequency of Observation	<p>2-Week Studies, Dosed Feed: Observed 2 x d for mortality/moribundity; 1 x wk for clinical signs of toxicity; food consumption measured weekly; weighed initially, after first week, at termination of dosing period, and at necropsy.</p> <p>13-Week Studies, Dosed Feed: Observed 2 x d for mortality/moribundity; 1 x wk for clinical signs of toxicity; food consumption measured weekly; weighed initially, weekly, and at necropsy.</p> <p>2-Week Studies, Dermal: Observed 2 x d for mortality/moribundity; 1 x wk for clinical signs of toxicity; site of application examined weekly; weighed initially, after the first week, and at necropsy.</p> <p>13-Week Studies, Dermal: Observed 2 x d for mortality/moribundity; 1 x wk for clinical signs of toxicity; site of application examined weekly; weighed initially, weekly, and at necropsy.</p>
Necropsy and Histologic Examinations	<p>Necropsy performed on all animals; the following tissues were examined microscopically from all high dose and controls:</p> <p>2-Week Studies Gross lesions, adrenal gland, brain, esophagus, femur with bone marrow, gall bladder (mice), heart, intestine (duodenum, jejunum, ileum, cecum, colon, rectum), kidney, liver, lungs and bronchi, mandibular and mesenteric lymph nodes, mammary gland with adjacent skin, nasal cavity and turbinates, ovary, pancreas, parathyroid, pituitary, preputial or clitoral gland (rats only) prostate, salivary gland, seminal vesicle, spleen, stomach (forestomach and glandular), testis and epididymis, thymus, thyroid, trachea, urinary bladder, uterus. Other tissues examined: skin (application site)(dermal studies,only)</p> <p>13-Week Studies Gross lesions, adrenal gland, brain, esophagus, eyes (if grossly abnormal), femur with bone marrow, gall bladder (mice), heart, intestine (duodenum, jejunum, ileum, cecum, colon, rectum), kidney, liver, lungs and bronchi, mandibular and mediastinal lymph nodes, nasal cavity with turbinates, ovary, pancreas, parathyroid, pituitary, preputial or clitoral gland (rats only), prostate, salivary gland, seminal vesicle, spinal cord (if neurologic signs present), spleen, stomach (forestomach and glandular), testis and epididymis, thymus, thyroid, trachea, urinary bladder, uterus. In addition to all gross lesions, the kidney was examined in all dose groups. Organ weights obtained from all core study animals include: liver, thymus, right kidney, right testis, heart, and lungs.</p>
Supplemental Evaluations	<p>Hematology, Clinical Chemistry, and Urinalysis: Hematology, clinical chemistry, and urinalysis were evaluated in rats, only, on day 3, day 15, and week 12.</p> <p>Sperm Morphology/Vaginal Cytology: Dosed Feed: sperm morphology and vaginal cytology were evaluated in rats and mice exposed to 0, 3125, 12500, and 50000 ppm HMB. Dermal: sperm morphology and vaginal cytology were evaluated in rats exposed to 0, 12.5, 50.0, and 200.0 mg/kg HMB and in mice exposed to 0, 22.8, 91.0, and 364.0 mg/kg HMB.</p>

RESULTS

2-Week Dosed Feed Studies in Rats

One female rat in the 50000 ppm dose group died on day 8; the cause of death could not be determined. No clinical observations or gross pathological changes were noted that were considered related to chemical exposure. Feed consumption of male and female rats given diet containing 50000 ppm HMB was reduced compared to controls, and body weight gains of male rats also were decreased (Table 2).

TABLE 2 Survival, Weight Gain, and Feed Consumption of F344/N Rats in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone

Dose (ppm) In Feed	Survival ^a	Mean Body Weight (grams)			Final Weight Relative to Controls (%) ^c	Average Feed Consumption ^d	Estimated Chemical Consumed ^e
		Initial	Final	Change ^b			
MALE							
0	5/5	123.6	203.9	80.3		15.8	
3125	5/5	122.7	208.6	85.9	102	15.8	295
6250	5/5	122.1	208.7	86.6	102	15.8	589
12500	5/5	122.5	209.3	86.8	103	15.5	1159
25000	5/5	120.8	200.2	79.4	98	14.7	2259
50000	5/5	125.1	178.2	53.1	87	12.9	4210
FEMALE							
0	5/5	100.5	135.6	35.1		10.9	
3125	5/5	104.8	133.8	29.0	99	12.0	311
6250	5/5	100.8	131.2	30.4	97	10.6	564
12500	5/5	102.1	139.9	37.8	103	10.8	1104
25000	5/5	103.1	141.4	38.3	104	11.0	2218
50000	4/5	103.1	139.7	36.6	103	8.7	3527

^a Number surviving to study termination / number of animals per group.

^b Mean weight change of the animals in each dose group.

^c [Dosed group mean / control group mean] x 100.

^d Food consumption is given in grams/animal/day.

^e Time-weighted compound consumption = average compound consumed during the 2-week study (mg/kg body weight/day).

Marked increases in liver weights were seen in dosed male and female rats; kidney weights were increased in dosed male rats (Table 3). Increased liver weights were associated with the presence of cytoplasmic vacuolization of hepatocytes in males and females in the 6250 ppm and higher dose groups. This change was characterized by an irregular perinuclear vacuolization of the cytoplasm, resembling that typically observed after cytoplasmic glycogen deposits are dissolved during tissue processing for histopathologic examination. However, this vacuolization was much more extensive than that which occurred in the control and low dose groups. Special stains for fat and glycogen did not reveal a difference between livers from dosed and control animals.

Chemically-related microscopic lesions in the kidney were limited to male rats given feed containing 50000 ppm HMB. Focal dilatation of renal tubules in the cortex and/or medulla (Plate 1) was present in 4/5 male rats. Minimal to mild regeneration of the renal tubular epithelium, associated with these foci, was present in 3 of these rats; a focal area of necrosis in the renal papilla was present in 1 rat (Plate 2).

TABLE 3 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone^a

Dose	0 ppm	3125 ppm	6250 ppm	12500 ppm	25000 ppm	50000 ppm
MALE						
n	5	5	5	5	5	5
Necropsy body wt	203.9 ± 2.4	208.6 ± 5.2	208.7 ± 2.9	208.6 ± 5.8	200.2 ± 3.5	178.2 ± 3.3
R. Kidney						
Absolute	0.955 ± 0.017	1.058 ± 0.047	1.067 ± 0.014**	1.092 ± 0.039*	1.006 ± 0.030	0.996 ± 0.021
Relative	4.686 ± 0.055	5.073 ± 0.017	5.118 ± 0.040**	5.229 ± 0.050**	5.024 ± 0.135*	5.590 ± 0.105**
Liver						
Absolute	10.22 ± 0.39	12.65 ± 0.30**	13.74 ± 0.43**	16.15 ± 0.69**	16.84 ± 0.68**	16.61 ± 0.74**
Relative	50.1 ± 1.4	60.7 ± 0.8**	65.8 ± 1.3**	77.3 ± 2.0**	84.0 ± 2.0**	93.2 ± 3.4**
FEMALE						
n	5	5	5	5	5	4
Necropsy body wt	135.6 ± 1.6	133.8 ± 2.4	131.2 ± 2.2	139.9 ± 1.7	141.4 ± 2.1	139.7 ± 2.8
R. Kidney						
Absolute	0.688 ± 0.011	0.733 ± 0.082	0.685 ± 0.0423	0.729 ± 0.020	0.735 ± 0.030	0.748 ± 0.049
Relative	4.099 ± 0.150	4.460 ± 0.387	4.152 ± 0.349	4.430 ± 0.191	4.452 ± 0.238	4.570 ± 0.409
Liver						
Absolute	6.60 ± 0.21	6.54 ± 0.32	7.72 ± 0.27*	9.14 ± 0.20**	10.28 ± 0.21**	11.36 ± 0.47**
Relative	48.7 ± 1.6	48.8 ± 1.7	58.8 ± 1.9**	65.4 ± 1.4**	72.8 ± 2.2**	81.2 ± 1.9**

^a Organ weights and body weights are given in grams; organ-weight-to-body weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Student's t-test. (P 0.05).

** Significantly different from the control group by Student's t-test. (P 0.01).

13-Week Dosed Feed Studies in Rats

One low dose male rat was killed accidentally during the first week; there were no other deaths during the study (Table 4). Dose-related decreases in growth (Figure 1) and in final body weights were noted in male and female rats (Table 4). Chemically-related clinical signs were limited to urine-stained fur in the perineal area and a dark yellow to opaque-greenish urine.

At necropsy, chemically-related gross lesions were observed in the two highest dose groups of male rats and in the highest dose group of female rats. The kidneys were enlarged and had an abnormal shape and granular surface. In some animals both kidneys were affected, while in others, the changes were limited to one kidney. Absolute and relative right kidney weights were increased in males in the 50000 ppm group and in females in the 25000 and 50000 ppm groups (Table 5; Appendix A3).

Histopathologic lesions in the kidney of male and female rats were similar, consisting of dilatation of renal tubules, regeneration of tubule epithelial cells, papillary degeneration or necrosis, and inflammation (Table 6). The most prominent lesion was dilatation of the renal tubules (Plate 3), the severity of which was greater in males than in females, occurring in

TABLE 4 Survival, Weight Gain, and Feed Consumption of F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone

Dose (ppm) In Feed	Survival ^a	Mean Body Weight (grams)			Final Weight Relative to Controls (%) ^c	Average Feed Consumption ^d	Estimated Chemical Consumed ^e
		Initial	Final	Change ^b			
MALE							
0	10/10	116	333	217		16.4	
3125	9/10	115	335	220	101	16.9	213
6250	10/10	115	321	206	96	16.5	429
12500	10/10	114	318	204	95	16.6	875
25000	10/10	116	295	179	89	16.5	1805
50000	10/10	114	228	114	68	14.0	3656
FEMALE							
0	10/10	130	200	70		11.2	
3125	10/10	130	196	66	98	10.8	196
6250	10/10	130	190	60	95	10.6	393
12500	10/10	128	178	50	89	10.3	780
25000	10/10	129	179	50	90	10.4	1599
50000	10/10	131	171	40	86	10.2	3261

^a Number surviving to study termination / number of animals per group.

^b Mean weight change of the animals in each dose group.

^c [Dosed group mean / control group mean] x 100.

^d Food consumption is given in grams/animal/day.

^e Time-weighted compound consumption = average compound consumed during the 13-week study (mg/kg body weight/day).

TABLE 5 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone^a

Dose	0 ppm	3125 ppm	6250 ppm	12500 ppm	25000 ppm	50000 ppm
MALE						
n	10	9	10	10	10	10
Necropsy body wt	334 ± 5	333 ± 6	327 ± 6	321 ± 6	299 ± 7**	230 ± 9**
R. Kidney						
Absolute	1.26 ± 0.03	1.39 ± 0.03	1.42 ± 0.04	1.44 ± 0.03	1.48 ± 0.04	2.11 ± 0.32**
Relative	3.76 ± 0.07	4.19 ± 0.09	4.33 ± 0.05	4.49 ± 0.07	4.96 ± 0.09	9.73 ± 1.84**
Liver						
Absolute	14.41 ± 0.42	16.38 ± 0.32*	17.64 ± 0.56**	18.11 ± 0.46**	17.55 ± 0.80**	15.68 ± 0.71**
Relative	43.1 ± 0.97	49.2 ± 0.74**	53.9 ± 1.0**	56.5 ± 0.86**	58.5 ± 1.95**	68.3 ± 1.42**
FEMALE						
n	10	10	10	10	10	10
Necropsy body wt	186 ± 6	187 ± 2	188 ± 3	175 ± 3	181 ± 3	165 ± 3**
R. Kidney						
Absolute	0.781 ± 0.018	0.759 ± 0.011	0.851 ± 0.016	0.777 ± 0.010	0.857 ± 0.012*	0.842 ± 0.029*
Relative	4.23 ± 0.12	4.05 ± 0.07	4.52 ± 0.06	4.44 ± 0.06	4.74 ± 0.04**	5.10 ± 0.16**
Liver						
Absolute	6.97 ± 0.17	7.76 ± 0.18**	8.12 ± 0.07**	7.91 ± 0.21**	9.29 ± 0.21**	9.10 ± 0.24**
Relative	37.7 ± 1.22	41.4 ± 0.84**	43.2 ± 0.73**	45.1 ± 0.79**	51.3 ± 0.87**	55.00 ± 0.97**

^a Organ weights and body weights are given in grams; organ-weight-to-body weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Williams' or Dunnett's test. (P 0.05).

** Significantly different from the control group by Williams' or Dunnett's test. (P 0.01).

TABLE 6 Histopathologic Lesions in F344/N Rats in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone^a

Dose (ppm)	0	3 125	6 250	12 500	25 000	50 000
MALE						
Kidney						
Papilla						
necrosis	0	0	0	0	0	4 (2.3)
Interstitial						
inflammation	0	0	0	0	0	10 (2.2)
Renal tubule						
dilatation	0	0	0	3 (1.0)	10(1.2)	10 (2.8)
regeneration	9 (1.0)	9 (1.2)	10 (1.1)	10 (2.0)	10 (2.0)	10 (2.0)
FEMALE						
Kidney						
Papilla						
necrosis	0	0	0	0	0	5 (2.0)
degeneration	0	0	0	0	1 (1.0)	0
Interstitial						
inflammation	0	0	0	0	0	2 (1.5)
Renal tubule						
dilatation	0	0	0	0	0	9 (2.1)
regeneration	0	0	0	0	0	5 (2.0)

^a Incidence and severity score () based on a scale of 1 to 4; 1 = minimal, 2 = mild, 3 = moderate, 4 = marked. Severity scores are averages based on the number of animals with lesions from groups of 10.

at all exposure levels. The entire length of the nephron was generally affected, with dilated tubules present in the cortex, outer, and inner medulla. In kidneys with minimal to mild dilatation, there generally was a focal distribution of the lesion in which much of the kidney appeared relatively unaffected (Plates 3 and 5). The majority of the tubules from some of the more severely affected kidneys in the 50000 ppm groups of male and female rats were dilated and often contained protein casts and cell debris; more extensively dilated tubules were lined by a flattened epithelium. Renal tubule epithelial cell regeneration increased in severity and/or incidence in groups of rats with tubule dilatation. At the highest dose, particularly in male rats, there was mild to moderate inflammation with fibrosis in the renal interstitium. The cellular infiltrate was a mixture of neutrophils, lymphocytes, and macrophages. Necrosis of the tip of the renal papilla was also present in highest dose males and females (Plate 4). Adjacent to the area of papillary necrosis, there was minimal hyperplasia of the cuboidal epithelium on the surface of the renal papilla or the transitional epithelium of the renal pelvis. There was no evidence of inflammation or hyperplasia of the transitional epithelium of the urinary bladder in male or female rats.

Both absolute and relative liver weights increased markedly in a dose-related fashion in males and females (Table 5, Appendix A3). There were no histopathologic changes associated with the weight increase, but changes in activities of hepatic enzymes in serum occurred (described below).

In hematologic evaluations, male rats given 25000 or 50000 ppm HMB exhibited significant increases in platelet counts beginning at day 3 of the study and persisting at day 15 and week 12. Similar responses occurred in the 12500 ppm dose groups at day 15 and week 12 as well as in the 2 lower dose groups at day 15 (Appendix B). Sporadic increases occurred during the study in counts of segmented neutrophils and reticulocytes. There were increases in serum




Figure 1 Body Weights of F344/N Rats Exposed to 2-Hydroxy-4-methoxybenzophenone by Dosed Feed for 13 Weeks

concentrations of UN at 3 and 15 days (50000 ppm dose groups), and increases in activities of serum ALT at 3 days (6250 to 50000 ppm groups) and in serum GGT at all time points (50000 ppm and lower dose groups at 15 days). Urine volume in male rats was increased in animals at 15 days and 12 weeks (50000 ppm group), and specific gravity was increased at 3 days and decreased at 12 weeks (50000 ppm) (Appendix B).

In female rats, there were increases in HCT, HGB concentration, MCHC, and RBC count at 3 days in animals treated with 6250 to 50000 ppm HMB (25000 and 50000 ppm for MCHC). Other hematologic findings included decreases in HGB concentration at 15 days and decreases in MCV at 3 days and 12 weeks. Significant changes in serum enzyme activities in treated female rats included minimal to mild increases in ALT at 3 days (25000 and 50000 ppm) and in SDH at 12 weeks (all treatment groups). GGT increased in female rats at 15 days (25000 and 50000 ppm) and 12 weeks (all treatment groups). Urine volume was increased in female rats at 15 days and 12 weeks (50000 ppm), and specific gravity was increased at 3 days (25000 and 50000 ppm).

In reproductive system evaluations, a significant decrease in epididymal sperm density and a non-significant increase in the percentage of abnormal sperm were observed in male rats. An increase in the length of the estrous cycle was seen in female rats receiving the highest concentration of HMB in the diet (Appendix C).

2-Week Dermal Studies in Rats, with Acetone and Lotion Vehicles

All animals survived to the end of the studies. There were no changes observed in body weight gains, food consumption, clinical observations, necropsy findings, or by histologic examination of all tissues including skin samples from the site of application for male or female rats with HMB applied to the skin in either the acetone or lotion vehicle. Liver weights were slightly increased in female rats given HMB in acetone and in lotion at the 3 highest dose levels (Tables 8, 9). Smaller increases also were noted in the liver weights of male rats given the higher doses of HMB in lotion. Kidney weights were minimally increased in male rats given the highest dose of HMB in lotion and in female rats given the highest dose in acetone. There were no discernible histopathologic changes associated with the increases in liver or kidney weights.

TABLE 7 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Acetone^a

Dose (mg)	0	1.25	2.50	5.00	10.00	20.00
MALE (n=5)						
Necropsy body wt	213 ± 4	207 ± 3	218 ± 4	210 ± 1	214 ± 3	213 ± 4
R. Kidney						
Absolute	1.08 ± 0.03	1.05 ± 0.04	1.08 ± 0.05	1.02 ± 0.02	1.06 ± 0.08	1.10 ± 0.03
Relative	5.06 ± 0.05	5.06 ± 0.13	4.93 ± 0.16	4.87 ± 0.10	5.01 ± 0.08	5.17 ± 0.07
Liver						
Absolute	12.75 ± 0.32	12.16 ± 0.17	13.20 ± 0.47	11.65 ± 0.70	12.71 ± 0.15	13.84 ± 0.69
Relative	59.82 ± 0.76	58.79 ± 0.13	60.34 ± 1.17	55.45 ± 3.25	59.22 ± 0.57	64.76 ± 2.14
FEMALE (n=5)						
Necropsy body wt	145 ± 3	150 ± 1	150 ± 3	151 ± 3	150 ± 3	151 ± 2
R. Kidney						
Absolute	0.73 ± 0.019	0.75 ± 0.02	0.77 ± 0.018	0.76 ± 0.03	0.77 ± 0.023	0.80 ± 0.015
Relative	5.06 ± 0.10	4.96 ± 0.13	5.16 ± 0.12	5.06 ± 0.09	5.11 ± 0.09	5.30 ± 0.04*
Liver						
Absolute	6.68 ± 0.27	7.06 ± 0.10	7.14 ± 0.18	7.71 ± 0.30*	7.89 ± 0.29*	7.75 ± 0.19*
Relative	46.06 ± 1.50	47.01 ± 0.36	47.75 ± 1.32	51.10 ± 0.98*	53.26 ± 1.66*	51.27 ± 0.73*

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Student's t-test (P 0.05).

** Significantly different from the control group by Student's t-test (P 0.01).

TABLE 8 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Lotion^a

Dose (mg)	0	1.25	2.50	5.00	10.00	20.00
MALE (n=5)						
Necropsy body wt	202 ± 4	212 ± 3	204 ± 3	210 ± 5	206 ± 5	211 ± 3
Kidney						
Absolute	1.05 ± 0.04	1.11 ± 0.02	1.08 ± 0.02	1.07 ± 0.04	1.09 ± 0.02	1.14 ± 0.02*
Relative	5.18 ± 0.12	5.22 ± 0.06	5.28 ± 0.08	5.09 ± 0.07	5.28 ± 0.07	5.43 ± 0.07
Liver						
Absolute	12.26 ± 0.16	13.40 ± 0.33*	12.41 ± 0.28	13.88 ± 0.36**	13.16 ± 0.62	13.80 ± 0.34**
Relative	61.30 ± 0.65	63.06 ± 0.91	60.76 ± 0.48	66.08 ± 0.63**	63.89 ± 0.18	65.41 ± 0.78**
FEMALE (n=5)						
Necropsy body wt	141 ± 2	138 ± 2	141 ± 2	143 ± 3	142 ± 1	139 ± 2
R. Kidney						
Absolute	0.75 ± 0.01	0.72 ± 0.01*	0.78 ± 0.01	0.78 ± 0.02	0.77 ± 0.01	0.76 ± 0.02
Relative	5.30 ± 0.07	5.18 ± 0.01	5.50 ± 0.07	5.48 ± 0.11	5.42 ± 0.08	5.48 ± 0.10
Liver						
Absolute	7.19 ± 0.16	7.24 ± 0.03	7.50 ± 0.21	7.70 ± 0.31	7.87 ± 0.19*	7.93 ± 0.15**
Relative	51.18 ± 1.01	52.41 ± 0.48	53.20 ± 1.58	53.93 ± 1.30	55.40 ± 0.99*	56.91 ± 0.54**

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Student's t-test (P 0.05).

** Significantly different from the control group by Student's t-test (P 0.01).

13-Week Dermal Studies in Rats, with the Acetone Vehicle

All animals survived to the end of the studies. No chemically-related changes were observed in body weight gains (Figure 2), food consumption, clinical observations, reproductive system evaluations (Appendix C), necropsy findings, or by histologic examination of skin samples from the site of application. Relative kidney weights were increased in a non-dose-related manner in female rats treated topically with 25 mg/kg or larger doses of HMB (Table 9; Appendix A1).

In male rats, there were no changes that were considered chemically-related in serum hematologic, biochemical, or urinary variables at any time point (Appendix B). In female rats, there were decreases in reticulocyte counts in animals in all dose groups at 12 weeks, increases in platelet counts in animals in the 50, 100, and 200 mg/kg dose groups at 15 days, and an increase in WBC count produced by a lymphocytosis in the 200 mg/kg group at 12 weeks. There were no relevant changes in biochemical or urinalysis variables in female rats at any time point.

TABLE 9 **Kidney and Organ-Weight-to-Body-Weight Ratios of F344/N Rats in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone^a**

Dose (mg/kg)	0.0	12.5	25.0	50.0	100.0	200.0
MALE (n=10)						
Necropsy body wt.	313 ± 7	303 ± 7	310 ± 8	313 ± 7	312 ± 9	314 ± 5
R. Kidney						
Absolute	1.23 ± 0.03	1.19 ± 0.04	1.34 ± 0.04	1.22 ± 0.04	1.34 ± 0.02	1.22 ± 0.03
Relative	3.93 ± 0.06	3.92 ± 0.10	4.34 ± 0.07**	3.90 ± 0.09	4.30 ± 0.09*	3.89 ± 0.07
FEMALE (n=10)						
Necropsy body wt.	193 ± 4	181 ± 3	183 ± 3	188 ± 4	186 ± 4	182 ± 4
R. Kidney						
Absolute	0.781 ± 0.029	0.832 ± 0.017	0.862 ± 0.012*	0.817 ± 0.023	0.892 ± 0.013**	0.797 ± 0.017
Relative	4.04 ± 0.12	4.61 ± 0.10	4.72 ± 0.09**	4.35 ± 0.06**	4.80 ± 0.07**	4.38 ± 0.09*

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Statistically significant from the control group by Williams' or Dunnett's test (P 0.05).

** Statistically significant from the control group by Williams' or Dunnett's test (P 0.01).




Figure 2 Body Weights of F344/N Rats Exposed Dermally to 2-Hydroxy-4-methoxybenzophenone for 13 Weeks

2-Week Dosed Feed Studies in Mice

All animals survived to the end of the studies (Table 10). No clinical signs were noted that could be clearly related to chemical administration. Body weight gains were variable, but only in female mice receiving feed containing 50000 ppm HMB did weight gains clearly appear to be decreased because of the chemical. Feed consumption was increased somewhat at higher HMB concentrations, but the data were not corrected for scattering of feed. A dose-related increase was seen in liver weights in male and female mice; a decrease was seen in right kidney weights in male mice in the top 2 dose groups (Table 11).

TABLE 10 Survival, Weight Gain, and Feed Consumption of B6C3F₁ Mice in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone

Dose (ppm) In Feed	Survival(a)	Mean Body Weight (grams)			Final Weight Relative to Controls (percent) (c)	Average Feed Consumption (d)	Estimated Chemical Consumed (e)
		Initial	Final	Change (b)			
MALE							
0	5/5	19.2	21.6	2.4		5.0	
3125	5/5	20.0	22.1	2.1	102	6.8	992
6250	5/5	19.7	22.3	2.6	103	6.0	1752
12500	5/5	19.4	22.0	2.6	102	6.6	3947
25000	5/5	19.5	22.1	2.6	102	6.3	7438
50000	5/5	19.3	22.7	3.4	105	7.9	18624
FEMALE							
0	5/5	16.5	18.7	2.2		5.2	
3125	5/5	16.9	18.9	2.0	101	6.1	1050
6250	5/5	16.7	19.6	2.9	105	6.9	2330
12500	5/5	16.1	18.9	2.8	101	7.0	4914
25000	5/5	16.8	18.5	1.7	99	7.1	9859
50000	5/5	16.7	18.0	1.3	96	8.1	22968

a Number surviving to study termination / number of animals per group.

b Mean weight change of the animals in each dose group.

c $[\text{Dosed group mean} / \text{control group mean}] \times 100$.

d Food consumption is given in grams/animal/day.

e Time-weighted compound consumption = average compound consumed during the 2-Week study (mg/kg body weight/day).

Increased liver weights were associated with the presence of cytoplasmic vacuolization of hepatocytes in males and females in the 6250 ppm and higher dose groups; this change was also present in one female mouse in the 3125 ppm group. The morphologic appearance of the hepatocyte vacuolization was the same as that described for the rat in 2-week feed studies in that it was characterized by an irregular perinuclear vacuolization of the cytoplasm which was centrilobular to diffuse in distribution, and likely represented areas of glycogen deposition that had been dissolved during tissue processing. Special stains for glycogen did not demonstrate differences between the groups. There were no microscopic lesions associated with the increased kidney weights.

Plates

Plate 1. Kidney from male rat exposed to 50000 ppm 2-hydroxy-4-methoxybenzophenone in the diet for two weeks. A focal area of tubular dilatation (outlined by arrows) extends from the outer stripe of the outer medulla to the tip of the papilla. Detail of area in [] (lower right of photomicrograph) is shown in Plate 2. H&E 10X.

Plate 2. Higher magnification of papilla from kidney in Plate 1 shows focal necrosis (N) at the tip of the papilla and hyperplasia of the cuboidal epithelium (arrows) at the margin of the area of necrosis. H&E 110X.

Plate 3. Kidney from male rat exposed to 25000 ppm 2-hydroxy-4-methoxybenzophenone in the diet for 13 weeks. Focal wedge-shaped area of tubular dilatation (outlined by arrows) extends from the capsular surface to the inner medulla. Papillary degeneration or necrosis was not present in this rat. H&E 10X.

Plate 4. Kidney from female rat exposed to 50000 ppm 2-hydroxy-4-methoxybenzophenone in the diet for 13 weeks. There is necrosis of the entire tip (arrows) of renal papilla and minimal hyperplasia of the transitional epithelium of the renal pelvis at the top right. H&E 60X.

Plate 5. Kidney from female rat exposed to 50000 ppm 2-hydroxy-4-methoxybenzophenone in the diet for 13 weeks. Detail of junction between normal (N) tubules and focal area of dilatation consisting of distended tubules lined by flattened epithelium. H&E 135X.

Plate 6. Kidney from male mouse exposed to 50000 ppm 2-hydroxy-4-methoxybenzophenone in the diet for 13 weeks. Protein casts fill lumen of several tubules of the outer medulla. Note mild increase in inflammatory cells in the renal interstitium adjacent to these dilated tubules. H&E 165X.




Plate 1



Plate 2



Plate 3




Plate 4




Plate 5




Plate 6

TABLE 11 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of B6C3F₁ Mice in the 2-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone^a

Dose (ppm)	0	3125	6250	12500	25000	50000
MALE (n=5)						
Necropsy body wt	22.7 ± 0.6	22.1 ± 0.2	22.3 ± 0.5	22.0 ± 0.4	22.1 ± 0.3	21.6 ± 0.4
R. Kidney						
Absolute	0.242 ± 0.011	0.221 ± 0.009	0.227 ± 0.008	0.226 ± 0.008	0.215 ± 0.005	0.210 ± 0.007
Relative	10.6 ± 0.29	9.99 ± 0.36	10.17 ± 0.30	10.27 ± 0.20	9.76 ± 0.23*	9.73 ± 0.20*
Liver						
Absolute	1.378 ± 0.037	1.405 ± 0.029	1.548 ± 0.047*	1.646 ± 0.105*	1.920 ± 0.088**	2.078 ± 0.135
Relative	60.8 ± 1.0	63.5 ± 0.9	69.3 ± 1.7	74.6 ± 3.5	86.9 ± 3.8	96.2 ± 5.5
FEMALE (n=5)						
Necropsy body wt	18.0 ± 0.72	18.9 ± 0.4	19.6 ± 0.1	18.8 ± 0.3	18.5 ± 0.3	18.7 ± 0.7
R. Kidney						
Absolute	0.162 ± 0.007	0.165 ± 0.004	0.173 ± 0.005	0.173 ± 0.003	0.161 ± 0.003	0.171 ± 0.005
Relative	9.03 ± 0.21	8.71 ± 0.24	8.84 ± 0.21	9.24 ± 0.17	8.67 ± 0.05	9.19 ± 0.23
Liver						
Absolute	0.95 ± 0.08	1.23 ± 0.06*	1.37 ± 0.02**	1.37 ± 0.06**	1.61 ± 0.06**	1.83 ± 0.09**
Relative	52.6 ± 2.9	64.9 ± 2.2**	69.7 ± 1.0**	73.0 ± 2.4**	87.1 ± 2.8**	98.2 ± 3.4**

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error). All animals survived to the end of the study.

* Significantly different from the control group by Student's t-test (P < 0.05).

** Significantly different from the control group by Student's t-test (P < 0.01).

13-Week Dosed Feed Studies in Mice

One female mouse in the 50000 ppm group was accidentally killed during week 11 of the study (Table 12). A female mouse in the 3125 ppm group was killed in a moribund condition during week 1. There were no other unscheduled deaths of mice. Body weight gains were decreased in both males and females fed diets with the higher doses of HMB (Figure 3). Final body weights of males and females in the top 2 dose groups were significantly less than controls. Food consumption appeared to increase with increasing HMB concentration, but the data were not corrected for scattering of feed by the animals.

There were no clinical signs attributed to consumption of the HMB diets. At necropsy, there were no gross lesions related to the chemical. Consistent organ weight changes were seen in the liver of male and female mice and in the kidney of females; a moderate, dose-related increase in both absolute and relative weights was seen in liver (Table 13). The increase in relative kidney weight was not dose-related. Chemically-related histopathologic changes were present in the kidney of male mice fed a diet containing 50000 ppm HMB. Seven mice from this dose group exhibited a minimal lesion consisting of several homogeneous eosinophilic protein casts in renal tubules located within the inner stripe of the outer medulla or in collecting ducts of the inner medulla (Plate 6). Tubules containing these casts were slightly dilated; in a few of these mice there was a mild inflammatory cell infiltrate in the renal interstitium adjacent to the dilated tubules. No renal lesions were observed in female mice or in the lower dose groups of male mice.

TABLE 12 Survival, Weight Gain, and Feed Consumption of B6C3F₁ Mice in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone

Dose (ppm) In Feed	Survival ^a	Mean Body Weight (grams)			Final Weight Relative to Controls (percent) ^c	Average Feed Consumption ^d	Estimated Chemical Consumed ^e
		Initial	Final	Change ^b			
MALE							
0	10/10	19.9	30.5	10.6		4.0	
3125	10/10	20.5	30.5	10.0	100	4.0	480
6250	10/10	19.9	30.2	10.3	99	4.5	1068
12500	10/10	19.8	28.3	8.5	93	5.0	2487
25000	10/10	19.9	26.2	6.3	86	5.5	5981
50000	10/10	19.9	25.7	5.8	84	6.3	13937
FEMALE							
0	10/10	16.7	25.0	8.3		4.8	
3125	9/10	17.1	24.7	7.6	99	4.5	629
6250	10/10	17.5	25.3	7.8	101	5.0	1425
12500	10/10	17.8	24.4	6.6	98	5.5	3232
25000	10/10	17.2	23.0	5.8	92	6.2	7579
50000	9/10	16.9	22.0	5.1	88	7.2	18539

^a Number of animals surviving at 13 weeks/number/dose group.

^b Mean weight change of the animals in each dose group.

^c (Dosed group mean/Control group mean) x 100.

^d Food consumption is given in grams/animal/day.

^e Time weighted compound consumption = average compound consumed during the 13-week study (mg/kg body weight/day).

TABLE 13 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of B6C3F₁ Mice in the 13-Week Dosed Feed Studies of 2-Hydroxy-4-methoxybenzophenone^a

Dose (ppm)	0	3125	6250	12500	25000	50000
MALE						
n	10	10	10	10	10	10
Necropsy body wt	28.0 ± 0.1	27.9 ± 1.0	28.8 ± 0.6	25.6 ± 0.4**	25.1 ± 0.4**	23.6 ± 0.3**
R. Kidney						
Absolute	0.255 ± 0.008	0.243 ± 0.005	0.294 ± 0.008	0.238 ± 0.005	0.262 ± 0.005	0.209 ± 0.007**
Relative	9.13 ± 0.29	8.81 ± 0.25	10.21 ± 0.23**	9.31 ± 0.12	10.47 ± 0.14**	8.84 ± 0.19
Liver						
Absolute	1.38 ± 0.03	1.44 ± 0.06	1.58 ± 0.04**	1.54 ± 0.03**	1.61 ± 0.03**	1.69 ± 0.03**
Relative	49.4 ± 1.1	51.5 ± 1.0	55.0 ± 1.3**	60.1 ± 0.7**	64.3 ± 1.6**	71.7 ± 1.4**
FEMALE						
n	10	9	10	10	10	9
Necropsy body wt	23.4 ± 0.9	23.1 ± 0.6	23.6 ± 0.4	22.4 ± 0.4	21.9 ± 0.3	20.3 ± 0.2**
R. Kidney						
Absolute	0.177 ± 0.005	0.179 ± 0.005	0.213 ± 0.003*	0.174 ± 0.004	0.194 ± 0.005*	0.163 ± 0.002
Relative	7.64 ± 0.16	7.81 ± 0.21	9.02 ± 0.13**	7.79 ± 0.16**	8.88 ± 0.15**	8.03 ± 0.11**
Liver						
Absolute	1.16 ± 0.02	1.27 ± 0.03	1.35 ± 0.04**	1.40 ± 0.03**	1.47 ± 0.05**	1.41 ± 0.04**
Relative	50.1 ± 1.1	54.9 ± 1.0*	57.1 ± 1.1**	62.4 ± 1.2**	66.8 ± 1.6**	69.5 ± 1.9**

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Statistically significant from the control group by Williams' or Dunnett's test (P 0.05).

** Statistically significant from the control group by Williams' or Dunnett's test (P 0.01).




Figure 3 Body Weights of Mice Exposed to 2-Hydroxy-4-methoxybenzophenone by Dosed Feed for 13 Weeks

Although liver weights were mildly increased at 6250 ppm and higher doses, microscopic changes were limited to the 25000 and 50000 ppm groups. Four males and 6 females in the top concentration group had minimal cytoplasmic vacuolization of hepatocytes. This change was also present in 3 male and 2 female mice from the 25000 ppm group.

A decrease in sperm density as well as an increase in abnormal sperm was noted in mice given 50000 ppm HMB in the feed. Female mice in the 50000 ppm dose group exhibited an increase in the length of the estrous cycle (Appendix C).

2-Week Dermal Studies in Mice, with Acetone and Lotion Vehicles

All animals survived to the end of the studies. No chemically-related changes were observed in body weight gain, food consumption, clinical observations, necropsy findings or by histologic examination of skin samples from the site of application in male or female mice receiving HMB in the acetone or lotion vehicles. Relative kidney weights were variably increased in male mice receiving HMB in the acetone vehicle (Table 14). Relative liver weights were increased in male and female mice given the higher doses of HMB in acetone or lotion (Tables 14, 15).

TABLE 14 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of B6C3F₁ Mice in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Acetone^a

Dose (mg)	0	0.5	1.0	2.0	4.0	8.0
MALE (n=5)						
Necropsy body wt	20.9 ± 0.4	21.7 ± 0.9	21.9 ± 0.8	21.8 ± 0.4	21.6 ± 0.3	22.6 ± 0.5*
Kidney						
Absolute	0.22 ± 0.01	0.23 ± 0.01	0.25 ± 0.02	0.23 ± 0.01	0.24 ± 0.01	0.25 ± 0.04**
Relative	10.37 ± 0.01	10.57 ± 0.02	11.24 ± 0.05	10.77 ± 0.04	11.11 ± 0.01**	11.20 ± 0.01**
Liver						
Absolute	1.38 ± 0.05	1.32 ± 0.07	1.46 ± 0.07	1.46 ± 0.02	1.53 ± 0.03*	1.62 ± 0.03**
Relative	64.56 ± 1.22	60.81 ± 2.43	66.94 ± 2.74	67.74 ± 0.55	70.86 ± 0.69**	71.86 ± 0.55**
FEMALE (n=5)						
Necropsy body wt	17.5 ± 0.41	18.6 ± 0.59	19.4 ± 0.19**	18.1 ± 0.39	19.1 ± 0.47*	18.6 ± 0.67
R. Kidney						
Absolute	0.17 ± 0.00	0.17 ± 0.01	0.18 ± 0.00	0.17 ± 0.00	0.18 ± 0.00	0.17 ± 0.01
Relative	9.84 ± 0.17	9.33 ± 0.25	9.42 ± 0.18	9.60 ± 0.15	9.64 ± 0.19	9.33 ± 0.13
Liver						
Absolute	1.09 ± 0.42	1.20 ± 0.23	1.27 ± 0.02**	1.20 ± 0.06	1.35 ± 0.03**	1.28 ± 0.04*
Relative	61.99 ± 1.59	64.31 ± 2.18	65.40 ± 0.91	66.31 ± 2.16	70.45 ± 0.89**	68.38 ± 1.42*

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Student's t-test (P 0.05).

** Significantly different from the control group by Student's t-test (P 0.01).

TABLE 15 Kidney and Liver Weights and Organ-Weight-to-Body-Weight Ratios of B6C3F₁ Mice in the 2-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone in Lotion^a

Dose (mg)	0	0.5	1.0	2.0	4.0	8.0
MALE (n=5)						
Necropsy body wt	22.0 ± 0.38	22.6 ± 0.21	22.2 ± 0.43	22.5 ± 0.25	23.2 ± 0.42	23.5 ± 0.55*
Kidney						
Absolute	0.26 ± 0.01	0.26 ± 0.01	0.26 ± 0.01	0.26 ± 0.01	0.26 ± 0.01	0.28 ± 0.01
Relative	11.87 ± 0.45	11.52 ± 0.34	11.47 ± 0.19	11.52 ± 0.29	11.26 ± 0.28	11.95 ± 0.33
Liver						
Absolute	1.35 ± 0.05	1.46 ± 0.03	1.44 ± 0.06	1.46 ± 0.03	1.62 ± 0.05**	1.62 ± 0.02**
Relative	61.23 ± 1.55	64.48 ± 1.43	64.84 ± 2.16	64.76 ± 1.30	69.84 ± 1.13**	69.09 ± 0.90**
FEMALE (n=5)						
Necropsy body wt	19.2 ± 0.3	20.2 ± 0.5	19.7 ± 0.3	20.2 ± 0.3*	19.2 ± 0.7	20.0 ± 0.3
R. Kidney						
Absolute	0.18 ± 0.00	0.19 ± 0.01	0.19 ± 0.00	0.19 ± 0.01	0.18 ± 0.01	0.19 ± 0.01
Relative	9.21 ± 0.11	9.25 ± 0.35	9.42 ± 0.19	9.56 ± 0.26	9.37 ± 0.11	9.33 ± 0.31
Liver						
Absolute	1.20 ± 0.05	1.33 ± 0.06	1.31 ± 0.05	1.36 ± 0.06	1.26 ± 0.08	1.47 ± 0.04**
Relative	62.41 ± 1.75	65.86 ± 1.56	66.73 ± 1.62	67.55 ± 2.47	65.63 ± 2.79	73.30 ± 1.18**

^a Organ weights and body weights are given in grams; organ-weight-to-body-weight ratios are given as mg organ weight/g body weight (mean ± standard error).

* Significantly different from the control group by Student's t-test (P = 0.05).

** Significantly different from the control group by Student's t-test (P = 0.01).

13-Week Dermal Studies in Mice, with Acetone Vehicle

All mice survived to the end of the studies. No chemically-related changes were observed in body weight gains (Figure 4), food consumption, clinical observations, necropsy findings (including organ weights) (Appendix A2) or by histologic examination of skin samples from the site of application. A mild increase in relative kidney weights in dosed male mice was possibly significant; the increases were not dose related, however, and no abnormal histopathologic findings were seen in this tissue. A significant dose-related decrease in epididymal sperm density was seen in mice at all doses studied (22.75, 91.0, and 364.0 mg/kg) (Appendix C).




Figure 4 Body Weights of B6C3F1 Mice Exposed Dermally to 2-Hydroxy-4-methoxybenzophenone for 13 Weeks

Genetic Toxicology

HMB was tested using a preincubation protocol in 2 independent studies for induction of gene mutations in *Salmonella typhimurium*. In the first study, strains TA100, TA1535, TA97, TA1537, and TA98 were used with 10% liver S9 from rats and hamsters. No mutagenicity was seen in any of the strains under these conditions (Appendix D, Table D1; Zeiger *et al.*, 1987).

The second study, performed at a later date, used TA97 in place of TA1537, and both 10% and 30% rat and hamster S9. In this study, HMB was weakly mutagenic only in strain TA97 with 30% hamster S9. These conditions were not used in the first study. On the basis of this finding, it is concluded that HMB is weakly mutagenic in *Salmonella* (Appendix D, Table D2).

In cytogenetic tests with Chinese hamster ovary cells, HMB induced sister-chromatid exchanges (effective dose range 5-50 µg/ml) and chromosomal aberrations (20-45 µg/ml) in the presence of Aroclor 1254-induced male Sprague-Dawley rat liver S9. In the ABS test with S9, the lack of a dose response in Trial 2 may have been due to cytotoxic delay or to precipitation of the test chemical at the higher doses. In the single SCE trial without S9, a questionable response was obtained; a dose-related increase in SCE was observed, but no single dose level was significantly elevated over the control frequency. The ABS test without S9 was negative (Appendix D, Tables D3 and D4).

Peripheral blood smears from the mice used in the 13-week toxicity studies were analyzed for frequency of micronucleated normochromatic erythrocytes; no increases were noted in either male or female mice treated with up to 50000 ppm HMB in feed (Appendix D, Table D5).

DISCUSSION

Because of its widespread use in sunscreens and cosmetics, comparative toxicity studies by the oral and dermal routes were performed with 2-hydroxy-4-methoxybenzophenone. When HMB was administered at 3125 to 50000 ppm in the diet of F344/N rats and B6C3F₁ mice (approximately 200 to 4200 mg/kg/day for rats and 500 to 23000 mg/kg/day for mice), gross and microscopic injury to the liver and kidney and adverse effects upon body weight gain and the reproductive system were noted. When administered on the skin at up to 200 mg/kg to F344/N rats or 384 mg/kg to B6C3F₁ mice, there were fewer adverse effects, although decreased sperm density was seen in mice receiving as little as 23 mg/kg/day. The only effect on the kidney was an increase in weight in male mice, which was not related to dose.

HMB is excreted primarily through the kidney after oral or topical exposure (El Dareer *et al.*, 1986). The absence of microscopic liver and kidney lesions in the dermal studies is likely due to lower systemic exposure levels, because the maximum dose which could be administered dermally was similar to the lowest dose administered orally, which also produced little systemic toxicity.

The renal toxicity produced by feeding diets containing HMB was more severe in rats than in mice. A spectrum of morphologic lesions including tubule dilatation with regeneration of tubular epithelial cells, interstitial inflammation, and papillary necrosis was present in both sexes of rats, but was generally more severe in males.

The occurrence of both papillary necrosis and renal tubule dilatation has been reported in several studies with rats; however, the relationship between the two lesions is not clear. Renal cortical lesions may develop secondary to total papillary necrosis and obstruction, or occlusion, of the tubules at the tip of the papilla with cell debris or hyperplastic uroepithelium (Nanra *et al.*, 1986; Elliot, 1986; Black, 1986); however, when rats were administered phenylbutazone, dilatation of renal tubules occurred in some rats without evidence of papillary necrosis, while other rats had papillary necrosis without dilatation of tubules (Arnold *et al.* 1976). In studies with phenacetin, cortical lesions, including dilatation, inflammation, and atrophy, were seen only in rats also exhibiting papillary necrosis (Molland, 1978). A number of mechanisms have been proposed for the development of drug-induced renal papillary necrosis (Sabatini, 1989). These mechanisms are interrelated and include such factors as redistribution of renal blood flow, free radical formation with direct chemical injury to the papillary cells, and inhibition of prostaglandin synthesis. It also has been demonstrated that decreased urinary flow and increased urinary solute concentration contribute to the development of papillary necrosis (Sabatini *et al.*, 1983).

While it was is not clear which mechanism(s) might apply to HMB, the urinalysis results suggested that if an increased urinary solute concentration was involved, the injury must have occurred very early. There was a transient increase in urine specific gravity in highest dose male and female rats at 3 days, likely due to dehydration. However, in highest dose male rats, changes at 15 days (increase in urine volume) and especially at 12 weeks (increase in urine

volume and decrease in specific gravity) were consistent with a decrease in urine concentrating ability. Although other causes of increases in volume and decreases in specific gravity cannot be excluded (e.g. polydipsia, osmotic diuresis, decrease in renal interstitial osmolality, diabetes insipidus, etc.), the findings are consistent with histopathologic evidence of renal papillary necrosis at 13 weeks.

Based upon the results in the 2- and 13-week studies of HMB, it appears that tubule dilatation and epithelial cell regeneration preceded the development of papillary necrosis and inflammation in the kidney of rats. The tubule dilatation in rats occurred often in the absence of papillary necrosis in both male and female rats, and in lower dose groups. Studies of HMB (10000 ppm in the diet) in Wistar rats showed tubule dilatation in the absence of papillary necrosis (Lewerenz *et al.*, 1972). It is possible that the tubule dilatation was of sufficient severity to restrict regional blood flow to the papilla, contributing to the development of papillary necrosis, although a number of xenobiotics, including diphenylthiazole and diphenylamine, have been demonstrated to cause tubular dilatation without affecting the renal papilla (Carone *et al.*, 1974; McCormack *et al.*, 1981; Kanwar *et al.*, 1984).

Kidney lesions in mice were minimal and occurred only in males at the highest exposure concentration. The predominant feature of the renal lesion in mice were protein casts in tubules in the inner stripe of the outer medulla or in collecting ducts of the inner medulla. There were no similarities in the kidney lesions between mice and rats. It is not unusual in short-term toxicity studies for a chemical to cause dissimilar lesions in the kidney of different species (Elwell *et al.*, 1989).

In the dosed feed studies, the only relevant hematologic changes were mild to moderate, persistent increases in platelet counts in dosed male rats at most timepoints and in female rats at 12 weeks. Thrombocytosis can be produced by increased production of platelets in the bone marrow and by decreased sequestration in the vasculature of tissues (for example, lung and spleen) produced by physiologic mechanisms (exercise, epinephrine release) or splenic atrophy or dysfunction. Primary increases in platelet production are associated with myeloproliferative diseases, regenerative processes, infectious and inflammatory disorders, certain neoplasms, and a variety of miscellaneous causes including nephrotic syndrome and other forms of chronic renal disorders (Wintrobe, 1981). In the current study, the development of renal lesions in rats provides a possible explanation for the thrombocytosis. However, this and other mechanisms would have to be specifically examined before a clear association could be established.

Decreases in activity of AP, as occurred in male and female rats at 15 days and in male rats at 12 weeks, are generally associated with decreased intake of food and not from direct, chemically-related effects. The mild increase in activity of ALT at 3 days in male and female rats does indicate release of the cytosolic enzyme from damaged or necrotic hepatocytes. Additionally, the significant increase in SDH at 12 weeks in female rats is consistent with minimal hepatocellular damage. Moderate increases in activity of GGT at all time points in male rats and at 15 days and 12 weeks in female rats are consistent with impairment in bile flow and release of the enzyme from canalicular membranes. Together, the increases in ALT and GGT provide biochemical evidence of early damage to the hepatobiliary system, evidence of

minimal hepatocellular damage in female rats at 12 weeks, and persistent, increasing cholestasis in animals of both sexes. In some cases, these cellular biochemical responses were associated with markedly enlarged livers and hepatocyte vacuolization which appeared much more severe in comparable rat and mouse dose groups in the 2-week than in the 13-week studies, suggesting that the lesion was reversible. Characteristic rarefaction and "clumping" of the stainable cytoplasm has previously been described as a potentially reversible, treatment-related effect (Newberne, 1982; Gopinath *et al.*, 1987). Although the appearance of the livers returned to near normal in the 13-week study, the persistent cholestasis noted in rats at the top dose indicated that hepatobiliary function remained impaired.

Topical application of HMB resulted in no relevant changes in hematologic, biochemical, or urinary variables in male rats. In female rats, sporadic changes in HGB concentration and in RBC, platelet, leukocyte, and lymphocyte counts were not considered biologically important. Although reticulocyte counts were decreased in female rats in all dermal treatment groups at 12 weeks, lack of additional hematologic evidence consistent with decreased regeneration of RBC lessened the importance of this finding. In female rats, there were no significant changes in urine variables, and serum biochemical changes were minimal in magnitude and were not considered biologically meaningful.

Reproductive system toxicity was associated with both oral and topical administration in rats and mice. The most common finding was a decrease in epididymal sperm density, and, in some studies, the number of abnormal sperm increased. Female rats and mice were observed to have an increased estrous cycle length. These findings, which were consistent across species and sex, prompted further evaluation of HMB in a continuous breeding study. Parental generations of CD-1 mice were given up to 50000 ppm HMB in feed and were maintained on these diets for sufficient time to produce 5 litters. In contrast to the results with the B6C3F₁ mice, there were no observed changes in CD-1 mice for sperm density or abnormal sperm, or for estrous cycle length. The CD-1 mice were observed to have dose-related decreases in dam weights and total number of litters produced. The number of live pups born per litter also decreased in a dose-related manner. There was no evidence for a dominant lethal effect reflected in the sex of the pups. There was, however, a dose-related decrease in pup survival in litters with dams receiving 25000 and 50000 ppm HMB in the diet. The first 3 F₁ generation litters in the 2 highest dose groups were observed to have an increased number of days to parturition. These data demonstrate moderate reproductive toxicity of HMB in CD-1 mice at high dietary levels (National Toxicology Program, 1991). Whether the B6C3F₁ mouse would prove more sensitive to the reproductive toxicity of HMB in continuous breeding studies remains to be determined. On the whole, increases in estrous cycle length in B6C3F₁ mice and time to parturition in CD-1 mice suggest possible effects on hormonal mechanisms in females.

In summary, administration of HMB was associated with effects on the liver, kidney, and reproductive organs of rats and mice. Although these effects were observed primarily in dietary studies at concentrations that also affected body weight gain, these effects are considered to be tissue specific and dose-responsive. A no-observed-adverse-effect level (NOAEL) for microscopic kidney lesions was 25000 ppm HMB in the feed for mice and 6250 ppm for rats. An apparently reversible enlargement and cytoplasmic vacuolization of the livers of rats and mice

was noted at dietary concentrations of 6250 ppm and above. The dermal studies were limited by the reduced systemic exposure achievable by this route, but indicated that rats and mice are generally similarly affected by oral and dermal exposures. Consistent findings included decreases in epididymal sperm density, lengthened estrous cycle, and increased liver and kidney weights. A NOAEL was not reached for decreased epididymal sperm density in the 13-week dermal study in mice (<23 mg/kg/day).

REFERENCES

- Abramoff, C.S. (1978-79) Ultraviolet stabilizers, in *Modern Plastics Encyclopedia, 1978-1979*, Vol. 55, No. 10a. New York: McGraw-Hill, pp. 222-226, 692-693.
- Arnold, L., Collins, C., and Starmer, G.A. (1976) Further studies of the acute effects of phenylbutazone, oxyphenbutazone, and indomethacin on the rat kidney. *Pathology* **8**, 135-141.
- Black, Hugh E. (1986) Renal toxicity of non-steroidal anti-inflammatory drugs. *Toxicol. Path.* **14**, 83-90.
- Bonin, A.M., Arlauskas, A.P., Angus, D.S., Baker, R.S.U., Gallagher, C.H., Greenoak, G., Meher-Homji, K.M., and Reeve, K. (1982) UV-absorbing and other sun-protecting substances: Genotoxicity of 2-ethylhexyl p-methoxycinnamate. *Mutat. Res.* **105**, 303-308.
- Boorman, G.A., Montgomery, C.A., Eustis, S.L., Wolfe, M.J., McConnell, E.E., and Hardisty, J. (1985) Quality assurance in pathology for rodent carcinogenicity studies, in Milman, H., and Weisburger, E. (eds.), *Handbook of Carcinogen Testing*. Park Ridge, NJ: Noyes Publications, pp. 345-357.
- Carone, F.A., Rowland, R.G., Perlman, S.G., and Ganote, C.R. (1974) The pathogenesis of drug-induced renal cystic disease. *Kidney Int.* **5**, 411-21.
- Code of Federal Regulations, Title 21 CFR, Pt. 58. Washington: National Archives, 1990.
- Code of Federal Regulations, Title 21 CFR, Pt. 177.1010 (1978) Washington: National Archives, 1990.
- Cosmetic Ingredient Review (1983a) Final report on the safety assessment of benzophenones-1, -3, -4, -5, -9 and -11. *J. Amer. Coll. Toxicol.* **2**, 35-77.
- Cosmetic Ingredient Review (1983b) Addendum to the final report on the safety assessment of benzophenones-1, -3, -4, -5, -9, and -11 to include benzophenones -2, -6, and -8. *J. Amer. Coll. Toxicol.* **2**, 79-84.
- Cripps, D.J., and de Dennis, S.R.K. (1981) Sunscreens: sun protection factor with modified Oriel solar simulator. *Cosmet. Technol.*, January 1981, pp. 41-45.
- Dixon, W., and Massey, F. (1951) *Introduction to Statistical Analysis*. New York: McGraw Hill, pp. 145-147.
- Dunn, O.J. (1964) Multiple comparisons using rank sums. *Technometrics* **6**, 241-252.
- Dunnett, W. (1955) A multiple comparison procedure for comparing several treatments with a control. *J. Am. Stat. Assoc.* **50**, 1095-1121.
- El Dareer, S.M., Kalin, J.R., Tillery, K.F., Hill, D.L. (1986) Disposition of 2-Hydroxy-4-methoxybenzophenone in rats dosed orally, intravenously, or topically. *J. Toxicol. Environ. Hlth.* **19**, 491-502.
- Elliot, G.A. (1986) Papillary necrosis, rat, in Jones, T.C., Mohr, U., and Hunt., R.D. (eds.), *Urinary System*. Berlin and New York: Springer-Verlag, pp. 184-189.
- Elwell, M.R., Dunnick, J.K., Brown, H.R., and Montgomery, C.A. (1989) Kidney and urinary bladder lesions in F344/N rats and B6C3F₁ mice after 13 weeks of 2,2 Bis(bromomethyl)-1,3 propanediol administration. *Fundam. Appl. Toxicol.* **12**, 480-490.

Folsom, J., Gange, R.W., and Mendelson, I.R. (1983) Ornithine decarboxylase induction in psoralen-treated mouse epidermis used as a test of UV-A sunscreen potency. *Br. J. Dermatol.* **108**, 17-23.

Galloway, S., Armstrong, M., Reuben, C., Colman, S., Brown, B., Cannon, C., Bloom, A., Nakamura, F., Ahmed, M., Duk, S., Rimpo, J., Margolin, B., Resnick, M., Anderson, B., and Zeiger, E. (1987) Chromosome aberration and sister chromatid exchanges in Chinese hamster ovary cells: Evaluations of 108 chemicals. *Environ. Molec. Mutagen.* **10** (Suppl 10), 1-176.

Galloway, S., Bloom, A., Resnick, M., Margolin, B., Nakamura, F., Archer, P., and Zeiger, E. (1985) Development of a standard protocol for *in vitro* cytogenetic testing with CHO cells: Comparison of results for 22 compounds in two laboratories. *Environ. Mutagen.* **7**, 1-52.

Girard, J., Lafille, C., Unkovic, J., and Barbier, A. (1982) Experimental study of the protection index of sunscreen products: Prediction values in man. *Int. J. Cosmet. Sci.* **4**, 115-32.

Gopinath, C., Prentice, D.E., and Lewis, D.J. (1987) The urinary system, Chap. 5, in Gresham, G.A. (ed.), *Atlas of Experimental Toxicological Pathology, Current Histopathology*, V. 13. Norwell, Mass.: MTP Press, pp. 77-90.

Hölzle, E., and Plewig, G. (1982) Photoallergic contact dermatitis by benzophenone-containing sunscreens. *Hautarzt* **33**, 391-393.

Jonckheere, A.R. (1954) A distribution-free k-sample test against ordered alternatives. *Biometrika* **41**, 133-145.

Jonsen, J., Jacobsen, N., and Hensten-Pettersen, A. (1980) Bacterial mutagenesis (Ames Test) as a screening method for carcinogenic substances of dental materials, in Winter, G.D., Leroy, J.L., and de Groot, K. (eds.), *Evaluation of Biomaterials*. London: John Wiley & Sons, Ltd., pp. 333-339.

Kanwar, Y.S., and Carone, F.A. (1984) Reversible changes of tubular cell and basement membrane in drug-induced renal cystic disease. *Kidney Int.* **25**, 35-43.

Klingman, L.H., Akin, F.J., and Klingman, A.M. (1980) Sunscreens prevent ultraviolet photocarcinogenesis. *J. Am. Acad. Dermatol.* **3**, 30-35.

Lewerenz, H.J., Lewerenz, G., and Plass, R. (1972a) Acute and sub-acute toxicity studies of the UV absorber, MOB, in rats. *Food Cosmet. Toxicol.* **10**, 41-50.

Lewerenz, H.J., Lewerenz, G., and Plass, R. (1972b) Contribution to the toxicology of the UV absorber, MOB 2-hydroxy-4-methoxy benzophenone. *Nahrung* **16**, 133-134.

MacGregor, J.T., Wehr, C.M., and Langlois, R.G. (1983) A simple fluorescent staining procedure for micronuclei and RNA in erythrocytes using Hoechst 33258 and pyronin Y. *Mutat. Res.* **120**, 269-275.

Margolin, B.H., Resnick, M.A., Rimpo, J.Y., Archer, P., Galloway, S.M., Bloom, A.D., and Zeiger, E. (1986) Statistical analysis for *in vitro* cytogenetic assays using Chinese hamster ovary cells. *Environ. Mutagen.* **8**, 183-204.

Maronpot, R.R., and Boorman, G.A. (1982) Interpretation of rodent hepatocellular proliferative alterations and hepatocellular tumors in chemical safety assessment. *Toxicol. Pathol.* **10**, 71-80.

McCormack, K.M., Hook, J.B., and Gibson, J.E. (1981) Developmental abnormalities in the kidney: A review of normal and aberrant renal development, in Hook, J.B. (ed.), *Toxicology of the Kidney*. New York: Raven Press, pp. 227-250.

- Molland, E.A. (1978) Experimental renal papillary necrosis. *Kidney Int.* **13**, 5-14.
- Morita, K., Ishigaki, M., and Abe, T. (1981) Mutagenicity of materials related with cosmetics. *J. Somatic Cell Cytogen. Japan* **15**, 243-253.
- Morrison, D.F. (1976) *Multivariate Statistical Methods*. New York: McGraw Hill, pp. 170-179.
- Morrissey, R.E., Schwetz, B.A., Lamb, J.C., IV, Ross, M.C., Teague, J.L., and Morris, R.W. (1988) Evaluation of rodent sperm, vaginal cytology, and reproductive organ weight data from National Toxicology Program thirteen-week studies. *Fundam. Appl. Toxicol.* **11**, 343-358.
- Mortelmans, K., Haworth, S., Lawlor, T., Speck, W., Tainer, B., and Zeiger, E. (1986) *Salmonella* mutagenicity tests. II.: Results from the testing of 270 chemicals. *Environ. Mutagen.* **8** (Suppl 7), 1-119.
- Nanra, R.S., and Kincaid-Smith, P. (1986) Experimental renal effects of analgesics, rat, in Jones, T.C., Mohr, U., and Hunt., R.D. (eds.), *Urinary system..* Berlin and New York: Springer-Verlag, pp. 184-189.
- National Cancer Institute (1979) Bioassay of Michler's Ketone for Possible Carcinogenicity. CAS No. 90-94-8. NCI-CG-TR-181, in *Physician's Desk Reference* (1978), 32nd edition. Oradell, N.J.: Medical Economics Company, p. 1292.
- National Cancer Institute/Scientific Research, Inc., Mark II (1978) Data Base on Category E Drug Exposure, National Cancer Institute, Contract No. N01-CP-33285.
- National Toxicology Program (1991) *Reproductive Toxicity of 2-Hydroxy-4-methoxy-benzophenone in CD-1 Swiss Mice*. (Report No. T - 0195). Research Triangle Park, N.C.: National Toxicology Program.
- Newberne, P.M. (1982) Assessment of the hepatocarcinogenic potential of chemicals: response of the liver, in Plaa, G.L., and Hewitt, W.R. (eds.), *Toxicology of the Liver*. New York: Raven Press, pp. 243-290.
- Rao, G.N., Haseman, J.K., and Edmonson, J. (1989a) Influence of viral infections on body weight, survival, and tumor prevalence in Fischer 344/NCr rats on two-year studies. *Lab. Animal Sci.* **39**, 389-393.
- Rao, G.N., Piegorsch, W.W., Crawford, D.D., Edmondson, J., and Haseman, J.K. (1989b) Influence of viral infections on body weight, survival, and tumor prevalence of B6C3F₁ (C57BL/6N X C3H/Hen) mice in carcinogenicity studies. *Fundam. Appl. Toxicol.* **13**, 156-164.
- Reynolds, J.E.F. (ed.) (1982) Oxybenzone, in Martindale, W., *The Extra Pharmacopeia*, 28th ed., p. 1497.
- Sabatini, S. (1989) The analgesic agents and renal disease, in Amerio, A., Coratelli, P., Campese, V. M., and Massry, S. G. (eds.), *Drugs, Systemic Diseases, and the Kidney (Advances in Experimental Medicine and Biology, v. 252)*. New York: Plenum Press, pp. 199-215.
- Sabatini, S., Subbarayddu, K., Manaligod, J., Arruda, J.A.L., and Kurtzman, N.A. (1983) Role of urinary concentrating ability in the generation of toxic papillary necrosis. *Kidney Int.* **23**, 705-710..
- Sayre, R.M. (1981). Just how effective are today's sunscreens? *Cosmet Toiletries* 96, 49-50.
- Schmid, W. (1976) The micronucleus test for cytogenetic analysis, in A. Hollaender (ed.), *Chemical Mutagens*, Vol. 4. New York: Plenum Press, pp. 31-53.

Shirley, E. (1977) A non-parametric equivalent of Williams' test for contrasting increasing dose levels of a treatment. *Biometrics* **33**, 386-389.

Stecher, H. (1958) Ultraviolet-absorptive additives in adhesives, lacquers, and plastics. *Adhesion* **2**, 243-244.

U.S. Food and Drug Administration (1978) Sunscreen Drug Products for Over-the-Counter Human Drugs: Proposed Safety, Effective and Labeling Conditions. Federal Register: 43, 38206-38269. Part II. Friday, August 25. Washington: U.S. Government Printing Office.

U.S. International Trade Commission (1979) *Synthetic Organic Chemicals, US Production and Sales*. Washington, D.C.: US Government Printing Office.

Williams, D.A. (1971) A test for differences between treatment means when several dose levels are compared with a zero dose control. *Biometrics* **27**, 103-117.

Williams, D.A. (1972) The comparison of several dose levels with a zero dose control. *Biometrics* **28**, 519-531.

Wintrobe, M.M. (1981) Thrombocytosis, in *Clinical Hematology*. Philadelphia: Lea & Febiger, pp. 1128-1134.

Zeiger, E., Anderson, B., Haworth, S., Lawlor, T., Mortelmans, K., and Speck, W. (1987) *Salmonella* mutagenicity tests. III. Results from the testing of 225 chemicals. *Environ. Mutagen.* **9** (Suppl 9), 1-109.

APPENDIX A

Organ Weights and Organ-Weight-to-Body-Weight Ratios

Table A1	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone	A-2
Table A2	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone	A-4
Table A3	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone	A-6
Table A4	Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone	A-8

**TABLE A1 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats
In the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone¹**

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
MALE						
n	10	10	10	10	10	10
Necropsy body wt	313 ± 7	303 ± 7	310 ± 8	313 ± 7	312 ± 9	314 ± 5
Brain						
Absolute	1.88 ± 0.03	1.88 ± 0.03	1.90 ± 0.02	1.87 ± 0.02	1.87 ± 0.01	1.87 ± 0.02
Relative	6.03 ± 0.15	6.22 ± 0.14	6.17 ± 0.15	5.97 ± 0.08	6.03 ± 0.20	5.97 ± 0.12
Heart						
Absolute	0.989 ± 0.021	0.973 ± 0.029	0.993 ± 0.034	0.988 ± 0.024	0.968 ± 0.018	0.960 ± 0.041
Relative	3.17 ± 0.06	3.22 ± 0.07	3.22 ± 0.09	3.16 ± 0.04	3.13 ± 0.11	3.06 ± 0.13
Right Kidney						
Absolute	1.23 ± 0.03	1.19 ± 0.04	1.34 ± 0.04	1.22 ± 0.04	1.34 ± 0.02	1.22 ± 0.03
Relative	3.93 ± 0.06	3.92 ± 0.10	4.34 ± 0.07**	3.90 ± 0.09	4.30 ± 0.09*	3.89 ± 0.07
Liver						
Absolute	13.87 ± 0.51	12.47 ± 0.39	14.50 ± 0.49	14.34 ± 0.45	15.02 ± 0.57	14.50 ± 0.41
Relative	44.2 ± 0.93	41.2 ± 0.65	46.8 ± 0.89	45.7 ± 0.81	48.2 ± 1.51*	46.2 ± 0.99*
Lungs						
Absolute	1.86 ± 0.08	1.82 ± 0.11	1.79 ± 0.07	1.85 ± 0.05	1.84 ± 0.08	1.73 ± 0.10
Relative	5.92 ± 0.17	5.98 ± 0.27	5.79 ± 0.18	5.92 ± 0.19	5.95 ± 0.30	5.50 ± 0.24
Right Testis						
Absolute	1.44 ± 0.03	1.30 ± 0.05**	1.46 ± 0.02	1.43 ± 0.02	1.41 ± 0.01	1.43 ± 0.02
Relative	4.61 ± 0.07	4.32 ± 0.16	4.73 ± 0.07	4.56 ± 0.06	4.56 ± 0.14	4.58 ± 0.08
Thymus						
Absolute	0.304 ± 0.008	0.381 ± 0.035	0.337 ± 0.023	0.368 ± 0.029	0.282 ± 0.031 ²	0.330 ± 0.013
Relative	0.97 ± 0.02	1.25 ± 0.10*	1.09 ± 0.07	1.17 ± 0.08	0.89 ± 0.09 ²	1.05 ± 0.04
FEMALE						
n	10	10	10	10	10	10
Necropsy body wt	193 ± 4	181 ± 3	183 ± 3	188 ± 4	186 ± 4	182 ± 4
Brain						
Absolute	1.72 ± 0.02	1.78 ± 0.02	1.75 ± 0.02	1.80 ± 0.02*	1.75 ± 0.02	1.73 ± 0.02
Relative	8.92 ± 0.15	9.83 ± 0.17**	9.56 ± 0.16	9.62 ± 0.18*	9.44 ± 0.17	9.53 ± 0.20
Heart						
Absolute	0.707 ± 0.018	0.709 ± 0.026	0.692 ± 0.023	0.718 ± 0.026	0.710 ± 0.019	0.712 ± 0.032
Relative	3.67 ± 0.11	3.92 ± 0.13	3.78 ± 0.10	3.82 ± 0.11	3.82 ± 0.09	3.91 ± 0.16
Right Kidney						
Absolute	0.781 ± 0.029	0.832 ± 0.017	0.862 ± 0.012*	0.817 ± 0.023	0.892 ± 0.013**	0.797 ± 0.017
Relative	4.04 ± 0.12	4.61 ± 0.10	4.72 ± 0.09**	4.35 ± 0.06**	4.80 ± 0.07**	4.38 ± 0.09**
Liver						
Absolute	7.74 ± 0.34	7.26 ± 0.16	7.39 ± 0.21	7.45 ± 0.22	7.74 ± 0.16	7.49 ± 0.17
Relative	40.00 ± 1.50	40.1 ± 0.69	40.4 ± 1.05	39.8 ± 1.30	41.6 ± 0.83	41.2 ± 0.83
Lungs						
Absolute	1.27 ± 0.03	1.31 ± 0.04	1.37 ± 0.11	1.27 ± 0.04	1.30 ± 0.04	1.35 ± 0.03
Relative	6.57 ± 0.13	7.22 ± 0.19	7.47 ± 0.63	6.76 ± 0.16	6.99 ± 0.20	7.44 ± 0.24
Thymus						
Absolute	0.279 ± 0.020	0.268 ± 0.017	0.260 ± 0.018	0.272 ± 0.020	0.260 ± 0.016	0.245 ± 0.020
Relative	1.44 ± 0.09	1.49 ± 0.11	1.43 ± 0.10	1.45 ± 0.11	1.40 ± 0.09	1.34 ± 0.09

**TABLE A1 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats
in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

- ¹ Organ weights and body weights are given in grams, relative organ weights (organ-weight-to-body-weight ratios) are given as mg organ weight/g body weight (mean \pm standard error)
- ² n=9
- * Significantly different ($P \leq 0.05$) from the control group by Williams' or Dunnett's test
- ** Significantly different ($P \leq 0.01$) from the control group by Williams' or Dunnett's test

**TABLE A2 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice
In the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone¹**

	Vehicle Control	22.75 mg/kg	45.4 mg/kg	91 mg/kg	182 mg/kg	364 mg/kg
MALE						
n	10	10	9	10	10	10
Necropsy body wt	28.1 ± 0.4	28.2 ± 0.5	28.4 ± 0.4	28.6 ± 0.3	28.4 ± 0.6	28.1 ± 0.6
Brain						
Absolute	0.444 ± 0.004	0.451 ± 0.006	0.444 ± 0.010	0.437 ± 0.005	0.447 ± 0.004	0.445 ± 0.005
Relative	15.8 ± 0.27	16.00 ± 0.27	15.4 ± 0.31	15.3 ± 0.23	15.8 ± 0.26	15.9 ± 0.38
Heart						
Absolute	0.136 ± 0.001	0.157 ± 0.006	0.167 ± 0.010*	0.155 ± 0.008	0.169 ± 0.009*	0.150 ± 0.006
Relative	4.85 ± 0.06	5.56 ± 0.21*	5.86 ± 0.40*	5.41 ± 0.26*	5.95 ± 0.24*	5.37 ± 0.20*
Right Kidney						
Absolute	0.262 ± 0.005	0.290 ± 0.008	0.329 ± 0.012**	0.268 ± 0.005	0.322 ± 0.009**	0.285 ± 0.010
Relative	9.36 ± 0.20	10.29 ± 0.16**	11.54 ± 0.35**	9.38 ± 0.13**	11.36 ± 0.23**	10.14 ± 0.22**
Liver						
Absolute	1.46 ± 0.03	1.54 ± 0.05	1.67 ± 0.05**	1.47 ± 0.03	1.53 ± 0.05	1.54 ± 0.05
Relative	52.1 ± 1.15	54.5 ± 1.19	57.9 ± 1.28**	51.5 ± 0.97	54.1 ± 1.15	54.8 ± 1.31
Lungs						
Absolute	0.232 ± 0.017	0.222 ± 0.005	0.251 ± 0.006	0.280 ± 0.022	0.247 ± 0.010	0.241 ± 0.013
Relative	8.27 ± 0.60	7.90 ± 0.25	8.85 ± 0.26	9.84 ± 0.79	8.73 ± 0.31	8.61 ± 0.43
Right Testis						
Absolute	0.121 ± 0.003	0.121 ± 0.002	0.121 ± 0.003	0.118 ± 0.002	0.121 ± 0.001	0.122 ± 0.002
Relative	4.32 ± 0.11	4.31 ± 0.09	4.18 ± 0.07	4.13 ± 0.08	4.29 ± 0.12	4.36 ± 0.08
Thymus						
Absolute	0.034 ± 0.002	0.043 ± 0.004	0.041 ± 0.003	0.044 ± 0.004	0.050 ± 0.002*	0.043 ± 0.003*
Relative	1.23 ± 0.08	1.54 ± 0.14	1.44 ± 0.13	1.56 ± 0.15	1.77 ± 0.08*	1.56 ± 0.11*
FEMALE						
n	10	10	10	10	10	10
Necropsy body wt	23.3 ± 0.6	23.4 ± 0.7	25.3 ± 0.4*	24.1 ± 0.6	25.4 ± 0.4*	23.0 ± 0.3
Brain						
Absolute	0.438 ± 0.003	0.444 ± 0.008	0.452 ± 0.006	0.435 ± 0.003	0.448 ± 0.005	0.441 ± 0.004
Relative	18.9 ± 0.48	19.1 ± 0.57	17.9 ± 0.44	18.2 ± 0.46	17.7 ± 0.37	19.2 ± 0.34
Heart						
Absolute	0.121 ± 0.003	0.120 ± 0.002	0.128 ± 0.004	0.126 ± 0.006	0.136 ± 0.004	0.123 ± 0.004
Relative	5.21 ± 0.13	5.16 ± 0.12	5.07 ± 0.20	5.28 ± 0.23	5.39 ± 0.23	5.36 ± 0.17
Right Kidney						
Absolute	0.187 ± 0.003	0.181 ± 0.006	0.228 ± 0.006**	0.195 ± 0.005**	0.230 ± 0.005**	0.193 ± 0.005**
Relative	8.06 ± 0.19	7.79 ± 0.20	9.01 ± 0.18	8.16 ± 0.22	9.08 ± 0.19*	8.45 ± 0.28*
Liver						
Absolute	1.30 ± 0.03	1.26 ± 0.04	1.44 ± 0.03*	1.35 ± 0.04*	1.45 ± 0.03*	1.38 ± 0.02*
Relative	55.8 ± 0.96	53.7 ± 0.94	56.9 ± 0.69	56.3 ± 1.24	57.00 ± 0.47	60.00 ± 0.99**
Lungs						
Absolute	0.220 ± 0.010	0.229 ± 0.020	0.235 ± 0.004	0.240 ± 0.014	0.225 ± 0.006	0.242 ± 0.015 ²
Relative	9.55 ± 0.56	9.71 ± 0.56	9.32 ± 0.21	10.01 ± 0.64	8.86 ± 0.20	10.53 ± 0.59 ²
Thymus						
Absolute	0.053 ± 0.002	0.055 ± 0.004	0.055 ± 0.003	0.055 ± 0.004	0.044 ± 0.004	0.048 ± 0.002
Relative	2.30 ± 0.14	2.35 ± 0.17	2.18 ± 0.14	2.29 ± 0.18	1.75 ± 0.19	2.11 ± 0.12

**TABLE A2 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice
In the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

- ¹ Organ weights and body weights are given in grams; relative organ weights (organ-weight-to-body-weight ratios) are given as mg organ weight/g body weight (mean \pm standard error).
- ² n=9
- * Significantly different ($P \leq 0.05$) from the control group by Williams' or Dunnett's test.
- ** Significantly different ($P \leq 0.01$) from the control group by Williams' or Dunnett's test

**TABLE A3 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats
In the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone¹**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
MALE						
n	10	9	10	10	10	10
Necropsy body wt	334 ± 5	333 ± 6	327 ± 6	321 ± 6	299 ± 7**	230 ± 9**
Brain						
Absolute	1.90 ± 0.02	1.89 ± 0.02	1.90 ± 0.02	1.91 ± 0.02	1.83 ± 0.04	1.75 ± 0.03**
Relative	5.68 ± 0.06	5.68 ± 0.07	5.83 ± 0.06	5.97 ± 0.08	6.14 ± 0.19*	7.70 ± 0.21**
Heart						
Absolute	1.028 ± 0.027	1.035 ± 0.024	1.018 ± 0.040	1.011 ± 0.031	0.988 ± 0.022	0.796 ± 0.023**
Relative	3.08 ± 0.06	3.11 ± 0.06	3.11 ± 0.07	3.16 ± 0.08	3.32 ± 0.09*	3.49 ± 0.07**
Right Kidney						
Absolute	1.26 ± 0.03	1.39 ± 0.03	1.42 ± 0.04	1.44 ± 0.03	1.48 ± 0.04	2.11 ± 0.32**
Relative	3.76 ± 0.07	4.19 ± 0.09	4.33 ± 0.05	4.49 ± 0.07	4.96 ± 0.09	9.73 ± 1.84**
Liver						
Absolute	14.41 ± 0.42	16.38 ± 0.32*	17.64 ± 0.56**	18.11 ± 0.46**	17.55 ± 0.80**	15.68 ± 0.71**
Relative	43.1 ± 0.97	49.2 ± 0.74**	53.9 ± 1.01**	56.5 ± 0.86**	58.5 ± 1.95**	68.3 ± 1.42**
Lungs						
Absolute	1.83 ± 0.05	1.80 ± 0.04	1.71 ± 0.05	1.71 ± 0.04	1.69 ± 0.03** ²	1.43 ± 0.05** ²
Relative	5.47 ± 0.16	5.41 ± 0.12	5.26 ± 0.16	5.35 ± 0.13	5.68 ± 0.09 ²	6.24 ± 0.13** ²
Right Testis						
Absolute	1.46 ± 0.03	1.47 ± 0.03 ³	1.44 ± 0.02	1.44 ± 0.02	1.47 ± 0.02	1.34 ± 0.04*
Relative	4.38 ± 0.11	4.41 ± 0.09 ³	4.41 ± 0.05	4.50 ± 0.06	4.93 ± 0.07**	5.85 ± 0.13**
Thymus						
Absolute	0.320 ± 0.018	0.282 ± 0.022	0.302 ± 0.018	0.339 ± 0.030	0.277 ± 0.023	0.174 ± 0.024**
Relative	0.96 ± 0.05	0.84 ± 0.05	0.92 ± 0.04	1.05 ± 0.08	0.92 ± 0.06	0.75 ± 0.10
FEMALE						
n	10	10	10	10	10	10
Necropsy body wt	186 ± 6	187 ± 2	188 ± 3	175 ± 3	181 ± 3	165 ± 3**
Brain						
Absolute	1.78 ± 0.01	1.75 ± 0.02	1.79 ± 0.02	1.75 ± 0.02	1.79 ± 0.02	1.75 ± 0.01
Relative	9.66 ± 0.33	9.32 ± 0.07	9.51 ± 0.13	9.99 ± 0.13	9.91 ± 0.11	10.59 ± 0.13**
Heart						
Absolute	0.684 ± 0.011	0.650 ± 0.006	0.658 ± 0.011	0.652 ± 0.009	0.612 ± 0.010**	0.605 ± 0.018**
Relative	3.71 ± 0.14	3.47 ± 0.04	3.50 ± 0.04	3.73 ± 0.08	3.39 ± 0.08	3.66 ± 0.08
Right Kidney						
Absolute	0.781 ± 0.018	0.759 ± 0.011	0.851 ± 0.016	0.777 ± 0.010	0.857 ± 0.012*	0.842 ± 0.029*
Relative	4.23 ± 0.12	4.05 ± 0.07	4.52 ± 0.06	4.44 ± 0.06	4.74 ± 0.04**	5.10 ± 0.16**
Liver						
Absolute	6.97 ± 0.17	7.76 ± 0.18**	8.12 ± 0.07**	7.91 ± 0.21**	9.29 ± 0.21**	9.10 ± 0.24**
Relative	37.7 ± 1.22	41.4 ± 0.84**	43.2 ± 0.73**	45.1 ± 0.79**	51.3 ± 0.87**	55.00 ± 0.97**
Lungs						
Absolute	1.28 ± 0.03	1.29 ± 0.01	1.23 ± 0.02	1.13 ± 0.02**	1.19 ± 0.03**	1.11 ± 0.04**
Relative	6.95 ± 0.25	6.90 ± 0.08	6.53 ± 0.13	6.45 ± 0.14	6.55 ± 0.11	6.74 ± 0.23
Thymus						
Absolute	0.288 ± 0.015	0.232 ± 0.008*	0.253 ± 0.015*	0.226 ± 0.014**	0.214 ± 0.017**	0.154 ± 0.010**
Relative	1.57 ± 0.09	1.24 ± 0.04*	1.35 ± 0.08*	1.29 ± 0.07*	1.19 ± 0.10**	0.94 ± 0.06**

**TABLE A3 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Rats
in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

¹ Organ weights and body weights are given in grams, relative organ weights (organ-weight-to-body-weight ratios) are given as mg organ weight/g body weight (mean \pm standard error)

² n=9

³ n=8

* Significantly different ($P \leq 0.05$) from the control group by Williams' or Dunnett's test

** Significantly different ($P \leq 0.01$) from the control group by Williams' or Dunnett's test

**TABLE A4 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice
in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone¹**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
MALE						
n	10	10	10	10	10	10
Necropsy body wt	28 0 ± 0 1	27 9 ± 1 0	28 8 ± 0 6	25 6 ± 0 4**	25 1 ± 0 4**	23 6 ± 0 3**
Brain						
Absolute	0 439 ± 0 010	0 442 ± 0 007	0 438 ± 0 006	0 438 ± 0 005	0 443 ± 0 010	0 429 ± 0 007
Relative	15 7 ± 0 24	16 1 ± 0 62	15 3 ± 0 32	17 1 ± 0 33**	17 7 ± 0 28**	18 2 ± 0 31**
Heart						
Absolute	0 141 ± 0 005 ²	0 143 ± 0 005	0 145 ± 0 007	0 133 ± 0 003	0 132 ± 0 006	0 117 ± 0 002** ²
Relative	5 04 ± 0 22 ²	5 18 ± 0 22	5 02 ± 0 20	5 22 ± 0 13	5 27 ± 0 18	4 98 ± 0 09 ²
Right Kidney						
Absolute	0 255 ± 0 008	0 243 ± 0 005	0 294 ± 0 008	0 238 ± 0 005	0 262 ± 0 005	0 209 ± 0 007**
Relative	9 13 ± 0 29	8 81 ± 0 25	10 21 ± 0 23**	9 31 ± 0 12	10 47 ± 0 14**	8 84 ± 0 19
Liver						
Absolute	1 38 ± 0 03	1 44 ± 0 06	1 58 ± 0 04**	1 54 ± 0 03**	1 61 ± 0 03**	1 69 ± 0 03**
Relative	49 4 ± 1 14	51 5 ± 0 96	55 00 ± 1 28**	60 1 ± 0 65**	64 3 ± 1 56**	71 7 ± 1 43**
Lungs						
Absolute	0 216 ± 0 013	0 217 ± 0 009	0 213 ± 0 008	0 218 ± 0 008	0 229 ± 0 014	0 201 ± 0 012
Relative	7 72 ± 0 46	7 84 ± 0 27	7 38 ± 0 24	8 51 ± 0 30*	9 12 ± 0 54*	8 56 ± 0 56*
Right Testis						
Absolute	0 123 ± 0 005	0 124 ± 0 003	0 120 ± 0 001 ²	0 119 ± 0 003	0 114 ± 0 006	0 118 ± 0 002
Relative	4 43 ± 0 21	4 49 ± 0 14	4 19 ± 0 07 ²	4 67 ± 0 15	4 54 ± 0 21	5 04 ± 0 12*
Thymus						
Absolute	0 042 ± 0 002	0 040 ± 0 004	0 040 ± 0 002 ²	0 036 ± 0 002	0 043 ± 0 002	0 041 ± 0 002
Relative	1 51 ± 0 07	1 48 ± 0 14	1 39 ± 0 05 ²	1 45 ± 0 10	1 71 ± 0 10	1 74 ± 0 11
FEMALE						
n	10	9	10	10	10	9
Necropsy body wt	23 4 ± 0 9	23 1 ± 0 6	23 6 ± 0 4	22 4 ± 0 4	21 9 ± 0 3	20 3 ± 0 2**
Brain						
Absolute	0 441 ± 0 009	0 451 ± 0 008	0 442 ± 0 010	0 453 ± 0 007	0 437 ± 0 004	0 436 ± 0 004
Relative	19 1 ± 0 65	19 6 ± 0 49	18 8 ± 0 52	20 3 ± 0 52	20 00 ± 0 31	21 5 ± 0 26**
Heart						
Absolute	0 121 ± 0 004	0 126 ± 0 002	0 137 ± 0 007	0 114 ± 0 004	0 119 ± 0 003	0 104 ± 0 004*
Relative	5 26 ± 0 21	5 53 ± 0 19	5 81 ± 0 28	5 13 ± 0 19	5 45 ± 0 14	5 15 ± 0 19
Right Kidney						
Absolute	0 177 ± 0 005	0 179 ± 0 005	0 213 ± 0 003**	0 174 ± 0 004	0 194 ± 0 005*	0 163 ± 0 002
Relative	7 64 ± 0 16	7 81 ± 0 21	9 02 ± 0 13**	7 79 ± 0 16**	8 88 ± 0 15**	8 03 ± 0 11**
Liver						
Absolute	1 16 ± 0 02	1 27 ± 0 03	1 35 ± 0 04**	1 40 ± 0 03**	1 47 ± 0 05**	1 41 ± 0 04**
Relative	50 1 ± 1 14	54 9 ± 0 99*	57 1 ± 1 11**	62 4 ± 1 16**	66 8 ± 1 61**	69 5 ± 1 89**
Lungs						
Absolute	0 214 ± 0 009	0 227 ± 0 016	0 226 ± 0 013	0 204 ± 0 010	0 210 ± 0 004 ²	0 212 ± 0 013
Relative	9 25 ± 0 45	9 91 ± 0 76	9 60 ± 0 54	9 14 ± 0 47	9 73 ± 0 30 ²	10 42 ± 0 60
Thymus						
Absolute	0 043 ± 0 002	0 047 ± 0 004	0 045 ± 0 003	0 048 ± 0 002	0 044 ± 0 004	0 040 ± 0 005
Relative	1 87 ± 0 12	2 06 ± 0 16	1 93 ± 0 14	2 15 ± 0 11	1 99 ± 0 18	1 98 ± 0 26

**TABLE A4 Organ Weights and Organ-Weight-to-Body-Weight Ratios for Mice
in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

- ¹ Organ weights and body weights are given in grams, relative organ weights (organ-weight to-body-weight ratios) are given as mg organ weight/g body weight (mean ± standard error)
- ² n=9
- * Significantly different ($P \leq 0.05$) from the control group by Williams' or Dunnett's test
- ** Significantly different ($P \leq 0.01$) from the control group by Williams' or Dunnett's test

APPENDIX B

Hematology, Clinical Chemistry, and Urinalysis Results

Table B1	Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone	B-2
Table B2	Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone	B-7

**TABLE B1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone¹**

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
MALE						
n	10	10	10	10	10	10
Hematology						
Hematocrit (%)						
Day 3	43.6 ± 0.6	42.6 ± 0.4	42.7 ± 0.5 ²	42.6 ± 0.8	42.6 ± 0.6	42.0 ± 0.6
Day 15	44.6 ± 0.5 ³	44.4 ± 0.5	44.1 ± 0.8	44.7 ± 0.7	43.9 ± 0.7 ⁹	44.8 ± 0.6
Week 12	43.7 ± 0.7	44.2 ± 0.6	43.2 ± 0.7	43.8 ± 0.5	43.8 ± 0.7	43.9 ± 0.6
Hemoglobin (g/dL)						
Day 3	15.7 ± 0.2	15.3 ± 0.1	15.5 ± 0.1 ²	15.4 ± 0.2	15.2 ± 0.2	15.2 ± 0.1
Day 15	16.4 ± 0.1 ³	16.3 ± 0.2	16.5 ± 0.2	16.5 ± 0.2	16.2 ± 0.2 ³	16.4 ± 0.1
Week 12	15.9 ± 0.2	16.0 ± 0.2	15.9 ± 0.2	15.8 ± 0.2	15.8 ± 0.2	15.9 ± 0.2
Erythrocytes (10⁶/μL)						
Day 3	7.10 ± 0.10	6.95 ± 0.12	6.89 ± 0.11 ²	6.83 ± 0.21	7.02 ± 0.10	6.80 ± 0.15
Day 15	7.18 ± 0.08 ³	7.17 ± 0.13	7.34 ± 0.14	7.39 ± 0.14	7.25 ± 0.12 ³	7.30 ± 0.10
Week 12	8.42 ± 0.14	8.54 ± 0.11	8.36 ± 0.17	8.46 ± 0.11	8.53 ± 0.13	8.45 ± 0.13
Mean cell volume (fL)						
Day 3	61.5 ± 0.3	61.4 ± 0.8	62.0 ± 0.5 ²	62.6 ± 1.0	60.7 ± 0.5	61.9 ± 1.0
Day 15	62.0 ± 0.3 ³	61.8 ± 0.6	60.1 ± 0.6 [*]	60.5 ± 0.5 [*]	60.7 ± 0.4 ³	61.3 ± 0.3
Week 12	51.9 ± 0.2	51.7 ± 0.4	51.8 ± 0.4	51.8 ± 0.3	51.5 ± 0.3	51.9 ± 0.3
Mean cell hemoglobin (pg)						
Day 3	22.1 ± 0.2	22.0 ± 0.4	22.5 ± 0.3 ²	22.7 ± 0.6	21.7 ± 0.2	22.5 ± 0.3
Day 15	22.8 ± 0.2 ³	22.7 ± 0.2	22.5 ± 0.2	22.3 ± 0.5	22.3 ± 0.2 ³	22.5 ± 0.2
Week 12	18.9 ± 0.2	18.7 ± 0.1	19.1 ± 0.3	18.7 ± 0.1	18.6 ± 0.2	18.9 ± 0.1
Mean cell hemoglobin concentration (g/dL)						
Day 3	35.9 ± 0.3	35.8 ± 0.3	36.2 ± 0.3 ²	36.2 ± 0.4	35.7 ± 0.2	36.3 ± 0.5
Day 15	36.7 ± 0.3 ³	36.7 ± 0.2	37.4 ± 0.3	36.9 ± 0.7	36.8 ± 0.4 ³	36.7 ± 0.5
Week 12	36.3 ± 0.3	36.2 ± 0.3	36.9 ± 0.4	36.2 ± 0.2	36.2 ± 0.5	36.3 ± 0.4
Platelets (10³/μL)						
Day 3	864.9 ± 13.9	923.9 ± 50.4	886.6 ± 17.3 ²	909.5 ± 38.7	908.3 ± 40.3	944.1 ± 49.4
Day 15	739.4 ± 26.4 ³	775.5 ± 27.1	697.7 ± 20.3 ³	673.0 ± 24.6	747.7 ± 16.3 ³	716.5 ± 16.3
Week 12	567.3 ± 7.1	539.8 ± 10.8	563.3 ± 9.2	534.5 ± 15.9	563.6 ± 11.1	589.3 ± 7.7
Reticulocytes (10⁶/μL)						
Day 3	0.28 ± 0.03	0.46 ± 0.08	0.29 ± 0.03 ²	0.28 ± 0.04 ³	0.31 ± 0.05	0.39 ± 0.08
Day 15	0.12 ± 0.01 ³	0.15 ± 0.01	0.13 ± 0.01	0.12 ± 0.01	0.13 ± 0.01 ³	0.12 ± 0.01
Week 12	0.15 ± 0.01	0.13 ± 0.01	0.13 ± 0.02	0.15 ± 0.01	0.16 ± 0.01	0.15 ± 0.02
Leukocytes (10³/μL)						
Day 3	9.57 ± 0.52	8.64 ± 0.39	9.30 ± 0.41 ²	9.56 ± 0.30	8.72 ± 0.62	9.48 ± 0.41
Day 15	8.73 ± 0.40 ³	8.61 ± 0.34	8.28 ± 0.36	7.96 ± 0.46	8.19 ± 0.54 ³	8.30 ± 0.50
Week 12	10.60 ± 0.21	9.56 ± 0.34	9.88 ± 0.41	10.01 ± 0.31	10.13 ± 0.42	9.75 ± 0.40
Segmented neutrophils (10³/μL)						
Day 3	0.94 ± 0.09	1.01 ± 0.12	0.95 ± 0.07 ²	0.90 ± 0.09	1.03 ± 0.13	0.84 ± 0.15
Day 15	0.72 ± 0.07 ³	0.86 ± 0.07	0.85 ± 0.08	0.71 ± 0.13	0.90 ± 0.12 ³	0.79 ± 0.09
Week 12	1.38 ± 0.16	1.47 ± 0.16	1.52 ± 0.16	1.42 ± 0.13	1.62 ± 0.12	1.47 ± 0.11
Lymphocytes (10³/μL)						
Day 3	7.84 ± 0.44	7.09 ± 0.36	7.52 ± 0.37 ²	8.02 ± 0.26	7.13 ± 0.51	7.86 ± 0.30
Day 15	7.46 ± 0.32 ³	7.23 ± 0.27	7.10 ± 0.34	6.77 ± 0.36	6.84 ± 0.42 ³	6.91 ± 0.36
Week 12	8.80 ± 0.28	7.72 ± 0.30	7.88 ± 0.31	8.19 ± 0.32	8.18 ± 0.43	7.96 ± 0.33

TABLE B1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
MALE (continued)						
Hematology (continued)						
Monocytes ($10^3/\mu\text{L}$)						
Day 3	0.76 ± 0.05	0.48 ± 0.08	0.77 ± 0.10 ²	0.58 ± 0.07	0.54 ± 0.08	0.70 ± 0.07
Day 15	0.52 ± 0.09 ³	0.45 ± 0.08	0.28 ± 0.04	0.43 ± 0.08	0.37 ± 0.12 ³	0.56 ± 0.10
Week 12	0.35 ± 0.06	0.27 ± 0.05	0.43 ± 0.09	0.34 ± 0.08	0.24 ± 0.06	0.28 ± 0.05
Eosinophils ($10^3/\mu\text{L}$)						
Day 3	0.04 ± 0.02	0.03 ± 0.01	0.05 ± 0.02 ²	0.03 ± 0.01	0.03 ± 0.01	0.08 ± 0.03
Day 15	0.04 ± 0.02 ³	0.07 ± 0.03	0.05 ± 0.02	0.04 ± 0.02	0.08 ± 0.02 ³	0.03 ± 0.02
Week 12	0.07 ± 0.03	0.10 ± 0.04	0.05 ± 0.03	0.06 ± 0.03	0.09 ± 0.04	0.04 ± 0.03
Nucleated erythrocytes ($10^3/\mu\text{L}$)						
Day 3	0.06 ± 0.03	0.00 ± 0.00	0.00 ± 0.00 ³	0.00 ± 0.00	0.00 ± 0.00	0.03 ± 0.02
Day 15	0.01 ± 0.01 ³	0.00 ± 0.00	0.00 ± 0.00	0.02 ± 0.02	0.02 ± 0.02 ³	0.00 ± 0.00
Week 12	0.04 ± 0.03	0.05 ± 0.03	0.04 ± 0.02	0.02 ± 0.01	0.00 ± 0.00	0.02 ± 0.01
Clinical Chemistry						
Blood urea nitrogen (mg/dL)						
Day 3	25.8 ± 2.6	27.3 ± 1.4	24.9 ± 1.5	23.8 ± 1.3	24.9 ± 2.0	24.7 ± 1.3
Day 15	14.7 ± 1.3 ³	16.6 ± 0.8	15.2 ± 1.4	14.2 ± 1.4	16.7 ± 1.9 ³	13.9 ± 1.1
Week 12	15.0 ± 1.1	14.0 ± 0.8	14.8 ± 0.9	14.4 ± 0.6	14.0 ± 0.6	13.4 ± 0.5
Creatinine (mg/dL)						
Day 3	0.43 ± 0.03 ³	0.41 ± 0.04	0.40 ± 0.03	0.43 ± 0.02	0.41 ± 0.03	0.42 ± 0.03
Day 15	0.41 ± 0.04 ³	0.39 ± 0.03	0.42 ± 0.05	0.39 ± 0.02	0.41 ± 0.03 ³	0.38 ± 0.02
Week 12	0.43 ± 0.03	0.38 ± 0.02	0.43 ± 0.02	0.47 ± 0.03	0.46 ± 0.02	0.42 ± 0.03
Alkaline phosphatase (IU/L)						
Day 3	574 ± 23	535 ± 24	525 ± 13	520 ± 40	539 ± 20	563 ± 29
Day 15	420 ± 18	432 ± 14	427 ± 17	430 ± 21	448 ± 40	421 ± 14
Week 12	129 ± 2	113 ± 2**	133 ± 4	129 ± 3	123 ± 3	125 ± 4
Alanine aminotransferase (IU/L)						
Day 3	38 ± 2	41 ± 2	40 ± 2	39 ± 1	38 ± 2	42 ± 2
Day 15	33 ± 2	32 ± 2	32 ± 1	32 ± 2	35 ± 3	32 ± 1
Week 12	42 ± 2	40 ± 1	41 ± 2	38 ± 2 ³	39 ± 1	38 ± 1
Gamma glutamyltransferase (IU/L)						
Day 3	1.7 ± 0.3	1.6 ± 0.4	1.1 ± 0.3	1.5 ± 0.3	1.4 ± 0.3	1.6 ± 0.5
Day 15	1.2 ± 0.4 ³	1.7 ± 0.5	1.7 ± 0.4	1.5 ± 0.5	1.9 ± 0.6	1.6 ± 0.6
Week 12	0.5 ± 0.2	0.6 ± 0.2	0.6 ± 0.3	0.5 ± 0.2	1.1 ± 0.4	1.0 ± 0.5
Sorbitol dehydrogenase (IU/L)						
Day 3	5 ± 0	4 ± 1	5 ± 1	4 ± 1	6 ± 1	4 ± 0
Day 15	10 ± 1	10 ± 0	9 ± 1	10 ± 1	8 ± 0	10 ± 1
Week 12	10 ± 1	13 ± 1*	10 ± 1	10 ± 1	9 ± 1	11 ± 1

**TABLE B1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
In the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
MALE (continued)						
Urinalysis						
Urine volume (mL/16 hr)						
Day 3	1 ± 0	1 ± 0 ⁴	1 ± 0	1 ± 0	2 ± 0	2 ± 0
Day 15	2 ± 0 ³	3 ± 0 [*]	2 ± 0	1 ± 0	3 ± 0 [*]	3 ± 0 [*]
Week 12	2 ± 0	2 ± 0 ²	2 ± 0	1 ± 0 ³	3 ± 0	2 ± 0
Specific gravity						
Day 3	1 060 ± 0 005	1 064 ± 0 004 ⁴	1 069 ± 0 004 ³	1 070 ± 0 004 ³	1 067 ± 0 004 ³	1 066 ± 0 003
Day 15	1 052 ± 0 003 ³	1 051 ± 0 003	1 046 ± 0 005	1 056 ± 0 004	1 052 ± 0 002	1 053 ± 0 005
Week 12	1 066 ± 0 004	1 061 ± 0 004 ²	1 056 ± 0 004	1 060 ± 0 003 ⁴	1 057 ± 0 004	1 061 ± 0 003
Urine pH						
Day 3	5 95 ± 0 12	5 86 ± 0 14 ⁴	5 90 ± 0 12	5 85 ± 0 08	5 95 ± 0 09	5 85 ± 0 08
Day 15	6 06 ± 0 06 ³	6 05 ± 0 12	6 10 ± 0 19	6 00 ± 0 11	6 00 ± 0 11	6 00 ± 0 13
Week 12	6 10 ± 0 07	6 38 ± 0 13 ²	6 30 ± 0 15	6 22 ± 0 09 ³	6 05 ± 0 09	6 15 ± 0 08
FEMALE						
n	10	10	10	10	10	10
Hematology						
Hematocrit (%)						
Day 3	43 6 ± 0 6	43 8 ± 0 5	43 3 ± 0 5	43 1 ± 0 6	43 9 ± 0 7	42 9 ± 0 9
Day 15	45 7 ± 0 5	47 0 ± 0 3	45 8 ± 0 4	44 7 ± 0 5	45 0 ± 0 4	46 6 ± 0 6 ³
Week 12	43 1 ± 0 5	44 0 ± 0 6	45 3 ± 0 7	43 4 ± 0 5 ³	44 7 ± 0 6	43 6 ± 0 7
Hemoglobin (g/dL)						
Day 3	16 4 ± 0 2	16 8 ± 0 2	16 4 ± 0 3	16 4 ± 0 2	16 7 ± 0 2	16 3 ± 0 4
Day 15	17 2 ± 0 1	17 3 ± 0 1	17 1 ± 0 2	17 1 ± 0 1	16 8 ± 0 1	17 2 ± 0 2 ³
Week 12	15 4 ± 0 1	16 0 ± 0 2	16 2 ± 0 1 ^{**}	15 6 ± 0 1 ³	15 9 ± 0 2	15 5 ± 0 1
Erythrocytes (10 ⁶ /μL)						
Day 3	7 22 ± 0 15	7 41 ± 0 09	7 18 ± 0 18	7 27 ± 0 19	7 47 ± 0 12	7 39 ± 0 20
Day 15	7 57 ± 0 08	7 81 ± 0 08	7 54 ± 0 08	7 45 ± 0 07	7 46 ± 0 09	7 77 ± 0 09 ³
Week 12	7 69 ± 0 09	8 00 ± 0 12	8 17 ± 0 13 [*]	7 76 ± 0 07 ⁹	8 02 ± 0 11	7 76 ± 0 11
Mean cell volume (fL)						
Day 3	60 6 ± 0 8	59 4 ± 0 5	60 5 ± 0 9	59 5 ± 1 1	58 7 ± 0 4	58 1 ± 0 7 [*]
Day 15	60 3 ± 0 5	60 2 ± 0 4	60 9 ± 0 6	60 1 ± 0 4	60 4 ± 0 5	60 0 ± 0 5 ³
Week 12	56 1 ± 0 3	54 9 ± 0 2	55 4 ± 0 3	55 8 ± 0 3 ³	55 7 ± 0 5	56 1 ± 0 4
Mean cell hemoglobin (pg)						
Day 3	22 8 ± 0 4	22 7 ± 0 3	22 9 ± 0 3	22 6 ± 0 5	22 4 ± 0 2	22 1 ± 0 2
Day 15	22 7 ± 0 2	22 1 ± 0 2	22 7 ± 0 2	23 0 ± 0 2	22 5 ± 0 2	22 1 ± 0 1 ³
Week 12	20 0 ± 0 2	20 1 ± 0 1	19 8 ± 0 2	20 1 ± 0 2 ³	19 8 ± 0 2	20 0 ± 0 1
Mean cell hemoglobin concentration (g/dL)						
Day 3	37 7 ± 0 6	38 3 ± 0 6	37 8 ± 0 3	38 1 ± 0 4	38 1 ± 0 3	37 9 ± 0 2
Day 15	37 6 ± 0 3	36 8 ± 0 2	37 4 ± 0 3	38 2 ± 0 3	37 3 ± 0 3	36 9 ± 0 3 ³
Week 12	35 8 ± 0 4	36 5 ± 0 2	35 8 ± 0 4	35 9 ± 0 4 ³	35 6 ± 0 3	35 6 ± 0 4
Platelets (10 ³ /μL)						
Day 3	858 9 ± 45 3	800 9 ± 18 7	840 3 ± 41 6	839 2 ± 42 1	786 5 ± 20 3	795 7 ± 17 4
Day 15	658 1 ± 10 4	671 2 ± 15 0	678 2 ± 10 8	707 9 ± 13 5 [*]	706 5 ± 22 3 [*]	707 0 ± 19 8 ^{*3}
Week 12	631 2 ± 11 0	588 3 ± 19 1	617 4 ± 14 3	643 2 ± 20 5 ³	644 4 ± 21 4	658 5 ± 17 0

**TABLE B1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
In the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
FEMALE (continued)						
Hematology (continued)						
Reticulocytes ($10^6/\mu\text{L}$)						
Day 3	0.37 ± 0.09	0.32 ± 0.03	0.35 ± 0.06	0.33 ± 0.06 ³	0.25 ± 0.03	0.28 ± 0.05
Day 15	0.14 ± 0.01	0.16 ± 0.01	0.14 ± 0.01	0.12 ± 0.01	0.17 ± 0.01	0.14 ± 0.01 ³
Week 12	0.21 ± 0.02	0.14 ± 0.01**	0.13 ± 0.01**	0.16 ± 0.01** ³	0.17 ± 0.01*	0.14 ± 0.01**
Leukocytes ($10^3/\mu\text{L}$)						
Day 3	8.82 ± 1.12	8.70 ± 0.49	8.33 ± 0.44	9.21 ± 1.10	9.82 ± 0.63	9.57 ± 0.68
Day 15	7.82 ± 0.51	8.36 ± 0.37	7.77 ± 0.30	8.61 ± 0.42	8.66 ± 0.43	8.92 ± 0.43 ³
Week 12	6.72 ± 0.46	7.23 ± 0.45	7.16 ± 0.47	7.09 ± 0.49 ³	7.49 ± 0.66	8.20 ± 0.24*
Segmented neutrophils ($10^3/\mu\text{L}$)						
Day 3	0.85 ± 0.10	0.84 ± 0.14	0.95 ± 0.09	0.68 ± 0.11	0.94 ± 0.10	1.11 ± 0.19
Day 15	0.88 ± 0.09	1.18 ± 0.08	0.87 ± 0.17	0.97 ± 0.08	1.07 ± 0.15	1.18 ± 0.11 ³
Week 12	0.99 ± 0.12	1.08 ± 0.14	1.24 ± 0.15	0.95 ± 0.12 ³	1.15 ± 0.13	1.19 ± 0.12
Lymphocytes ($10^3/\mu\text{L}$)						
Day 3	7.56 ± 1.04	7.31 ± 0.40	6.92 ± 0.36	7.93 ± 0.86	8.39 ± 0.55	7.76 ± 0.48
Day 15	6.42 ± 0.44	6.68 ± 0.27	6.42 ± 0.26	7.19 ± 0.41	7.06 ± 0.32	7.16 ± 0.47 ³
Week 12	5.35 ± 0.35	5.79 ± 0.36	5.61 ± 0.39	5.80 ± 0.44 ³	6.01 ± 0.54	6.48 ± 0.18*
Monocytes ($10^3/\mu\text{L}$)						
Day 3	0.34 ± 0.06	0.50 ± 0.08	0.40 ± 0.06	0.52 ± 0.18	0.38 ± 0.07	0.60 ± 0.12
Day 15	0.42 ± 0.09	0.41 ± 0.07	0.39 ± 0.08	0.37 ± 0.07	0.41 ± 0.07	0.48 ± 0.08 ³
Week 12	0.30 ± 0.06	0.30 ± 0.05	0.24 ± 0.04	0.28 ± 0.06 ³	0.25 ± 0.04	0.46 ± 0.07
Eosinophils ($10^3/\mu\text{L}$)						
Day 3	0.06 ± 0.03	0.05 ± 0.02	0.06 ± 0.02	0.08 ± 0.04	0.11 ± 0.04	0.08 ± 0.03
Day 15	0.08 ± 0.03	0.11 ± 0.03	0.09 ± 0.03	0.07 ± 0.02	0.10 ± 0.03	0.10 ± 0.03 ³
Week 12	0.07 ± 0.04	0.05 ± 0.02	0.07 ± 0.02	0.06 ± 0.02 ³	0.09 ± 0.04	0.05 ± 0.02
Nucleated erythrocytes ($10^3/\mu\text{L}$)						
Day 3	0.01 ± 0.01	0.02 ± 0.02	0.00 ± 0.00	0.01 ± 0.01	0.04 ± 0.03	0.09 ± 0.08
Day 15	0.00 ± 0.00	0.01 ± 0.01	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.02 ± 0.02 ³
Week 12	0.00 ± 0.00	0.01 ± 0.01	0.00 ± 0.00	0.01 ± 0.01 ³	0.00 ± 0.00	0.00 ± 0.00
Clinical Chemistry						
Blood urea nitrogen (mg/dL)						
Day 3	24.5 ± 2.1	25.7 ± 1.5	28.4 ± 1.7	25.0 ± 1.5	25.4 ± 1.7	25.4 ± 2.3
Day 15	18.7 ± 1.6	21.4 ± 1.1	21.1 ± 1.8	22.1 ± 1.3	20.9 ± 1.8	19.1 ± 0.9
Week 12	20.2 ± 1.0	18.9 ± 0.9	19.7 ± 0.9	17.1 ± 1.0	20.5 ± 2.5	17.2 ± 0.9
Creatinine (mg/dL)						
Day 3	0.40 ± 0.03	0.37 ± 0.02	0.39 ± 0.02	0.37 ± 0.02	0.41 ± 0.02	0.39 ± 0.03
Day 15	0.35 ± 0.03	0.30 ± 0.02	0.35 ± 0.03	0.35 ± 0.02	0.33 ± 0.02	0.34 ± 0.03
Week 12	0.58 ± 0.09	0.49 ± 0.06	0.44 ± 0.05	0.54 ± 0.06	0.46 ± 0.06	0.51 ± 0.06
Alkaline phosphatase (IU/L)						
Day 3	329 ± 10	328 ± 9	378 ± 40	325 ± 8	327 ± 15	291 ± 11*
Day 15	243 ± 7	248 ± 6	241 ± 9	241 ± 5	247 ± 10	233 ± 4
Week 12	84 ± 4	97 ± 3	93 ± 4	85 ± 3	100 ± 4*	85 ± 4

**TABLE B1 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
in the 13-Week Dermal Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	Vehicle Control	12.5 mg/kg	25 mg/kg	50 mg/kg	100 mg/kg	200 mg/kg
FEMALE (continued)						
Clinical Chemistry (continued)						
Alanine aminotransferase (IU/L)						
Day 3	35 ± 2	32 ± 1	35 ± 3	33 ± 2	35 ± 2	33 ± 1
Day 15	32 ± 1	30 ± 1	27 ± 2*	28 ± 1	29 ± 1	30 ± 1
Week 12	37 ± 3	35 ± 1	35 ± 2	34 ± 2	36 ± 3	31 ± 1
Gamma glutamyltransferase (IU/L)						
Day 3	1.9 ± 0.4	2.1 ± 0.4	1.9 ± 0.3	1.7 ± 0.5	2.6 ± 0.3	2.6 ± 0.3
Day 15	1.0 ± 0.3	0.6 ± 0.2	1.4 ± 0.5	1.0 ± 0.4	1.5 ± 0.3	0.7 ± 0.2
Week 12	2.2 ± 0.5	2.7 ± 0.5	3.1 ± 0.6	2.0 ± 0.4	2.1 ± 0.4	2.7 ± 0.3
Sorbitol dehydrogenase (IU/L)						
Day 3	7 ± 1	7 ± 1	6 ± 1	7 ± 1	7 ± 1	7 ± 1
Day 15	12 ± 1	12 ± 1	10 ± 1	12 ± 1	11 ± 1	11 ± 1
Week 12	8 ± 1	9 ± 0	9 ± 1	9 ± 0	9 ± 0	8 ± 1
Urinalysis						
Urine volume (mL/16 hr)						
Day 3	2 ± 0	2 ± 0	2 ± 0	1 ± 0	2 ± 0	2 ± 0
Day 15	3 ± 0	2 ± 0	2 ± 0	2 ± 0	2 ± 0	3 ± 0
Week 12	1 ± 0	1 ± 0 ³	1 ± 0	1 ± 0	1 ± 0 ³	2 ± 0 ³
Specific gravity						
Day 3	1.052 ± 0.005	1.040 ± 0.004	1.048 ± 0.003	1.054 ± 0.004	1.050 ± 0.004	1.049 ± 0.002
Day 15	1.033 ± 0.006	1.034 ± 0.003	1.036 ± 0.005	1.038 ± 0.006	1.041 ± 0.003	1.038 ± 0.002
Week 12	1.057 ± 0.005 ³	1.061 ± 0.007 ³	1.061 ± 0.006 ³	1.060 ± 0.006 ³	1.053 ± 0.004 ²	1.046 ± 0.005 ²
Urine pH						
Day 3	5.90 ± 0.07	6.30 ± 0.11	6.00 ± 0.07	5.75 ± 0.08	5.90 ± 0.12	6.00 ± 0.13
Day 15	6.10 ± 0.15	6.05 ± 0.12	6.20 ± 0.17	6.05 ± 0.09	6.05 ± 0.05	6.00 ± 0.11
Week 12	5.90 ± 0.10	5.94 ± 0.10 ³	6.05 ± 0.16	5.95 ± 0.12	5.94 ± 0.10 ¹	6.06 ± 0.10 ¹

¹ Mean ± standard error

² n=8

³ n=9

⁴ n=7

* Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

** Significantly different (P≤0.01) from the control group by Dunn's or Shirley's test

TABLE B2 Hematology, Clinical Chemistry, and Urinalysis Data for Rats in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone¹

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
MALE						
n	10	10	10	10	10	10
Hematology						
Hematocrit (%)						
Day 3	41.6 ± 0.9	41.1 ± 0.4	41.2 ± 0.4	41.5 ± 0.6	42.5 ± 0.8	43.7 ± 1.0
Day 15	44.1 ± 0.5	43.2 ± 0.3 ²	43.5 ± 0.3	43.6 ± 0.5	43.7 ± 0.4	44.2 ± 0.5
Week 12	45.1 ± 0.6	42.4 ± 0.7 ^{*2}	44.2 ± 0.5 ²	44.0 ± 0.5	44.3 ± 0.7 ²	43.8 ± 0.8
Hemoglobin (g/dL)						
Day 3	14.5 ± 0.1	14.1 ± 0.2	14.3 ± 0.1	14.5 ± 0.1	14.6 ± 0.3	15.0 ± 0.3
Day 15	15.3 ± 0.1	15.0 ± 0.1 ²	15.1 ± 0.1	15.2 ± 0.2	15.1 ± 0.2	15.4 ± 0.2
Week 12	16.5 ± 0.2	15.8 ± 0.2 ^{*2}	16.1 ± 0.1 ²	16.2 ± 0.2	16.1 ± 0.2 ²	16.0 ± 0.3
Erythrocytes (10 ⁶ /μL)						
Day 3	6.58 ± 0.11	6.42 ± 0.16	6.55 ± 0.11	6.70 ± 0.09	6.81 ± 0.16	7.01 ± 0.20
Day 15	7.02 ± 0.08	6.81 ± 0.08 ²	6.84 ± 0.06	6.79 ± 0.09	6.83 ± 0.10	7.04 ± 0.10
Week 12	8.88 ± 0.08	8.51 ± 0.12 ^{*2}	8.76 ± 0.08 ²	8.76 ± 0.09	8.74 ± 0.13 ²	8.38 ± 0.24
Mean cell volume (fL)						
Day 3	63.3 ± 1.1	64.3 ± 1.3	63.0 ± 0.8	62.1 ± 0.5	62.5 ± 0.7	62.6 ± 0.5
Day 15	62.9 ± 0.3	63.6 ± 0.6 ²	63.7 ± 0.6	64.1 ± 0.5	63.9 ± 0.7	63.0 ± 0.6
Week 12	50.8 ± 0.4	49.7 ± 0.5 ²	50.4 ± 0.3 ²	50.2 ± 0.4	50.7 ± 0.4 ²	52.5 ± 0.9
Mean cell hemoglobin (pg)						
Day 3	22.0 ± 0.3	22.1 ± 0.4	21.8 ± 0.2	21.7 ± 0.2	21.5 ± 0.3	21.5 ± 0.3
Day 15	21.8 ± 0.2	22.0 ± 0.2 ²	22.0 ± 0.2	22.3 ± 0.2	22.2 ± 0.2	21.9 ± 0.2
Week 12	18.6 ± 0.2	18.6 ± 0.2 ²	18.4 ± 0.1 ²	18.4 ± 0.1	18.4 ± 0.1 ²	19.2 ± 0.3
Mean cell hemoglobin concentration (g/dL)						
Day 3	34.9 ± 0.8	34.4 ± 0.3	34.6 ± 0.2	34.9 ± 0.2	34.5 ± 0.3	34.4 ± 0.3
Day 15	34.7 ± 0.2	34.7 ± 0.2 ²	34.6 ± 0.3	34.8 ± 0.1	34.6 ± 0.2	34.8 ± 0.3
Week 12	36.7 ± 0.5	37.3 ± 0.5 ²	36.4 ± 0.4 ²	36.7 ± 0.3	36.4 ± 0.4 ²	36.6 ± 0.4
Platelets (10 ³ /μL)						
Day 3	891.5 ± 14.4	988.9 ± 58.3	910.6 ± 38.8	967.5 ± 30.8	1039.2 ± 41.8 ^{**}	1058.3 ± 47.1 ^{**}
Day 15	770.0 ± 20.7	818.6 ± 12.0 ^{*2}	802.8 ± 12.0 [*]	826.8 ± 16.9 [*]	872.2 ± 40.5 ^{**2}	874.2 ± 41.3 ^{**}
Week 12	583.5 ± 12.8	604.0 ± 10.4 ²	624.0 ± 17.2 ²	636.5 ± 16.8 ^{**}	690.7 ± 26.0 ^{**2}	845.0 ± 58.5 ^{**}
Reticulocytes (10 ⁶ /μL)						
Day 3	0.92 ± 0.12	0.98 ± 0.07 ²	1.11 ± 0.13	0.89 ± 0.14	0.88 ± 0.11	0.76 ± 0.14
Day 15	0.27 ± 0.03	0.20 ± 0.03 ²	0.22 ± 0.02	0.21 ± 0.03	0.23 ± 0.03	0.23 ± 0.03
Week 12	0.15 ± 0.01	0.21 ± 0.02 ^{*2}	0.14 ± 0.02 ²	0.17 ± 0.01	0.19 ± 0.02 ²	0.27 ± 0.02 ^{**}
Leukocytes (10 ³ /μL)						
Day 3	8.55 ± 0.30	9.17 ± 0.97	11.01 ± 1.74	9.15 ± 0.25	9.62 ± 0.56	8.79 ± 0.41
Day 15	9.11 ± 0.32	9.00 ± 0.29 ²	7.94 ± 0.48	9.29 ± 0.59	9.65 ± 0.34	9.70 ± 0.44
Week 12	10.41 ± 0.23	9.79 ± 0.32 ²	9.71 ± 0.44 ²	10.09 ± 0.26	9.77 ± 0.48 ²	13.08 ± 1.33
Segmented neutrophils (10 ³ /μL)						
Day 3	0.86 ± 0.11	0.96 ± 0.09	1.25 ± 0.14 ^{*2}	0.97 ± 0.13	1.26 ± 0.18	1.13 ± 0.15
Day 15	0.86 ± 0.07	0.77 ± 0.05 ²	0.94 ± 0.13	0.84 ± 0.06	1.10 ± 0.15	1.16 ± 0.06 [*]
Week 12	1.76 ± 0.15	1.37 ± 0.18 ²	1.40 ± 0.11 ²	1.32 ± 0.12	1.27 ± 0.17 ²	4.06 ± 0.89
Lymphocytes (10 ³ /μL)						
Day 3	7.17 ± 0.25	7.60 ± 0.85	8.92 ± 1.30	7.77 ± 0.18	7.94 ± 0.51	7.24 ± 0.36
Day 15	7.65 ± 0.32	7.76 ± 0.27 ²	6.53 ± 0.36	7.92 ± 0.52	8.02 ± 0.23	7.88 ± 0.34
Week 12	7.93 ± 0.27	7.71 ± 0.26 ²	7.70 ± 0.33 ²	8.29 ± 0.24	8.00 ± 0.43 ²	8.07 ± 0.47

**TABLE B2 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
in the 13-week feed studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
MALE (continued)						
Hematology (continued)						
Monocytes (10 ³ /μL)						
Day 3	0.43 ± 0.10	0.54 ± 0.12	0.35 ± 0.07	0.36 ± 0.06	0.36 ± 0.08	0.38 ± 0.10
Day 15	0.55 ± 0.05	0.39 ± 0.06 ²	0.41 ± 0.07	0.48 ± 0.09	0.51 ± 0.06	0.57 ± 0.06
Week 12	0.62 ± 0.10	0.56 ± 0.12 ²	0.50 ± 0.07 ²	0.38 ± 0.05	0.42 ± 0.10 ²	0.89 ± 0.19
Eosinophils (10 ³ /μL)						
Day 3	0.08 ± 0.02	0.05 ± 0.02	0.06 ± 0.02	0.03 ± 0.01	0.05 ± 0.02	0.03 ± 0.01
Day 15	0.02 ± 0.01	0.07 ± 0.02 ²	0.04 ± 0.02	0.05 ± 0.03	0.02 ± 0.01	0.08 ± 0.03
Week 12	0.09 ± 0.03	0.13 ± 0.03 ²	0.11 ± 0.05 ²	0.10 ± 0.04	0.06 ± 0.02 ²	0.06 ± 0.03
Nucleated erythrocytes ³ (10 ³ /μL)						
Day 3	0.01 ± 0.01	0.07 ± 0.04	0.03 ± 0.03	0.05 ± 0.02	0.03 ± 0.02	0.04 ± 0.02
Clinical Chemistry						
Blood urea nitrogen (mg/dL)						
Day 3	21.2 ± 0.9	19.9 ± 1.1	21.6 ± 1.6	23.2 ± 1.8	24.2 ± 1.1	25.5 ± 1.4*
Day 15	16.3 ± 0.8	16.1 ± 1.0 ²	16.9 ± 0.9	17.5 ± 0.6	18.5 ± 0.9	23.0 ± 1.5**
Week 12	18.9 ± 0.9	16.1 ± 1.0 ²	17.6 ± 0.8	18.9 ± 0.5	19.7 ± 0.6	22.3 ± 2.3
Creatinine (mg/dL)						
Day 3	0.38 ± 0.02	0.39 ± 0.02	0.36 ± 0.04	0.38 ± 0.02	0.38 ± 0.03	0.39 ± 0.02
Day 15	0.38 ± 0.01	0.33 ± 0.02 ²	0.33 ± 0.02	0.32 ± 0.02	0.31 ± 0.01	0.37 ± 0.03
Week 12	0.52 ± 0.05	0.49 ± 0.04 ²	0.52 ± 0.03	0.52 ± 0.04	0.44 ± 0.02 ²	0.56 ± 0.05 ²
Alkaline phosphatase (IU/L)						
Day 3	592 ± 31	569 ± 59	515 ± 35	569 ± 34	626 ± 74	505 ± 32
Day 15	429 ± 16	390 ± 5 ²	379 ± 14*	359 ± 10**	315 ± 7**	261 ± 9**
Week 12	145 ± 4	138 ± 13**	140 ± 4	126 ± 8*	108 ± 5**	95 ± 6**
Alanine aminotransferase (IU/L)						
Day 3	33 ± 2	34 ± 1	38 ± 1**	42 ± 1**	43 ± 2**	48 ± 3**
Day 15	29 ± 1	25 ± 1 ²	30 ± 2	27 ± 1	28 ± 1	33 ± 3
Week 12	44 ± 2	34 ± 1**	37 ± 1	34 ± 1**	35 ± 2*	53 ± 10 ⁴
Gamma glutamyltransferase (IU/L)						
Day 3	1.2 ± 0.4	0.9 ± 0.4	1.2 ± 0.4	2.3 ± 0.5	2.4 ± 0.5	3.7 ± 0.6**
Day 15	1.5 ± 0.5	1.9 ± 0.7 ²	3.6 ± 0.7*	2.9 ± 0.5*	3.3 ± 0.6*	9.5 ± 0.9**
Week 12	0.7 ± 0.2	0.7 ± 0.4 ²	0.2 ± 0.1	1.0 ± 0.5	1.6 ± 0.3	13.0 ± 2.1**
Sorbitol dehydrogenase (IU/L)						
Day 3	9 ± 1	9 ± 0	9 ± 1 ²	9 ± 1	9 ± 0	8 ± 1
Day 15	8 ± 0	9 ± 0 ²	8 ± 0	9 ± 1	9 ± 0	8 ± 0
Week 12	10 ± 1	10 ± 0 ²	9 ± 1	8 ± 0*	9 ± 1 ²	11 ± 2 ²

**TABLE B2 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
MALE (continued)						
Urinalysis						
Urine volume (mL/16 hr)						
Day 3	1 ± 0	1 ± 0	1 ± 0 ²	1 ± 0 ²	2 ± 1 ⁴	1 ± 0 ⁴
Day 15	1 ± 0 ²	2 ± 0 ²	2 ± 0	1 ± 0	1 ± 0	2 ± 0 [*]
Week 12	2 ± 0	3 ± 0 ²	3 ± 0	2 ± 0	3 ± 0 ²	7 ± 1 ^{**}
Specific gravity						
Day 3	1 041 ± 0 005 ²	1 040 ± 0 005 ²	1 049 ± 0 004 ²	1 045 ± 0 007 ²	1 049 ± 0 009 ⁴	1 077 ± 0 003 ^{***5}
Day 15	1 049 ± 0 006 ²	1 047 ± 0 007 ⁴	1 054 ± 0 002	1 061 ± 0 008 ²	1 062 ± 0 005 ⁴	1 062 ± 0 003 ²
Week 12	1 066 ± 0 004	1 059 ± 0 003 ²	1 052 ± 0 003 [*]	1 068 ± 0 005	1 064 ± 0 003 ²	1 027 ± 0 001 ^{**}
Urine pH						
Day 3	6 45 ± 0 16	6 15 ± 0 08	6 06 ± 0 06 ^{**2}	6 22 ± 0 09 ²	6 19 ± 0 13 ⁴	6 06 ± 0 06 ^{**4}
Day 15	6 06 ± 0 06 ²	6 06 ± 0 06 ⁴	6 20 ± 0 08	6 35 ± 0 13	6 00 ± 0 00	6 17 ± 0 08 ²
Week 12	6 00 ± 0 00	6 11 ± 0 07 ²	6 00 ± 0 07	5 80 ± 0 08	5 67 ± 0 08 ^{**2}	5 90 ± 0 07
FEMALE						
n	10	10	10	10	10	10
Hematology						
Hematocrit (%)						
Day 3	42 4 ± 0 6	42 1 ± 0 6	43 7 ± 0 5 [*]	45 3 ± 0 6 ^{**}	43 7 ± 0 9 ^{**}	43 6 ± 1 0 [*]
Day 15	44 9 ± 0 4	44 2 ± 0 7	43 5 ± 0 6	43 2 ± 0 5	44 2 ± 0 7 ²	44 3 ± 0 7
Week 12	42 4 ± 0 7	41 5 ± 0 7 ²	40 7 ± 1 0	40 4 ± 0 7	41 2 ± 0 9	41 0 ± 0 6
Hemoglobin (g/dL)						
Day 3	15 0 ± 0 3	15 0 ± 0 2	15 7 ± 0 2 [*]	16 2 ± 0 3 ^{**}	15 8 ± 0 3 ^{**}	15 8 ± 0 4 [*]
Day 15	16 5 ± 0 1	16 1 ± 0 1 [*]	15 9 ± 0 2 ^{**}	15 8 ± 0 2 ^{**}	15 9 ± 0 2 ^{*2}	16 0 ± 0 1 [*]
Week 12	15 6 ± 0 2	15 1 ± 0 2 ²	15 2 ± 0 2	15 0 ± 0 1	15 1 ± 0 2	15 2 ± 0 2
Erythrocytes (10 ⁶ /μL)						
Day 3	6 84 ± 0 19	6 93 ± 0 14	7 31 ± 0 14 [*]	7 67 ± 0 15 ^{**}	7 33 ± 0 21 ^{**}	7 43 ± 0 21 [*]
Day 15	7 39 ± 0 09	7 29 ± 0 11	7 21 ± 0 10	7 23 ± 0 08	7 38 ± 0 14 ²	7 37 ± 0 09
Week 12	7 77 ± 0 10	7 57 ± 0 13 ²	7 49 ± 0 19	7 59 ± 0 13	7 71 ± 0 16	7 71 ± 0 13
Mean cell volume (fL)						
Day 3	62 4 ± 1 2	60 6 ± 0 5	59 8 ± 0 6 [*]	59 2 ± 0 6 ^{**}	59 8 ± 0 7 [*]	58 8 ± 0 4 ^{**}
Day 15	60 9 ± 0 5	60 7 ± 0 5	60 3 ± 0 6	59 7 ± 0 4	60 0 ± 0 6 ²	60 1 ± 0 5
Week 12	54 5 ± 0 4	54 7 ± 0 2 ²	54 3 ± 0 2	53 3 ± 0 4 ^{**}	53 5 ± 0 4 [*]	53 3 ± 0 3 ^{**}
Mean cell hemoglobin (pg)						
Day 3	21 9 ± 0 3	21 6 ± 0 2	21 5 ± 0 2	21 2 ± 0 1 [*]	21 7 ± 0 3	21 3 ± 0 2
Day 15	22 4 ± 0 2	22 1 ± 0 2	22 0 ± 0 3	21 9 ± 0 2	21 6 ± 0 4 ²	21 7 ± 0 2 [*]
Week 12	20 1 ± 0 1	20 0 ± 0 2 ²	20 3 ± 0 3	19 8 ± 0 2	19 6 ± 0 2	19 7 ± 0 1
Mean cell hemoglobin concentration (g/dL)						
Day 3	35 2 ± 0 3	35 6 ± 0 2	35 9 ± 0 2	35 8 ± 0 3	36 2 ± 0 2 ^{**}	36 2 ± 0 2 ^{**}
Day 15	36 7 ± 0 2	36 4 ± 0 4	36 5 ± 0 4	36 7 ± 0 3	36 1 ± 0 7 ²	36 1 ± 0 4
Week 12	36 8 ± 0 3	36 4 ± 0 4 ²	37 5 ± 0 5	37 2 ± 0 4	36 7 ± 0 4	37 0 ± 0 1
Platelets (10 ³ /μL)						
Day 3	876 5 ± 71 2	859 6 ± 38 0	858 2 ± 48 1	798 2 ± 36 3	950 7 ± 109 0	915 5 ± 59 4
Day 15	729 3 ± 21 2	752 8 ± 14 4	752 9 ± 18 1	744 1 ± 21 5	784 0 ± 57 5 ²	686 4 ± 22 8
Week 12	653 6 ± 19 2	733 8 ± 37 4 ^{**2}	703 6 ± 19 0 [*]	730 6 ± 40 1	685 1 ± 16 2	754 8 ± 14 8 ^{**}

**TABLE B2 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
in the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
FEMALE (continued)						
Hematology (continued)						
Reticulocytes ($10^6/\mu\text{L}$)						
Day 3	0.64 ± 0.14	0.47 ± 0.10	0.44 ± 0.09	0.31 ± 0.09	0.49 ± 0.16	0.30 ± 0.08*
Day 15	0.16 ± 0.02	0.19 ± 0.01	0.18 ± 0.01	0.16 ± 0.01	0.19 ± 0.02 ²	0.25 ± 0.03
Week 12	0.18 ± 0.01	0.19 ± 0.00 ²	0.20 ± 0.01	0.18 ± 0.02	0.21 ± 0.02	0.19 ± 0.02
Leukocytes ($10^3/\mu\text{L}$)						
Day 3	8.69 ± 0.62 ²	9.83 ± 0.73	9.24 ± 0.67	10.50 ± 0.60	11.28 ± 1.48	9.20 ± 0.75
Day 15	8.69 ± 0.39	8.60 ± 0.45	7.91 ± 0.30	8.03 ± 0.59	8.57 ± 0.54 ²	8.62 ± 0.43
Week 12	9.13 ± 0.31	8.53 ± 0.54 ²	8.82 ± 0.42	8.55 ± 0.30	9.94 ± 0.33	9.11 ± 0.68
Segmented neutrophils ($10^3/\mu\text{L}$)						
Day 3	1.29 ± 0.15 ²	1.11 ± 0.13	0.96 ± 0.06	1.15 ± 0.16	1.44 ± 0.26	0.95 ± 0.09
Day 15	0.93 ± 0.12	1.07 ± 0.10	0.96 ± 0.12	0.95 ± 0.13	1.02 ± 0.05 ²	1.13 ± 0.12
Week 12	1.44 ± 0.17	1.05 ± 0.18 ²	1.49 ± 0.20	1.26 ± 0.07	1.15 ± 0.12	1.43 ± 0.20
Lymphocytes ($10^3/\mu\text{L}$)						
Day 3	8.69 ± 1.65	8.43 ± 0.63	7.78 ± 0.60	8.87 ± 0.60	9.40 ± 1.18	7.96 ± 0.67
Day 15	7.17 ± 0.34	6.94 ± 0.45	6.44 ± 0.22	6.64 ± 0.43	7.05 ± 0.51 ²	7.07 ± 0.37
Week 12	7.14 ± 0.21	7.07 ± 0.42 ²	6.88 ± 0.37	6.90 ± 0.28	8.21 ± 0.26	7.22 ± 0.50
Monocytes ($10^3/\mu\text{L}$)						
Day 3	0.24 ± 0.05	0.25 ± 0.07	0.36 ± 0.07	0.41 ± 0.10	0.33 ± 0.09	0.24 ± 0.06
Day 15	0.50 ± 0.09	0.48 ± 0.10	0.41 ± 0.06	0.38 ± 0.09	0.43 ± 0.08 ²	0.36 ± 0.06
Week 12	0.43 ± 0.07	0.36 ± 0.07 ²	0.39 ± 0.07	0.26 ± 0.07	0.52 ± 0.09	0.39 ± 0.13
Eosinophils ($10^3/\mu\text{L}$)						
Day 3	0.07 ± 0.03	0.05 ± 0.02	0.14 ± 0.04	0.08 ± 0.03	0.10 ± 0.02	0.06 ± 0.04
Day 15	0.10 ± 0.04	0.11 ± 0.05	0.02 ± 0.01	0.05 ± 0.03	0.06 ± 0.02 ²	0.07 ± 0.02
Week 12	0.12 ± 0.03	0.05 ± 0.03 ²	0.07 ± 0.02	0.12 ± 0.03	0.06 ± 0.02	0.08 ± 0.03
Nucleated erythrocytes ³ ($10^3/\mu\text{L}$)						
Day 3	0.02 ± 0.01	0.01 ± 0.01	0.01 ± 0.01	0.00 ± 0.00	0.04 ± 0.04	0.00 ± 0.00*
Clinical Chemistry						
Blood urea nitrogen (mg/dL)						
Day 3	20.7 ± 0.5	19.8 ± 1.1	18.8 ± 0.9	19.3 ± 0.9	17.5 ± 0.8*	17.7 ± 1.0*
Day 15	18.6 ± 0.9	19.1 ± 0.9	16.8 ± 1.2	17.7 ± 1.1	20.8 ± 1.2	16.7 ± 1.1
Week 12	15.5 ± 1.1	15.0 ± 0.9	16.5 ± 1.6	14.9 ± 0.8	19.3 ± 2.5	20.6 ± 1.7
Creatinine (mg/dL)						
Day 3	0.42 ± 0.02	0.44 ± 0.03	0.40 ± 0.03	0.44 ± 0.02	0.42 ± 0.01	0.40 ± 0.02
Day 15	0.40 ± 0.02	0.38 ± 0.03	0.39 ± 0.02	0.39 ± 0.02	0.43 ± 0.03	0.40 ± 0.02
Week 12	0.42 ± 0.03	0.41 ± 0.02	0.37 ± 0.03	0.43 ± 0.02	0.40 ± 0.02	0.46 ± 0.02
Alkaline phosphatase (IU/L)						
Day 3	268 ± 9	264 ± 6	262 ± 6	255 ± 7	268 ± 6	263 ± 11
Day 15	237 ± 6	227 ± 7	213 ± 7*	219 ± 3*	213 ± 7*	198 ± 5**
Week 12	87 ± 5	83 ± 4	82 ± 3	74 ± 3	78 ± 3	85 ± 2
Alanine aminotransferase (IU/L)						
Day 3	27 ± 1	26 ± 1	29 ± 1	29 ± 1	33 ± 2**	34 ± 1**
Day 15	27 ± 1	25 ± 1	24 ± 1	24 ± 1	27 ± 1	24 ± 1
Week 12	27 ± 1	28 ± 1	31 ± 2	28 ± 1	28 ± 1	30 ± 1

**TABLE B2 Hematology, Clinical Chemistry, and Urinalysis Data for Rats
In the 13-Week Feed Studies of 2-Hydroxy-4-methoxybenzophenone (continued)**

	0 ppm	3,125 ppm	6,250 ppm	12,500 ppm	25,000 ppm	50,000 ppm
FEMALE (continued)						
Clinical Chemistry (continued)						
Gamma-glutamyltransferase (IU/L)						
Day 3	24 ± 07	37 ± 08	42 ± 09	39 ± 06	43 ± 10	42 ± 10
Day 15	15 ± 04	15 ± 05	15 ± 06	26 ± 05	38 ± 07*	115 ± 09**
Week 12	09 ± 03	29 ± 07*	42 ± 05**	42 ± 04**	96 ± 10**	192 ± 10**
Sorbitol dehydrogenase (IU/L)						
Day 3	9 ± 0	8 ± 0	9 ± 1	8 ± 1	9 ± 0	9 ± 0
Day 15	8 ± 0	8 ± 0	8 ± 0	8 ± 0	8 ± 1	7 ± 1
Week 12	8 ± 0	9 ± 1*	10 ± 0**	9 ± 0**	9 ± 1**	11 ± 1**
Urinalysis						
Urine volume (mL/16 hr)						
Day 3	2 ± 0	2 ± 0 ²	1 ± 0	2 ± 0 ²	1 ± 0 ²	1 ± 0
Day 15	1 ± 0	1 ± 0	1 ± 0 ⁴	1 ± 0 ⁴	1 ± 0 ⁴	3 ± 0**
Week 12	1 ± 0 ⁴	1 ± 0	1 ± 0	1 ± 0 ²	1 ± 0	5 ± 1**
Specific gravity						
Day 3	1 033 ± 0 006	1 036 ± 0 007 ⁴	1 028 ± 0 007 ⁶	1 039 ± 0 006 ²	1 059 ± 0 007** ⁴	1 062 ± 0 005** ⁵
Day 15	1 053 ± 0 004	1 059 ± 0 005 ²	1 064 ± 0 006 ⁶	1 057 ± 0 003 ⁵	1 067 ± 0 006 ⁵	1 052 ± 0 005
Week 12	1 061 ± 0 007 ⁴	1 062 ± 0 004	1 068 ± 0 003 ²	1 076 ± 0 005 ⁴	1 068 ± 0 004 ⁴	1 039 ± 0 004
Urine pH						
Day 3	6 30 ± 0 15	6 19 ± 0 09 ⁴	6 64 ± 0 21 ⁵	6 44 ± 0 15 ²	6 31 ± 0 16 ⁴	6 00 ± 0 00 ⁵
Day 15	6 20 ± 0 15	5 90 ± 0 16	6 25 ± 0 16 ⁴	6 25 ± 0 13 ⁴	5 93 ± 0 17 ⁵	6 00 ± 0 07
Week 12	5 88 ± 0 13 ⁴	6 05 ± 0 16	6 45 ± 0 14 [*]	6 22 ± 0 15 ²	5 95 ± 0 09	6 10 ± 0 12

¹ Mean ± standard error

² n=9

³ No measurement recorded for Day 15 and Week 12

⁴ n=8

⁵ n=7

⁶ n=6

* Significantly different (P≤0.05) from the control group by Dunn's or Shirley's test

** Significantly different (P≤0.01) from the control group by Dunn's or Shirley's test

APPENDIX C

**Reproductive Tissue Evaluations
and Estrous Cycle Characterization**

Table C1	Summary of Reproductive Tissue Evaluations in Male Rats in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone	C-2
Table C2	Summary of Estrous Cycle Characterization in Female Rats in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone	C-2
Table C3	Summary of Reproductive Tissue Evaluations in Male Mice in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone	C-3
Table C4	Summary of Estrous Cycle Characterization in Female Mice in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone	C-3
Table C5	Summary of Reproductive Tissue Evaluations in Male Rats in the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone	C-4
Table C6	Summary of Estrous Cycle Characterization in Female Rats in the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone	C-4
Table C7	Summary of Reproductive Tissue Evaluations in Male Mice in the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone	C-5
Table C8	Summary of Estrous Cycle Characterization in Female Mice in the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone	C-5

**TABLE C1 Summary of Reproductive Tissue Evaluations in Male Rats
in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	0 ppm	3,125 ppm	12,500 ppm	50,000 ppm
n	10	9	10	10
Weights (g)				
Necropsy body weight	334 ± 5	333 ± 6	321 ± 6	230 ± 9**
Right epididymis	0.437 ± 0.008	0.439 ± 0.008	0.426 ± 0.010	0.362 ± 0.016**
Right epididymal tail	0.189 ± 0.004	0.188 ± 0.007	0.181 ± 0.006	0.148 ± 0.010**
Spermatozoal measurements				
Motility (%)	99 ± 0	99 ± 0	99 ± 0	98 ± 0
Concentration (10 ⁶ /g)	821 ± 48	787 ± 37	705 ± 36	597 ± 42**
Sperm cell abnormalities (%)	0.66 ± 0.10	0.64 ± 0.10	0.68 ± 0.09	0.80 ± 0.19

¹ Data presented as mean ± standard error. Differences from the control group for reproductive tissue weights and necropsy body weights are significant by Williams' or Dunnett's test, spermatozoal measurements are significant by Dunn's or Shirley's test.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C2 Summary of Estrous Cycle Characterization in Female Rats
in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	0 ppm	3,125 ppm	12,500 ppm	50,000 ppm
n	10	9	9	8
Necropsy body weight (g)	186 ± 6	187 ± 2 ²	175 ± 3 ²	165 ± 3 ² **
Estrous cycle length (days)	4.40 ± 0.16	4.67 ± 0.24 ³	5.00 ± 0.17 ³	5.25 ± 0.16 ³ **
Estrous stages as % of cycle				
diestrus	35.7	35.7	34.3	41.4
proestrus	22.9	21.4	17.1	11.4
estrus	24.3	30.0	30.0	27.1
metestrus	14.3	12.9	17.1	20.0

¹ Data presented as mean ± standard error. Differences from the control group for necropsy body weights are significant by Williams' or Dunnett's test, estrous cycle lengths are significant by Shirley's test.

² n=10

³ For 1/10 animals in the 3,125 ppm and 12,500 ppm dose groups, estrous cycle exceeded 7 days or was not clear.

⁴ For 2/10 animals in the 50,000 ppm dose group, estrous cycle length exceeded 7 days or was not clear.

* Significantly different (P ≤ 0.05) from the control group.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C3 Summary of Reproductive Tissue Evaluations in Male Mice
in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	0 ppm	3,125 ppm	12,500 ppm	50,000 ppm
n	10	10	10	10
Weights (g)				
Necropsy body weight	28.0 ± 0.6	27.9 ± 1.0	25.6 ± 0.4**	23.6 ± 0.3**
Right epididymis	0.042 ± 0.001	0.042 ± 0.001	0.041 ± 0.001	0.039 ± 0.001
Right epididymal tail	0.015 ± 0.001	0.015 ± 0.001	0.014 ± 0.000	0.014 ± 0.000
Spermatozoal measurements				
Motility (%)	92 ± 3	86 ± 6	79 ± 7	83 ± 7
Concentration (10 ⁶ /g)	1,776 ± 146	1,617 ± 63	1,481 ± 66	1,300 ± 52**
Sperm cell abnormalities (%)	0.58 ± 0.13	0.90 ± 0.12*	0.92 ± 0.13*	1.20 ± 0.09**

¹ Data presented as mean ± standard error. Necropsy body weights are significant by Williams' or Dunnett's test, reproductive tissue weights are not significant by Williams' or Dunnett's test, spermatozoal measurements are significant by Dunn's or Shirley's test.

* Significantly different (P ≤ 0.05) from the control group.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C4 Summary of Estrous Cycle Characterization in Female Mice
in the 13-Week Feed Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	0 ppm	3,125 ppm	12,500 ppm	50,000 ppm
n	10	9	8	6
Necropsy body weight (g)	23.4 ± 0.9	23.1 ± 0.6	22.4 ± 0.4 ²	20.3 ± 0.2** ³
Estrous cycle length (days)	4.20 ± 0.13	4.11 ± 0.11	4.13 ± 0.13 ⁴	4.67 ± 0.21 ⁵
Estrous stages as % of cycle				
diestrus	31.4	34.9	35.7	28.6
proestrus	27.1	23.8	18.6	19.0
estrus	32.9	27.0	31.4	36.5
metestrus	8.6	14.3	14.3	15.9

¹ Data presented as mean ± standard error. Differences from the control group for necropsy body weights are significant by Williams' or Dunnett's test, estrous cycle lengths are significant by Shirley's test.

² n=10

³ n=9

⁴ For 2/10 animals in the 12,500 ppm dose group, estrous cycle exceeded 7 days or was not clear.

⁵ For 3/9 animals in the 50,000 ppm dose group, estrous cycle exceeded 7 days or was not clear.

* Significantly different (P ≤ 0.05) from the control group.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C5 Summary of Reproductive Tissue Evaluations in Male Rats
In the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	Vehicle Control	12.5 mg/kg	50 mg/kg	200 mg/kg
n	10	10	10	10
Weights (g)				
Necropsy body weight	313 ± 7	303 ± 7	313 ± 7	314 ± 5
Right epididymis	0.429 ± 0.009	0.372 ± 0.010**	0.424 ± 0.011*	0.409 ± 0.006
Right epididymal tail	0.198 ± 0.005	0.162 ± 0.006**	0.191 ± 0.008*	0.182 ± 0.004*
Spermatozoal measurements				
Motility (%)	98 ± 1	99 ± 0	98 ± 1	98 ± 1
Concentration (10 ⁶ /g)	581 ± 28	673 ± 40	579 ± 40	621 ± 33
Sperm cell abnormalities (%)	0.84 ± 0.13	0.64 ± 0.09	0.66 ± 0.11	0.54 ± 0.07

¹ Data presented as mean ± standard error. Differences from the control group for reproductive tissue weights are significant by Williams' or Dunnett's test, spermatozoal measurements are not significant by Dunn's or Shirley's test and necropsy body weights are not significant by Williams' or Dunnett's test.

* Significantly different (P ≤ 0.05) from the control group.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C6 Summary of Estrous Cycle Characterization in Female Rats
In the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	Vehicle Control	12.5 mg/kg	50 mg/kg	200 mg/kg
n	10	10	10	10
Necropsy body weight (g)	193 ± 4	181 ± 3	188 ± 4	182 ± 4
Estrous cycle length (days)	4.70 ± 0.15	5.13 ± 0.23 ²	4.50 ± 0.27 ²	4.50 ± 0.17
Estrous stages as % of cycle				
diestrus	45.7	48.6	42.9	40.0
proestrus	14.3	17.1	17.1	12.9
estrus	24.3	17.1	21.4	30.0
metestrus	15.7	17.1	18.6	17.1

¹ Data presented as mean ± standard error. Differences from the control group for necropsy body weights are not significant by Williams' or Dunnett's test, estrous cycle lengths are not significant by Shirley's test.

² For 2/10 animals in the 12.5 mg/kg and 50 mg/kg dose groups, estrous cycle exceeded 7 days or was not clear.

**TABLE C7 Summary of Reproductive Tissue Evaluations in Male Mice
In the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	Vehicle Control	22.75 mg/kg	91 mg/kg	364 mg/kg
n	10	10	10	10
Weights (g)				
Necropsy body weight	28.1 ± 0.4	28.2 ± 0.5	28.6 ± 0.3	28.1 ± 0.6
Right epididymis	0.043 ± 0.001	0.044 ± 0.001	0.044 ± 0.000	0.045 ± 0.001
Right epididymal tail	0.017 ± 0.001	0.017 ± 0.001	0.017 ± 0.000	0.017 ± 0.001
Spermatozoal measurements				
Motility (%)	98 ± 0	98 ± 0	98 ± 0	88 ± 7
Concentration (10 ⁶ /g)	1,861 ± 59	1,688 ± 61*	1,564 ± 65**	1,234 ± 49**
Sperm cell abnormalities (%)	1.66 ± 0.12	1.28 ± 0.12	1.56 ± 0.36	1.62 ± 0.13

¹ Data presented as mean ± standard error. Spermatozoal data are significant by Dunn's or Shirley's test. Necropsy body weights and reproductive tissue weights are not significant by Williams' or Dunnett's test.

* Significantly different (P ≤ 0.05) from the control group.

** Significantly different (P ≤ 0.01) from the control group.

**TABLE C8 Summary of Estrous Cycle Characterization in Female Mice
In the 13-Week Dermal Study of 2-Hydroxy-4-methoxybenzophenone¹**

Study Parameters	Vehicle Control	22.75 mg/kg	91 mg/kg	364 mg/kg
n	10	10	10	10
Necropsy body weight (g)	23.3 ± 0.6	23.4 ± 0.7	23.6 ± 0.3	23.0 ± 0.3
Estrous cycle length (days)	4.50 ± 0.22	4.80 ± 0.25	4.33 ± 0.24 ²	4.40 ± 0.16
Estrous stages as % of cycle				
diestrus	31.4	32.9	34.3	30.0
proestrus	24.3	18.6	21.4	24.3
estrus	32.9	35.7	32.9	30.0
metestrus	11.4	12.9	11.4	15.7

¹ Data presented as mean ± standard error. Differences from the control group for necropsy weights are not significant by Williams' or Dunnett's test, estrous cycle lengths are not significant by Shirley's test.

² For 1/10 animals in the 91 mg/kg dose group, estrous cycle length was not clear.

APPENDIX D

Genetic Toxicology

Table D1	Mutagenicity of 2-Hydroxy-4-methoxybenzophenone in <i>Salmonella typhimurium</i> Strains TA100, TA1535, TA1537, and TA98	D-2
Table D2	Mutagenicity of 2-Hydroxy-4-methoxybenzophenone in <i>Salmonella typhimurium</i> Strains TA100, TA1535, TA97, and TA98	D-4
Table D3	Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by 2-Hydroxy-4-methoxybenzophenone	D-7
Table D4	Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells by 2-Hydroxy-4-methoxybenzophenone	D-9
Table D5	Frequency of Micronucleated Erythrocytes in Peripheral Blood of Mice Exposed for 13 Weeks to 2-Hydroxy-4-methoxybenzophenone	D-10

**TABLE D1 Mutagenicity of 2-Hydroxy-4-methoxybenzophenone
in *Salmonella typhimurium* Strains TA100, TA1535, TA1537, and TA98¹**

Strain	Dose ($\mu\text{g}/\text{plate}$)	Revertants/plate ²					
		-S9		+10% hamster S9		+10% rat S9	
		Trial 1	Trial 2	Trial 1	Trial 2	Trial 1	Trial 2
TA100							
	0	97 \pm 6.1	104 \pm 9.5	112 \pm 13.1	117 \pm 8.8	85 \pm 6.5	104 \pm 2.6
	3		121 \pm 8.6				
	10	104 \pm 5.1	118 \pm 6.5	113 \pm 9.1	128 \pm 12.0	99 \pm 9.6	140 \pm 5.5
	33	102 \pm 7.9	118 \pm 3.0	126 \pm 6.7	146 \pm 9.0	115 \pm 7.2	138 \pm 10.1
	100	97 \pm 5.1	109 \pm 12.8	130 \pm 11.9	135 \pm 9.8	98 \pm 3.8	125 \pm 8.4
	333	66 \pm 8.5 ³	88 \pm 0.9 ³	106 \pm 5.3	106 \pm 9.3	85 \pm 0.9	124 \pm 15.2
	1,000	12 \pm 9.1 ⁴		12 \pm 6.0 ⁴	16 \pm 4.5 ⁴	21 \pm 7.2 ⁴	56 \pm 4.9 ⁴
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative
Positive control ⁵		322 \pm 9.3	235 \pm 6.4	1,506 \pm 62.8	1,207 \pm 26.5	504 \pm 29.3	335 \pm 6.4
TA1535							
	0	26 \pm 0.7	20 \pm 2.3	9 \pm 3.2	9 \pm 2.7	5 \pm 1.3	10 \pm 2.5
	3		22 \pm 3.8				
	10	25 \pm 2.0	24 \pm 1.7	9 \pm 1.5	6 \pm 1.5	11 \pm 3.5	7 \pm 0.7
	33	22 \pm 4.4	26 \pm 2.3	6 \pm 0.3	11 \pm 2.0	9 \pm 2.1	9 \pm 2.4
	100	14 \pm 1.0	19 \pm 4.4	9 \pm 2.2	7 \pm 1.2	8 \pm 0.7	11 \pm 3.0
	333	8 \pm 2.0 ³	14 \pm 3.5 ³	5 \pm 1.5	6 \pm 1.5	7 \pm 3.1	5 \pm 1.7
	1,000	2 \pm 0.7 ³		0 \pm 0.0 ⁴	1 \pm 1.0 ⁴	2 \pm 0.3 ⁴	5 \pm 0.7
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative
Positive control		334 \pm 10.6	288 \pm 25.5	396 \pm 5.3	460 \pm 10.7	185 \pm 10.4	148 \pm 14.7

**TABLE D1 Mutagenicity of 2-Hydroxy-4-methoxybenzophenone
In *Salmonella typhimurium* Strains TA100, TA1535, TA1537, and TA98 (continued)**

Strain	Dose ($\mu\text{g}/\text{plate}$)	Revertants/plate					
		-S9		+ hamster S9		+ rat S9	
		Trial 1	Trial 2	10% Trial 1	30% Trial 2	10% Trial 1	30% Trial 2
TA1537							
	0	5 \pm 0 0	3 \pm 0 7	8 \pm 1 3	6 \pm 0 7	10 \pm 3 2	5 \pm 1 5
	3		7 \pm 3 7				
	10	4 \pm 1 2	6 \pm 0 3	5 \pm 0 7	8 \pm 2 3	8 \pm 3 2	8 \pm 1 9
	33	3 \pm 0 6	4 \pm 1 2	4 \pm 0 9	7 \pm 1 7	4 \pm 0 7	10 \pm 1 5
	100	4 \pm 1 5	3 \pm 0 9	9 \pm 2 7	5 \pm 0 3	6 \pm 2 6	7 \pm 2 5
	333	2 \pm 0 9 ³	4 \pm 0 0 ³	5 \pm 1 0	4 \pm 0 6	4 \pm 1 8	7 \pm 0 6
	1,000	2 \pm 0 9 ³		1 \pm 1 0 ⁴	Toxic	1 \pm 0 3 ⁴	4 \pm 1 5
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative
Positive control		143 \pm 15 1	145 \pm 17 8	400 \pm 16 2	341 \pm 29 2	142 \pm 8 6	99 \pm 19 2
TA98							
	0	15 \pm 2 0	14 \pm 2 9	21 \pm 2 7	33 \pm 2 7	24 \pm 3 0	26 \pm 1 9
	3		15 \pm 4 1				
	10	16 \pm 1 2	20 \pm 2 5	20 \pm 4 7	27 \pm 2 8	19 \pm 1 2	25 \pm 4 4
	33	12 \pm 2 3	11 \pm 3 8	17 \pm 1 5	27 \pm 1 8	19 \pm 2 8	33 \pm 2 7
	100	11 \pm 1 2	11 \pm 1 7	21 \pm 2 6	20 \pm 3 0	21 \pm 5 6	34 \pm 4 7
	333	6 \pm 1 2 ³	6 \pm 1 8 ³	16 \pm 2 7	15 \pm 3 2	14 \pm 0 7	22 \pm 2 1
	1,000	3 \pm 1 0 ⁴		11 \pm 2 6	9 \pm 2 4 ⁴	14 \pm 3 4	19 \pm 3 5
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative
Positive control		707 \pm 19 1	642 \pm 49 4	1,126 \pm 35 9	579 \pm 25 8	194 \pm 9 3	291 \pm 18 6

¹ Both studies were performed at SRI International. The detailed protocol and these data are presented in Zeiger *et al.* (1987). Cells and 4-hydroxy-2-methoxybenzophenone or solvent (dimethylsulfoxide) were incubated in the absence of exogenous metabolic activation (S9) or with Aroclor 1254-induced S9 from male Syrian hamster liver or male Sprague Dawley rat liver. High dose was limited by toxicity. 0 $\mu\text{g}/\text{plate}$ dose is the solvent control.

² Revertants are presented as mean \pm standard error from 3 plates.

³ Precipitate on plate.

⁴ Slight toxicity.

⁵ 2-aminoanthracene was used on all strains in the presence of S9. In the absence of metabolic activation, 4-nitro-o-phenylenediamine was tested on TA98, sodium azide was tested on TA100 and TA1535, and 9-aminoacridine was tested on TA1537 and TA97.

TABLE D2 Mutagenicity of 2-Hydroxy-4-methoxybenzophenone in *Salmonella typhimurium* Strains TA100, TA1535, TA97, and TA98¹

Strain	Dose (µg/plate)	Revertants/plate ²						
		-S9		+ hamster S9			+10% rat S9	
		Trial 1	Trial 2	10% Trial 1	30% Trial 2	30% Trial 3	Trial 1	Trial 2
TA100								
	0	136 ± 6.9	108 ± 6.9	130 ± 0.9	138 ± 2.7	142 ± 2.8	129 ± 3.2	143 ± 2.6
	1	102 ± 3.4	122 ± 10.1					
	3	111 ± 9.4	109 ± 4.2					
	10	110 ± 4.3	109 ± 11.9	112 ± 1.9	138 ± 19.5	133 ± 5.5	153 ± 11.0	152 ± 7.3
	33	103 ± 8.9	106 ± 11.4	151 ± 4.9	141 ± 16.6	154 ± 5.5	155 ± 3.5	150 ± 10.5
	66					197 ± 12.2		
	100	83 ± 2.7	83 ± 3.1	146 ± 4.7	247 ± 16.1	213 ± 20.8	145 ± 3.4	159 ± 4.8
	333			103 ± 8.3	246 ± 15.1	187 ± 7.9	120 ± 12.4	151 ± 11.9
	666				188 ± 21.0			82 ± 9.0
	1 000			45 ± 2.0			58 ± 10.0	
Trial summary		Negative	Negative	Negative	Positive	Equivocal	Negative	Negative
Positive control ^f		507 ± 1.3	517 ± 0.7	933 ± 40.9	411 ± 21.2	572 ± 20.0	627 ± 37.3	350 ± 15.3
TA1535								
	0	36 ± 0.6	24 ± 2.7	13 ± 0.9	7 ± 1.0		14 ± 1.2	14 ± 2.6
	1	34 ± 2.0	25 ± 4.2					
	3	34 ± 3.2	25 ± 3.0					
	10	35 ± 2.3	24 ± 1.5	10 ± 2.6	8 ± 4.0		12 ± 2.2	15 ± 3.0
	33	33 ± 6.3	23 ± 1.2	12 ± 1.5	9 ± 0.3		13 ± 1.5	17 ± 1.9
	100	33 ± 4.1	16 ± 2.3	10 ± 0.9	12 ± 1.5		12 ± 2.5	18 ± 1.7
	333			10 ± 1.5	11 ± 2.4		10 ± 1.2	14 ± 0.7
	666				7 ± 1.7			8 ± 2.3
	1 000			4 ± 0.3			3 ± 0.3	
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative	Negative
Positive control		347 ± 43.9	413 ± 11.4	284 ± 13.9	192 ± 15.2	152 ± 13.6	86 ± 0.9	

**TABLE D2 Mutagenicity of 2-Hydroxy-4-methoxybenzophenone
in *Salmonella typhimurium* Strains TA100, TA1535, TA97, and TA98 (continued)**

Strain	Dose ($\mu\text{g}/\text{plate}$)	Revertants/plate					
		-S9		+ hamster S9			
		Trial 1	Trial 2	10% Trial 1	30% Trial 2	30% Trial 3	30% Trial 4
TA97	0	160 \pm 9.5	167 \pm 15.0	163 \pm 3.6	188 \pm 6.2	190 \pm 5.2	171 \pm 5.6
	1	162 \pm 13.2	171 \pm 10.8				
	3	156 \pm 13.5	181 \pm 2.3				
	10	149 \pm 4.8	169 \pm 11.4	199 \pm 12.1	214 \pm 18.1	200 \pm 8.8	183 \pm 19.0
	33	122 \pm 6.6	142 \pm 8.2	218 \pm 9.2	222 \pm 20.0	264 \pm 17.0	275 \pm 11.5
	100	86 \pm 11.0 ^a	59 \pm 16.0 ^a	194 \pm 2.5	287 \pm 32.7	294 \pm 5.5	270 \pm 8.7
	166						227 \pm 23.8
	333			64 \pm 5.9 ^a	235 \pm 16.8	121 \pm 8.7	109 \pm 5.9
	666				10 \pm 5.6	3 \pm 2.7 ^a	
	1,000			0 \pm 0.0 ^a			
Trial summary		Negative	Negative	Equivocal	Equivocal	Weakly Positive	Weakly Positive
Positive control		641 \pm 22.4	455 \pm 46.4	678 \pm 32.2	356 \pm 15.0	370 \pm 34.7	522 \pm 5.0

Strain	Dose ($\mu\text{g}/\text{plate}$)	Revertants/plate	
		+ rat S9	
		10% Trial 1	30% Trial 2
TA97 (continued)	0	193 \pm 4.5	184 \pm 12.0
	3		
	10	203 \pm 12.7	185 \pm 5.8
	33	195 \pm 3.8	200 \pm 6.6
	100	173 \pm 11.7	196 \pm 6.5
	166		
	333	66 \pm 17.8	114 \pm 11.7
	666		7 \pm 3.0
	1 000	0 \pm 0.0 ^a	
Trial summary		Negative	Negative
Positive control		545 \pm 36.3	408 \pm 7.9

**TABLE D2 Mutagenicity of 2-Hydroxy-4-methoxybenzophenone
in *Salmonella typhimurium* Strains TA100, TA1535, TA97, and TA98 (continued)**

Strain	Dose ($\mu\text{g}/\text{plate}$)	Revertants/plate					
		-S9		+ hamster S9		+ rat S9	
		Trial 1	Trial 2	10% Trial 1	30% Trial 2	10% Trial 1	30% Trial 2
TA98	0	22 \pm 23	21 \pm 29	26 \pm 44	38 \pm 39	44 \pm 30	32 \pm 30
	1	21 \pm 46	19 \pm 10				
	3	21 \pm 24	22 \pm 42				
	10	17 \pm 24	19 \pm 10	29 \pm 26	27 \pm 36	36 \pm 31	32 \pm 27
	33	13 \pm 13	17 \pm 28	37 \pm 26	33 \pm 49	36 \pm 70	42 \pm 20
	100	6 \pm 10 ⁴	9 \pm 15 ⁴	32 \pm 21	41 \pm 23	36 \pm 30	42 \pm 09
	333			28 \pm 20	30 \pm 52	24 \pm 35	37 \pm 46
	666				19 \pm 12		19 \pm 47
	1,000			11 \pm 03 ⁴		9 \pm 26 ⁴	
Trial summary		Negative	Negative	Negative	Negative	Negative	Negative
Positive control		1,124 \pm 36 5	906 \pm 16 1	651 \pm 19 4	171 \pm 21 7	384 \pm 22 2	136 \pm 4 4

¹ Both studies were performed at SRI, International. The detailed protocol is presented in Zeiger *et al* (1987). Cells and 4-hydroxy-2-methoxybenzophenone or solvent (dimethylsulfoxide) were incubated in the absence of exogenous metabolic activation (-S9) or with Aroclor 1254-induced S9 from male Syrian hamster liver or male Sprague-Dawley rat liver. High dose was limited by toxicity. 0 $\mu\text{g}/\text{plate}$ dose is the solvent control.

² Revertants are presented as mean \pm standard error from 3 plates.

³ 2-aminoanthracene was used on all strains in the presence of S9. In the absence of metabolic activation, 4-nitro-*o*-phenylenediamine was tested on TA98, sodium azide was tested on TA100 and TA1535, and 9-aminoacridine was tested on TA1537 and TA97.

⁴ Slight toxicity.

⁵ Precipitate on plate.

TABLE D3 Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by 2-Hydroxy-4-methoxybenzophenone¹

Compound	Dose (µg/mL)	Total Cells	No. of Chromosomes	No. of SCEs	SCEs/Chromosome	SCEs/Cell	Hrs in BrdU	Relative SCEs/Chromosome (%) ²
-S9³								
Trial 1								
Summary Questionable								
Dimethylsulfoxide		50	1,036	407	0.39	8.1	26.0	
		50	1,050	397	0.37	7.9	31.0 ⁴	
Mitomycin-C	0.001	50	1,046	680	0.65	13.6	26.0	71.94
	0.004	10	209	203	0.97	20.3	26.0	156.89
2-Hydroxy-4-methoxybenzophenone	1.700	50	1,038	390	0.37	7.8	26.0	-0.63
	5.000	50	1,043	439	0.42	8.8	26.0	11.32
	17.000	50	1,042	464	0.44	9.3	31.0 ⁴	17.77
								P=0.003 ⁵
+S9⁶								
Trial 1								
Summary Positive								
Dimethylsulfoxide		50	1,049	387	0.36	7.7	26.0	
Cyclophosphamide	0.125	50	1,044	579	0.55	11.6	26.0	50.33
	0.500	10	210	244	1.16	24.4	26.0	214.95
2-Hydroxy-4-methoxybenzophenone	5.000	50	1,042	464	0.44	9.3	26.0	20.70*
	17.000	50	1,045	623	0.59	12.5	26.0	61.60*
	50.000	50	1,045	626	0.59	12.5	26.0	62.38*
								P<0.000

TABLE D3 Induction of Sister Chromatid Exchanges in Chinese Hamster Ovary Cells by 2-Hydroxy-4-methoxybenzophenone (continued)

Compound	Dose (µg/mL)	Total Cells	No. of Chromosomes	No. of SCEs	SCEs/Chromosome	SCEs/Cell	Hrs in BrdU	Relative SCEs/Chromosome (%)
+S9								
Trial 2								
Summary Positive								
Dimethylsulfoxide		50	1,050	383	0.36	7.7	26.0	
Cyclophosphamide	0.125	50	1,049	609	0.58	12.2	26.0	59.16
	0.500	10	212	245	1.15	24.5	26.0	216.83
2-Hydroxy-4-methoxybenzophenone	12.500	50	1,054	547	0.51	10.9	26.0	42.28*
	25.000	50	1,046	715	0.68	14.3	26.0	87.40*
	50.000	50	1,048	701	0.66	14.0	26.0	83.38*
								P < 0.000

¹ Study performed at Sitek Research Laboratories. SCE = sister chromatid exchange, BrdU = bromodeoxyuridine. A detailed description of the SCE protocol is presented by Galloway *et al* (1987). Briefly, Chinese hamster ovary cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent (dimethylsulfoxide) as described in ³ and ⁶ below, and cultured for sufficient time to reach second metaphase division. Cells were then collected by mitotic shake-off, fixed, air-dried, and stained.

² Percent increase in SCEs/chromosome of culture exposed to 2-hydroxy-4-methoxybenzophenone relative to those of culture exposed to solvent.

³ In the absence of S9, cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent for 2 hours at 37° C. Then BrdU was added and incubation was continued for 24 hours. Cells were washed, fresh medium containing BrdU and Colcemid was added, and incubation was continued for 2 hours.

⁴ Because 2-hydroxy-4-methoxybenzophenone induced a delay in the cell division cycle at this dose, harvest time was extended 5 hours to maximize the proportion of second division cells available for analysis. The solvent control was also analyzed for SCE frequency at this same time point.

⁵ Significance of relative SCEs/chromosome tested by the linear regression trend test vs. log of the dose.

⁶ In the presence of S9, cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent for 2 hours at 37° C. The cells were then washed and medium containing BrdU was added. Cells were incubated for a further 26 hours, with Colcemid present for the final 2 to 3 hours. S9 was from the livers of Aroclor 1254-induced male Sprague-Dawley rats.

* Positive (>20% increase over solvent control)

TABLE D4 Induction of Chromosomal Aberrations in Chinese Hamster Ovary Cells by 2-Hydroxy-4-methoxybenzophenone¹

-S9 ²					+S9 ²				
Dose (µg/mL)	Total Cells	No. of Abs	Abs/ Cell	Percent Cells with Abs	Dose (µg/mL)	Total Cells	No. of Abs	Abs/ Cell	Percent Cells with Abs
Trial 1 – Harvest time 18 0 hours					Trial 1 – Harvest time 13 5 hours				
Summary Negative					Summary Positive				
Dimethylsulfoxide					Dimethylsulfoxide				
	200	0	0 00	0 0		200	2	0 01	1 0
Mitomycin C					Cyclophosphamide				
0 40	25	45	1 80	56 0	20 00	25	20	0 80	44 0
2 Hydroxy 4-methoxybenzophenone					2 Hydroxy-4-methoxybenzophenone				
9 40	200	2	0 01	1 0	9 40	200	2	0 01	1 0
20 00	200	1	0 01	0 5	20 00	200	18	0 09	7 5*
43 00	200	2	0 01	1 0	43 00	200	13	0 07	6 5*
93 00	17	0	0 00	0 0					
				P=0 193 ⁴					P<0 000
					Trial 2 – Harvest time 13 5 hours				
					Summary Positive				
					Dimethylsulfoxide				
						200	0	0 00	0 0
					Cyclophosphamide				
					20 00	25	31	1 24	44 0
					2 Hydroxy-4-methoxybenzophenone				
					30 00	200	22	0 11	9 5*
					45 00	200	16	0 08	7 0*
					60 00	200	3	0 02	1 5
					75 00	200	4	0 02	2 0
									P=0 793

¹ Study performed at Sitek Research Laboratories. Abs = aberrations. A detailed presentation of the technique for detecting chromosomal aberrations and the statistical treatment of the data is found in Galloway *et al.*, (1987). Briefly, Chinese hamster ovary cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent (dimethylsulfoxide) as indicated in ² and ³. Cells were arrested in first metaphase by addition of Colcemid and harvested by mitotic shake-off, fixed, and stained in 6% Giemsa.

² In the absence of S9, cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent for 15 hours at 37° C. Because of significant chemical-induced cell cycle delay, incubation time prior to addition of Colcemid was lengthened to provide sufficient metaphases at harvest. Cells were then washed and fresh medium containing Colcemid was added for an additional 2 to 3 hours followed by harvest.

³ In the presence of S9, cells were incubated with 2-hydroxy-4-methoxybenzophenone or solvent for 2 hours at 37° C. Cells were then washed, medium was added, and incubation was continued for 12 hours. Colcemid was added for the last 2 to 3 hours of incubation before harvest. S9 was from the livers of Aroclor 1254-induced male Sprague-Dawley rats.

⁴ Significance of percent cells with aberrations tested by the linear regression trend test vs log of the dose.

* Positive (P<0 05)

TABLE D5 Frequency of Micronucleated Erythrocytes in Peripheral Blood of Mice Exposed for 13 Weeks to 2-Hydroxy-4-methoxybenzophenone¹

	Dose (mg/kg)	Micronucleated NCE/ 1,000 Cells ²	Number of Animals
Male	0	0.072 ± 0.006	10
	3,125	0.068 ± 0.010	10
	6,250	0.046 ± 0.007	10
	12,500	0.059 ± 0.012	10
	25,000	0.053 ± 0.008	10
	50,000	0.054 ± 0.009	10
Female	0	0.050 ± 0.009	5
	3,150	0.043 ± 0.012	10
	6,250	0.035 ± 0.006	10
	12,500	0.042 ± 0.004	10
	25,000	0.055 ± 0.008	10
	50,000	0.060 ± 0.012	10
Urethane positive control³	0.2	1.10 ± 0.064	3

¹ Smears were prepared from peripheral blood samples obtained by cardiac puncture of dosed and control mice at the termination of the 13-week studies. Slides were stained with Hoechst 33258/pyronin Y (MacGregor *et al.*, 1983). 10,000 NCEs from each animal were scored for micronuclei. No significant elevation in the frequency of micronucleated erythrocytes was observed in either male or female mice following administration of 2-hydroxy-4-methoxybenzophenone in feed.

² Values are mean ± standard error of the mean.

³ Positive control. Three male mice were treated for 4 weeks with 2% urethane in drinking water, these mice were not part of the main 13 week studies, but were added to provide an indication of a positive response in this assay.

APPENDIX E

**Disposition of
2-Hydroxy-4-methoxybenzophenone
in Rats Dosed Orally, Intravenously,
or Topically**

DISPOSITION OF 2-HYDROXY-4-METHOXYBENZOPHENONE IN RATS DOSED ORALLY, INTRAVENOUSLY, OR TOPICALLY

Salah M. El Dareer, Jack R. Kalin, Kathleen F. Tillery,
Donald L. Hill

Southern Research Institute, Birmingham, Alabama

Administration to rats of oral doses of [¹⁴C]-2-hydroxy-4-methoxybenzophenone (HMB) in the range of 3.01–2570 mg/kg revealed that a dose-dependent elimination process was operative at the highest dose. Urinary excretion (63.9–72.9% of the dose in 72 h) was the major route for elimination of radioactivity. An intravenous dose (4.63 mg/kg) distributed rapidly throughout the body of rats and appeared in the urine in an amount (67.4%) similar to those for the oral doses. Rats absorbed large portions of doses of [¹⁴C]HMB administered topically, either as an ethanolic solution (50, 200, or 800 µg/rat) or formulated in a lotion (50 µg/rat). For rats with biliary cannulas, 36.6% of the radioactivity of an intravenous dose (4.46 mg/kg) appeared in the bile in 4 h; the initial half-life for biliary elimination was 40 min. In the bile, at least five radioactive components, none of which was intact HMB, were present. The two major components were glucuronides of HMB and demethylated HMB, and a third was probably a sulfate ester of hydroxylated HMB. In urine, there were nine radioactive components, two of which were unchanged HMB and its glucuronide.

INTRODUCTION

2-Hydroxy-4-methoxybenzophenone (HMB), used commercially as an ultraviolet stabilizer in plastics and cosmetically as a sunscreen, had a U.S. production of 3.6×10^8 g in 1977. The compound was only mildly toxic to rats; its acute oral LD_{50} was >12.8 g/kg (Lewerenz et al., 1972). Fed in the diet for 90 d at levels of 0.5–1%, HMB suppressed growth, caused nephrotoxicity, and reduced the relative weights of the hypophysis, thymus, heart, and adrenals. It was not mutagenic to either of two *Salmonella typhimurium* tester strains (Jonsen et al., 1980). The compound has been considered safe for topical application to humans (Cosmetic Ingredient Review Expert Panel, 1983).

The objectives of these studies were to determine, for [¹⁴C]HMB, the degree of absorption and the rates and routes of elimination for Fischer 344 male rats dosed orally, intravenously, or topically.

This work was supported by contract NO1-ES-1-5008 from the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services.

We are grateful to Dr. Clinton Grubbs for help with biliary cannulations, to Bessie Ingram, Alvin Moore, and Thomas Herren for technical assistance, and to Dr. H. B. Matthews for his advice.

Requests for reprints should be sent to Donald L. Hill, Southern Research Institute, P. O. Box 55305, Birmingham, Alabama 35255-5305.

MATERIALS AND METHODS

Unlabeled HMB was purchased from Aldrich Chemical Co., Milwaukee, Wis. [Ring-UL- ^{14}C]HMB was supplied by Midwest Research Institute. β -Glucuronidase (Bacterial Type VII) was purchased from Sigma Chemical Co., St. Louis, Mo.; *Helix pomatia* β -glucuronidase/sulfatase from CalBiochem, LaJolla, Calif.; and 2,4-dihydroxybenzophenone (DHB) from Aldrich Chemical Co., Milwaukee, Wis. Fischer 344 male rats (8 wk old, 127–191 g) were purchased from Charles River Laboratories, Stoneridge, N.Y.

By high-pressure liquid chromatography (HPLC), the radiochemical purity of the [^{14}C]HMB used in the dosing solutions was determined to be 97.7–99.9% and the chemical purity of unlabeled HMB to be 99.1%. Solutions for dosing were prepared at room temperature and used immediately. The homogeneity and stability of HMB in the preparations were established by measuring HMB concentrations, before and after dosing, by ultraviolet (UV) analysis. The specific activity of the [^{14}C]HMB in the dosing solutions was determined by liquid scintillation analysis of portions dissolved in Scintiverse I scintillator (Fisher Scientific Co., Fair Lawn, N.J.).

For oral dosing, [^{14}C]HMB in corn oil was administered by gavage to rats (3/group) at 4 dose levels: 3.01 mg/kg (88.0 $\mu\text{Ci}/\text{kg}$); 28.1 mg/kg (94.0 $\mu\text{Ci}/\text{kg}$); 293 mg/kg (94.7 $\mu\text{Ci}/\text{kg}$); and 2570 mg/kg (825 $\mu\text{Ci}/\text{kg}$). Urine and feces were collected daily for 3 d. At 72 h after dosing, selected tissues and other samples were collected separately from each rat. Prior to combustion and radioassay, feces from each rat were dried and pulverized; portions of urine, plasma, and whole blood were dried; and intestinal tissue and contents were homogenized separately in 9 volumes of water. Combustion was accomplished in a Packard model 306 oxidizer (Packard Instruments, Downers Grove, Ill.).

Rats (3–5/group) were also injected intravenously via the tail vein (1.33 ml/kg) with [^{14}C]HMB (4.63 mg/kg, 136 $\mu\text{Ci}/\text{kg}$) in ethanol–Emulphor–water (5:2:3, v/v). For rats kept for 24 h or longer after dosing, urine and feces were collected separately each day. At selected times after dosing, tissues and other samples were collected from each rat and analyzed for radioactivity as described above. Pharmacokinetic half-lives were estimated with modified forms of the NONLIN (Metzler et al., 1974) and CSTRIP (Sedman and Wagner, 1976) programs. The data were fitted to three-compartment open models, with statistical weights related to the measured concentrations.

In another experiment involving intravenous dosing, 4 rats were anesthetized with pentobarbital (30 mg/kg, ip), and their bile ducts were cannulated. The rats were allowed to recover from the anesthesia before [^{14}C]HMB (4.46 mg/kg, 122 $\mu\text{Ci}/\text{kg}$, 1.33 ml/kg) in ethanol:Emulphor:water (5:2:3, v/v) was injected. Bile was collected at designated

times over a 4-h period; and portions were analyzed for radioactivity after combustion, as described above.

For topical dosing, hair was removed from one side of rats 3 d prior to dosing. [^{14}C]HMB was applied as ethanolic solutions (20 μl) to an area of 1 cm^2 of skin, and a special perforated metal cap was glued onto the skin to cover the area of application. The doses applied were 51.6 μg (3.60 μCi), 204 μg (13.5 μCi), and 800 μg (12.7 μCi). At 0, 4, 24, and 72 h after dosing, 3 rats from each dosing group were killed, and selected tissues and other samples were collected, processed, and analyzed for radioactivity as described above. For the zero-time rats, only the skin areas of application were collected and analyzed.

In an additional experiment involving topical dosing [^{14}C]HMB (50 μg) was administered to rats in a lotion (20 μl) containing lanolin (5.0 g), white petrolatum (2.5 g), stearic acid (4.0 g), propylparaben (50 mg), propylene glycol (5.0 ml), methylparaben (0.1 g), triethanolamine (1.0 ml), EDTA (50 mg), and water (74.3 ml). At 2, 6, 24, and 72 h after dosing 3 rats were killed, and selected tissue and other samples were collected. Urine and feces were collected daily from rats in the latter two groups. The samples were processed, and radioactivity was measured as already described.

RESULTS

For all doses, HMB was well absorbed and excreted primarily in the urine. With increasing dose, urinary excretion tended to increase and fecal excretion to decrease (Table 1). For the highest dose, the 0–72 h recovery in the feces was statistically lower ($p < 0.05$) than for the other doses; after normalization for total recovery, the percent of dose found in the urine was statistically higher than that for the low dose. The total amounts of radioactivity remaining in each tissue were less than 0.11% of the dose, and the amounts in the contents of each part of the gastrointestinal tract were less than 0.3%. The percent of dose present in tissues did not vary greatly with size of the dose, with the exception that, in rats administered the highest dose, there were higher concentrations of radioactivity in plasma and whole blood at 72 h.

At 72 h after an intravenous dose of 4.63 mg/kg of [^{14}C]HMB, 67.4% of the radioactivity was present in the urine and 21.2% in the feces (Table 1). In gut contents, the amount of radioactivity increased from 7.35% of the dose at 5 min after dosing to 27.4% at 60 min (not shown). These values remained high relative to those for tissues. In gut tissue, the concentration of radioactivity was higher than in other tissues, except for the 5-min, 15-min, and 72-h time points. The rate of elimination from whole blood was similar to that from plasma, liver, lung, muscle, and kidney (Fig. 1). Except for the 24- and 72-h time points,

TABLE 1. Disposition of Radioactivity from [¹⁴C]HMB in Rats Dosed Orally or Intravenously

Tissue	Dose									
	3.01 mg/kg (oral)		28.1 mg/kg (oral)		293 mg/kg (oral)		2570 mg/kg (oral)		4.63 mg/kg (iv)	
	% of Dose	µg-Equivs/g or ml	% of Dose	µg-Equivs/g or ml	% of Dose	µg-Equivs/g or ml	% of Dose	µg-Equivs/g or ml ^a	% of Dose	µg-Equivs/g or ml
Urine										
(0-24 h)	55.9 ± 11.8	56.8 ± 9.9 ^a	58.0 ± 4.9	56.4 ± 9.5 ^a	56.9 ± 6.5	56.10 ± 8.40 ^a	31.2 ± 5.2	12,000 ± 1100 ^a	62.8 ± 5.8	3010 ± 650 ^a
(24-48 h)	6.50 ± 3.2	63.0 ± 22.6 ^a	5.03 ± 1.32	519 ± 107 ^a	6.27 ± 1.26	6250 ± 260 ^a	35.2 ± 1.7	7060 ± 1240 ^a	3.73 ± 0.36	374 ± 127 ^a
(48-72 h)	1.57 ± 0.56	1.93 ± 0.78 ^a	0.890 ± 0.214	8.57 ± 0.72 ^a	1.31 ± 0.18	1.41 ± 31 ^a	6.54 ± 4.8	2670 ± 1200 ^a	0.913 ± 0.250	49.0 ± 55.4
Total	63.9 ± 8.2	— ^b	63.9 ± 5.8	—	64.5 ± 7.4	—	72.9 ± 7.1	—	67.4 ± 5.9	—
Feces										
(0-24 h)	25.8 ± 5.7	58.6 ± 8.9	20.8 ± 8.2	487 ± 69	17.4 ± 7.0	3870 ± 960	1.08 ± 0.66	3650 ± 1580	11.3 ± 2.0	1770 ± 230
(24-48 h)	13.9 ± 6.8	23.3 ± 13.4	13.7 ± 4.8	197 ± 62	12.0 ± 3.2	1850 ± 480	13.9 ± 5.8	33,400 ± 9000	6.89 ± 1.82	590 ± 160
(48-72 h)	1.92 ± 2.0	3.34 ± 3.35	0.944 ± 0.421	13.8 ± 5.8	1.37 ± 0.64	198 ± 87	4.31 ± 0.80	5480 ± 1150	106 ± 0.26	89.2 ± 22.9
Total	41.7 ± 4.8	—	35.4 ± 5.8	—	30.8 ± 4.6	—	19.3 ± 6.0	—	21.2 ± 2.2	—
Stomach contents	0.020 ± 0.018	0.073 ± 0.080	0.005 ± 0.008	0.181 ± 0.291	0.018 ± 0.028	5.73 ± 8.08	0.029 ± 0.047	52.3 ± 83.6	0.296 ± 0.120 ^c	5.58 ± 3.11 ^c
Small intestine contents	0.091 ± 0.078	0.143 ± 0.149	0.052 ± 0.020	0.597 ± 0.179	0.043 ± 0.013	5.08 ± 1.67	0.053 ± 0.025	57.3 ± 30.0	—	—
Large intestine contents	0.285 ± 0.315	0.253 ± 0.267	0.126 ± 0.052	0.919 ± 0.266	0.127 ± 0.062	9.75 ± 3.44	0.269 ± 0.096	157 ± 77	—	—
Stomach	0.002 ± 0.002	0.011 ± 0.010	0.001 ± 0.001	0.039 ± 0.044	0.002 ± 0.002	0.901 ± 0.988	0.003 ± 0.004	12.4 ± 16.4	0.037 ± 0.014 ^d	2.27 ± 0.99 ^d
Small intestine	0.039 ± 0.034	0.087 ± 0.075	0.019 ± 0.005	0.445 ± 0.116	0.016 ± 0.005	3.65 ± 0.77	0.018 ± 0.010	34.4 ± 17.6	—	—
Large intestine	0.013 ± 0.013	0.063 ± 0.070	0.008 ± 0.001	0.331 ± 0.036	0.009 ± 0.003	3.41 ± 0.96	0.011 ± 0.004	51.1 ± 18.3	—	—
Liver	0.108 ± 0.025	0.123 ± 0.026	0.096 ± 0.012	1.04 ± 0.03	0.073 ± 0.007	7.71 ± 0.88	0.071 ± 0.007	30.8 ± 1.9	0.076 ± 0.010	2.51 ± 0.27
Lungs	—	—	—	—	—	—	0.002 ± 0.000	10.3 ± 0.6	0.001	0.128 ± 0.019
Kidneys	—	—	—	—	—	—	0.009 ± 0.003	25.3 ± 7.3	0.021 ± 0.002	3.92 ± 0.67
Brain	—	—	—	—	—	—	<0.001	0.350 ± 0.015	—	—
Muscle ^e	—	—	—	—	—	—	0.022 ± 0.005	1.16 ± 0.30	0.016 ± 0.008	0.042 ± 0.023
Spleen	—	—	—	—	—	—	<0.001	1.54 ± 0.12	—	—
Fat ^f	—	—	—	—	—	—	0.021 ± 0.006	8.17 ± 2.60	0.025 ± 0.018	0.473 ± 0.365
Skin ^g	—	—	—	—	—	—	0.037 ± 0.003	6.25 ± 0.62	0.029 ± 0.016	0.243 ± 0.144
Plasma ^h	0.008 ± 0.004	0.004 ± 0.002	0.005 ± 0.001	0.029 ± 0.003	0.005 ± 0.001	0.266 ± 0.040	0.014 ± 0.003	7.62 ± 1.67	0.004 ± 0.001	0.119 ± 0.028
Whole blood ⁱ	0.011 ± 0.004	0.004 ± 0.001	0.008 ± 0.001	0.023 ± 0.004	0.008 ± 0.001	0.245 ± 0.031	0.020 ± 0.014	6.07 ± 1.02	0.008 ± 0.002	0.117 ± 0.025
Tail	—	—	—	—	—	—	—	—	0.673 ± 0.740	—
Total recovery	106 ± 5	—	99.7 ± 6.7	—	95.5 ± 4.0	—	92.8 ± 2.0	—	89.8 ± 7.2	—

494

^a Excluding cage rinses

^b not applicable or not determined

^c Combined gut contents

^d Combined gut tissue

^e Considered to be 50% of body weight

^f Considered to be 7% of body weight

^g Considered to be 16% of body weight

^h Considered to be 5% of body weight. Not included in totals

ⁱ Considered to be 9% of body weight




FIGURE 1. Elimination of radioactivity from plasma and various tissues of rats dosed intravenously with 4.63 mg/kg of [¹⁴C]HMB.

more than 90% of the radioactivity present in whole blood was in the plasma. The total radioactivity present in the liver decreased rapidly during the first hour after dosing, but was high (0.076% of the dose) relative to other tissues at 72 h. At all time points, however, the concentrations of radioactivity in the kidney surpassed those in the liver.

The concentrations of radioactivity in fat increased to a maximum at 30 min, and, after 15 min, remained higher than those in the blood.

For rats with biliary cannulas, 36.6% of the radioactivity administered intravenously appeared in the bile in 4 h (Fig. 2). The initial half-life for elimination was 40 min. Bile collected from these rats over the 90-min to 4-h period was pooled and extracted with an equal volume of methanol. At least five radioactive components were resolved (Fig. 3), of which three, designated C, D, and E, were purified by preparative HPLC.

Component D was converted to β -glucuronidase to a product having the same chromatographic and UV spectroscopic characteristics as




FIGURE 2. Biliary excretion of radioactivity by rats dosed intravenously with 4.46 mg/kg of [14 C]HMB.




FIGURE 3. Metabolites in bile and urine of rats dosed intravenously with [^{14}C]HMB. Elution from a Partisil 10/25 PXS ODS-2 column was accomplished with a 25-min linear gradient (Waters curve number 6) from 100% solvent A (20 mM ammonium acetate in 20% methanol) to 43% solvent B (20 mM ammonium acetate in 90% methanol), followed by a 10-min linear gradient to 100% solvent B and isocratic elution for 15 min. The arrows indicate the time of elution of authentic HMB.

HMB and was, therefore, identified as a β -glucuronide conjugate of HMB.

Component C was also cleaved by β -glucuronidase. The product, subjected to electron-impact mass spectrometry, had a molecular ion of 214 and additional ions of 213, 137, and 105, the same mass-spectral fragmentation pattern observed for authentic 2,4-dihydroxybenzophenone (DHB). Furthermore, mass-spectral analysis of the methylated hydrolysis product of component C and methylated DHB yielded for each a molecular ion of 242 and additional ions of 165 and 77, as expected for the addition of two methyl groups. Finally, DHB and the hydrolysis product of component C had identical chromatographic and UV spectral characteristics, allowing the conclusion that component C was a β -glucuronide of 2,4-dihydroxybenzophenone. The location of the glucuronide conjugation (position 2 or 4) was not established.

Component E, subjected to mass-spectral analysis by negative fast-atom bombardment, revealed a molecular ion of 324 and additional ions of 323 ($M - 1$) and 97 (sulfate). A mixture of β -glucuronidase/sulfatase, but not β -glucuronidase alone, hydrolyzed this material, allowing the tentative conclusion that component E was a sulfate ester of an hydroxylated derivative of HMB.

Urine collected from rats over a 24 h period following iv administration of [^{14}C]HMB contained 3 major and 5 minor metabolites and a minimally detectable amount of unchanged HMB (Fig. 3). The component eluting with a retention time of 25 min had the same chromatographic and UV spectroscopic characteristics as biliary component D and was thus the β -glucuronide of HMB. The component in urine eluting with a retention time of 28 min had the same chromatographic behavior as biliary component E but a different UV spectrum. Whereas biliary component C was essentially absent in urine, urine contained an additional, unidentified component eluting immediately after the glucuronide conjugate of HMB.

The skin of rats absorbed portions of the doses of [^{14}C]HMB applied as an ethanolic solution. The portion of the dose remaining on the skin at 72 h after application was 27.3, 24.8, and 57.9% for the low, medium and high dose, respectively (Table 2). Urine contained most of the absorbed radioactivity (32.4, 39.2, and 13.2% of the respective doses). Fecal excretion was also appreciable, with respective values of 16.9, 22.2, and 9.15%. For the low dose, the amounts of radioactivity in the tissues decreased with time. For the medium dose, these values were similar for the 4-h and 24-h time points and lower at the 72-h time point. For the high dose, most of these values were similar for the 24-h and 72-h time points and lower for the 4-h time point. At each of the three time points, gut tissue contained the highest concentration of radioactivity. Relative to those from rats given the medium and low doses, tissues from rats administered the high dose contained, at 4 and 24 h after dosing, concentrations of radioactivity less than proportional to the dose.

There was also considerable absorption by rats given the low dose in a lotion. In 72 h, 33.9% of the radioactivity recovered was in the urine; 17.9% was in the feces. Of the total radioactivity recovered at 2 h, 93.8% was present at the site of application, but at 72 h only 45.3% was present. The tissue contents of radioactivity were similar to those for rats dosed topically with an ethanolic solution.

DISCUSSION

For either oral or intravenous doses, rats rapidly excreted the radioactivity from HMB, with 88–105% of the dose appearing in the urine

and feces in 72 h. A dose-dependent elimination process was evident only with the highest oral dose (2570 mg/kg), for which recovery in the feces was less and urinary excretion greater than for the other doses. Either gastrointestinal absorption of the highest dose was more extensive, or rats converted more of this dose to a metabolite preferentially excreted in the urine. The relatively high concentrations of radioactivity in gut contents, gut tissue, and kidneys reflect the importance of the urinary and fecal routes of elimination. In contrast, male rats administered 2-hydroxy-4-*n*-octoxybenzophenone (HOB) in oral doses did not extensively absorb the compound but excreted 90% of the dose in the feces as the unchanged chemical (Patel et al., 1968). Like HMB, neither HOB nor its metabolites remained in the tissues of rats for long periods of time.

For the three lower doses of HMB, the concentration of radioactivity in the blood at 72 h was proportional to the dose. For the dose of 2570 mg/kg, however, blood and plasma concentrations were greater than proportional, perhaps related to the continued high rate of urinary excretion.

At 72 h after an intravenous dose of [¹⁴C]HMB, tissue concentrations and the values for percents of the dose excreted in the urine and the feces were similar to those for rats dosed orally. The compound initially distributed throughout the body, and most tissues eliminated it at similar rates, indicating that disposition of [¹⁴C]HMB in the rat was not greatly different for the two routes of administration. The relatively constant amounts of radioactivity in fat during the 1-h to 4-h period after dosing indicated that this tissue served as a temporary depot for HMB and/or its metabolites. At 72 h after dosing, gut tissue, liver, and kidneys contained high concentrations of radioactivity, regardless of whether HMB was administered orally, intravenously, or topically. Muscle consistently had low concentrations.

Biliary excretion of radioactivity from [¹⁴C]HMB by rats was rapid and extensive, accounting for the appearance of large amounts of radioactivity in the feces, gut contents, and gut tissue of rats dosed intravenously. The facts that most of the dose of [¹⁴C]HMB administered either orally or intravenously appeared in the urine and that tissue distribution was the same for both routes of administration suggested that absorption of the oral doses was extensive and that biliary excretion accounted for most of the radioactivity in the feces after oral dosing. Greater excretion in bile in 4 h than in feces in 72 h indicated that a significant portion of the dose excreted in bile was reabsorbed and excreted in urine. Data derived in the previous study of HOB (Patel et al., 1968) did not exclude enterohepatic circulation of the absorbed compound and its metabolites.

The observation that topical application of [¹⁴C]HMB in ethanol resulted in extensive absorption agreed with a previous report that the

TABLE 2. Disposition of Radioactivity in Rats Dosed Topically with [¹⁴C]HMB Dissolved in Ethanol

Tissue		Dose					
		0.0516 mg		0.204 mg		0.800 mg	
		% of Dose	ng-Equivs/g or ml	% of Dose	ng-Equivs/g or ml	% of Dose	ng-Equivs/g or ml
Urine	(0–24 h) ^a	18.6 ± 6.9	1660 ± 570 ^c	18.5 ± 5.4	8860 ± 2630 ^c	4.81 ± 1.49	9560 ± 6420 ^c
	(24–48 h)	7.56 ± 3.18	1410 ± 430 ^c	11.3 ± 2.2	8140 ± 2320 ^c	3.84 ± 0.61	14,100 ± 6000 ^c
	(48–72 h)	4.86 ± 1.67	804 ± 42 ^c	7.11 ± 1.04	5350 ± 1090 ^c	5.07 ± 1.81	12,600 ± 4700 ^c
	Total	32.4 ± 12.2	— ^b	39.2 ± 3.0	—	13.2 ± 2.5	—
Feces	(0–24 h) ^a	6.09 ± 2.10	1250 ± 430	6.30 ± 1.38	4350 ± 1070	1.59 ± 0.53	4320 ± 1620
	(24–48 h)	6.87 ± 2.27	1280 ± 450	8.23 ± 1.04	7270 ± 980	3.05 ± 1.05	10,000 ± 2600
	(48–72 h)	3.71 ± 0.44	620 ± 163	6.67 ± 1.47	4080 ± 820	4.44 ± 1.51	11,000 ± 3600
	Total	16.9 ± 3.6	—	22.2 ± 1.7	—	9.15 ± 2.99	—
Gut contents	(4 h)	3.76 ± 2.38	195 ± 74	2.02 ± 0.58	616 ± 289	0.357 ± 0.131	187 ± 147
	(24 h)	6.42 ± 2.70	350 ± 146	4.73 ± 1.16	947 ± 107	2.55 ± 0.87	1890 ± 570
	(72 h)	1.83 ± 0.50	79.8 ± 26.8	2.85 ± 0.38	459 ± 54	2.96 ± 0.73	2230 ± 400
Gut tissue	(4 h)	0.962 ± 0.389	152 ± 77	0.736 ± 0.290	385 ± 162	0.124 ± 0.059	239 ± 92
	(24 h)	0.771 ± 0.200	107 ± 26	0.958 ± 0.019	569 ± 66	0.334 ± 0.214	686 ± 384
	(72 h)	0.398 ± 0.053	53.7 ± 7.9	0.541 ± 0.084	281 ± 44	0.596 ± 0.170	1160 ± 302
Liver	(4 h)	0.300 ± 0.139	30.8 ± 15.3	0.159 ± 0.056	59.7 ± 16.5	0.037 ± 0.015	45.6 ± 13.1
	(24 h)	0.259 ± 0.097	22.1 ± 10.0	0.198 ± 0.036	76.1 ± 17.1	0.097 ± 0.030	138 ± 45
	(72 h)	0.106 ± 0.007	8.01 ± 0.57	0.135 ± 0.008	41.2 ± 4.4	0.108 ± 0.027	142 ± 35
Lungs	(4 h)	0.015 ± 0.009	11.9 ± 6.6	0.007 ± 0.002	20.4 ± 5.4	0.002 ± 0.001	18.6 ± 8.7
	(24 h)	0.006 ± 0.002	4.17 ± 1.50	0.006 ± 0.000	17.4 ± 1.4	0.003 ± 0.001	34.7 ± 10.9
	(72 h)	0.002 ± 0.000	1.63 ± 0.19	0.002 ± 0.000	6.07 ± 0.51	0.003 ± 0.001	27.2 ± 6.0
Kidneys	(4 h)	0.153 ± 0.109	70.3 ± 51.7	0.062 ± 0.018	108 ± 30	0.016 ± 0.007	96.2 ± 36.5
	(24 h)	0.108 ± 0.028	46.1 ± 10.9	0.120 ± 0.032	193 ± 50	0.065 ± 0.033	439 ± 262
	(72 h)	0.040 ± 0.007	16.6 ± 3.4	0.048 ± 0.007	77.3 ± 11.3	0.040 ± 0.004	264 ± 28
Muscle ^d	(4 h)	0.595 ± 0.240	4.23 ± 1.83	0.526 ± 0.272	14.0 ± 6.3	0.391 ± 0.059	39.1 ± 4.0

	(24 h)	0.365 ± 0.094	2.44 ± 0.47	0.312 ± 0.033	8.23 ± 0.63	0.162 ± 0.078	16.3 ± 7.0
	(72 h)	0.465 ± 0.179	2.91 ± 1.12	0.266 ± 0.085	6.51 ± 2.25	0.175 ± 0.036	19.9 ± 5.0
Fat ^a	(4 h)	1.01 ± 0.69	50.7 ± 35.1	0.520 ± 0.274	104 ± 64	0.074 ± 0.032	51.8 ± 19.9
	(24 h)	0.611 ± 0.169	30.1 ± 5.9	0.690 ± 0.255	134 ± 52	0.289 ± 0.123	213 ± 99
	(72 h)	0.239 ± 0.092	10.8 ± 4.6	0.195 ± 0.020	33.8 ± 1.7	0.138 ± 0.009	97.5 ± 6.9
Skin (site of application)	(0 h)	87.0 ± 4.0	—	93.1 ± 1.5	—	84.5 ± 5.9	—
	(4 h)	73.1 ± 5.9	—	92.4 ± 0.4	—	85.4 ± 15.1	—
	(24 h)	50.4 ± 9.8	—	65.4 ± 7.3	—	91.9 ± 9.2	—
	(72 h)	27.3 ± 13.9	—	24.8 ± 3.8	—	57.9 ± 11.1	—
Skin ^f (other than site of application)	(4 h)	0.624 ± 0.292	13.7 ± 6.6	0.181 ± 0.047	15.9 ± 5.4	0.077 ± 0.026	23.8 ± 6.4
	(24 h)	0.520 ± 0.026	11.0 ± 0.5	0.337 ± 0.044	28.5 ± 4.5	0.182 ± 0.053	58.0 ± 18.1
	(72 h)	0.161 ± 0.022	3.17 ± 0.53	0.135 ± 0.033	10.4 ± 2.9	0.165 ± 0.045	51.3 ± 15.2
Plasma ^g	(4 h)	0.265 ± 0.143	18.6 ± 10.3	0.105 ± 0.029	28.7 ± 7.3	0.022 ± 0.011	21.6 ± 9.4
	(24 h)	0.111 ± 0.051	12.3 ± 10.0	0.099 ± 0.007	26.7 ± 2.6	0.050 ± 0.017	51.4 ± 17.5
	(72 h)	0.035 ± 0.002	2.19 ± 0.23	0.038 ± 0.005	9.29 ± 0.9	0.044 ± 0.007	43.8 ± 8.0
Whole blood ^h	(4 h)	0.266 ± 0.130	10.4 ± 5.3	0.120 ± 0.032	18.1 ± 3.6	0.026 ± 0.014	14.0 ± 6.4
	(24 h)	0.121 ± 0.049	4.54 ± 1.91	0.109 ± 0.009	16.3 ± 1.8	0.057 ± 0.021	32.1 ± 12.4
	(72 h)	0.043 ± 0.005	1.49 ± 0.24	0.043 ± 0.004	5.83 ± 0.44	0.049 ± 0.009	26.9 ± 5.6
Total recovery	(0 h)	87.0 ± 4.0	—	93.1 ± 1.5	—	84.5 ± 5.9	—
	(4 h)	81.0 ± 2.2	—	96.7 ± 1.1	—	86.7 ± 14.6	—
	(24 h)	82.7 ± 1.7	—	94.4 ± 1.9	—	103 ± 7	—
	(72 h)	79.8 ± 5.5	—	90.3 ± 0.9	—	84.4 ± 6.1	—

^a These values were calculated for six rats per group. All the other values are for three rats per group.

^b —, not applicable or not determined.

^c Excluding cage rinses.

^d Considered to be 50% of body weight.

^e Considered to be 7% of body weight.

^f Considered to be 16% of body weight.

^g Considered to be 5% of body weight. Not included in totals.

^h Considered to be 9% of body weight.

compound penetrated intact skin (Broitman, 1962). In the present study, the rates of elimination, as related to the percents of dose and tissue concentrations of radioactivity, were faster for the lower doses, indicating that absorption became rate-limiting at the high dose. For the high dose, substantial absorption continued beyond 24 h after dose application. Since the values derived from experiments involving topical application of [¹⁴C]HMB dissolved in ethanol or suspended in a lotion were similar to those derived for application as an ethanolic solution, the vehicle had little or no effect on absorption and distribution of radioactivity from [¹⁴C]HMB.

The identified metabolites of HMB were glucuronide and sulfate conjugates, compounds that are highly water-soluble. The formation of such conjugates undoubtedly facilitated elimination of HMB from the body. For the related compound, HOB, the small amount of dose (10%) that was absorbed appeared in the urine as a glucuronide (Patel et al., 1968). Since benzophenone forms a metabolite in which the keto group is reduced to a secondary alcohol (Robinson, 1958), perhaps some of the unidentified metabolites of HMB are corresponding derivatives.

In summary, for rats dosed with HMB, there was extensive absorption of the compound, followed by rapid metabolism and elimination. Only trace amounts of radioactivity derived from HMB persisted in the tissues.

REFERENCES

- Broitman, A. Y. 1962. Comparative toxicity of some stabilizers applied to raise thermo and photo-resistance of polymer materials *Cig. Tr Prof Zabol* 6:20-26; also *Chem Abstr* 57.11486a
- Cosmetic Ingredient Review Expert Panel 1983 Final report on the safety assessment of the benzophenones-1, -3, -4, -5, -9, and -11 *J Am Coll Toxicol*. 2:35-77.
- Jonsen, J., Jacobsen, N., and Hensten-Pettersen, A. 1980. Bacterial mutagenesis (Ames' test) as a screening method for carcinogenic substances of dental materials. *Adv. Biomater.* 1:333-339
- Lewerenz, H.-J., Lewerenz, G., and Plass, R. 1972. Akute und subchronische Toxizitätsuntersuchungen des UV-Absorbers MOB an Ratten *Food Cosmet. Toxicol.* 10:41-50.
- Metzler, C. M., Elfring, G. K., and McEwen, A. J. 1974. A package of computer programs for pharmacokinetic modeling. *Biometrics* 30 562-563
- Patel, Y. M., Levinskas, G. J., and Shaffer, C. G. 1968. Toxicity and metabolism of 2-hydroxy-4-n-octoxybenzophenone. *Food Cosmet Toxicol* 6 199-208.
- Robinson, D. 1958. Studies in detoxication 74 The metabolism of benzhydrol, benzophenone, and *p*-hydroxybenzophenone. *Biochem J* 68 584-586.
- Sedman, A. J., and Wagner, T. G. 1976. CSTRIP, a FORTRAN IV computer program of obtaining initial poly-exponential parameter estimates *J Pharm Sci.* 65:1006-1010.

Received March 31, 1986

Accepted May 27, 1986